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Abstract 
 
CIRCULATING AUTOANTIBODIES IN HUMAN TRAUMATIC SPINAL CORD INJURY 
SUBJECTS AND THEIR RELATIONSHIP TO THE DEVELOPMENT OF NEUROPATHIC PAIN 
 
 
 
Georgene W. Hergenroeder, M.H.A., B.S.N.  
 
 
Advisory Professor:  Pramod K. Dash, Ph.D. 
 
 
Background:  
 Approximately 17,500 spinal cord injuries (SCI) occur yearly in the U.S. causing 
considerable morbidity and mortality.  Neuropathic pain (NP) ensues in 40-70% of SCI.  An 
autoimmune response resulting from disruption of the blood-spinal cord-barrier may be a 
contributor to NP. However, the relationship between autoantibodies and NP after SCI in 
humans has not been thoroughly characterized nor have autoantigens been identified.    Glial 
fibrillary acidic protein (GFAP) and collapsin response mediator protein2 (CRMP2) were 
identified as candidate autoantigens.  The hypothesis is that proteins from the injured spinal 
cord released by SCI trigger autoantibody production which can lead to the development of NP.   
 
Results:  
 The presence of autoantibodies to GFAP (GFAPab) and CRMP2 (CRMP2ab) and their 
correlation to the development of NP was evaluated. GFAPab was present in 21 of 38 (55%) 
acute SCI, 34 of 80 (43%) chronic SCI.  CRMP2ab was present in 8/35 (23%) acute SCI 
patient plasma samples.  Complement C3 and C5 were elevated in acute SCI.  Peak 
autoantibody levels were detected at 16±7 days post injury.  The peak plasma GFAPab levels 
were higher in patients that subsequently developed NP versus those who did not (T=219, 
p=0.02). Receiver operator characteristic curve analysis shows that plasma GFAPab levels had 
an area under the curve of 0.71 (95% CI, 0.53-0.89 p=0.03) for the discrimination of patients 
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that developed NP within 6 months after injury.   Patients with GFAPab and/or CRMP2ab had a 
9.5 times increased odds of developing NP.    
 
Discussion:  
 Results show that SCI triggers an autoimmune response leading to production of 
autoantibodies.  The 16±7 day level of GFAPab post-SCI is a predictor of the development of 
NP.  The levels of GFAPab returned to levels found in healthy volunteers by 96±54 days post-
injury. A panel of GFAPab and CRMP2ab showed 9.5 times increased odds of developing NP 
(95% CI, 2.08-43.50, p=0.006).  Future studies will examine the possibility that other 
autoantibodies contribute to the development of NP.  Measuring GFAPab and CRMP2ab post-
SCI may help identify patients at risk for subsequently developing NP.  A reduction of GFAPab 
and/or CRMP2ab in the acute stages of injury may decrease the likelihood for developing NP.   
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1. Rationale, Hypothesis, Specific Aims and Significance 
 
Rationale: Chronic neuropathic pain is a debilitating condition that commonly occurs 
after spinal cord injury (SCI). More than half of those with SCI-related neuropathic pain 
describe neuropathic pain as their primary problem, more significant than their loss of motor 
function.[1] Forty to seventy percent of those with SCI develop neuropathic pain, yet 
currently available treatments (e.g., gabapentin and pregabalin) are only partially effective, 
and only in some patients.[2]  Additionally, there are no predictors of post-SCI neuropathic 
pain.[3]  A potential contributor to SCI-induced neuropathic pain and inhibitor of recovery is 
the autoimmune response to damaged central nervous system (CNS) tissue. 
 The conditions for an autoimmune response occur as the primary trauma to the 
spinal cord disrupts the blood-spinal cord barrier (BSCB). This disruption allows previously 
sequestered CNS molecules to enter the systemic circulation where they may elicit an 
autoimmune response.  Increased permeability of the BSCB also allows circulating immune 
cells to infiltrate and access the injury site. The increased access of circulating immune 
cells to the injury site initiates the potential for an autoimmune response to ensue.[4]  
Rodent models using both rats and mice have demonstrated that SCI can lead to 
stimulated T- and B-lymphocyte responses leading to the production of immunoglobulin G 
(IgG) autoantibodies to CNS proteins.[5, 6]  These IgG autoantibodies from injured subjects 
can exacerbate tissue injury by causing ongoing inflammation, hinder recovery and promote 
chronic pain. Consistent with this, a study utilizing a constriction model of SCI showed less 
mechanical allodynia and hyperalgesia in rats lacking functional T cells compared to 
controls.[7] The recognition of antigen by T cells and major histocompatibility complex II 
generates inflammatory mediators and facilitates the presence of chronic pain.[8] 
Furthermore, SCI in B cell knockout mice that are incapable of generating an antibody 
response were shown to have better locomotor function and smaller lesion volume 
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compared to SCI wild-type mice.[9]  Additionally, injecting purified IgG obtained from SCI 
mice into uninjured mice resulted in spinal cord pathology and decreased motor function, 
similar to that of the SCI mice.[5]  These studies demonstrate negative effects of 
autoimmune responses in rodent models.  Relatively few human studies have identified 
autoantibodies produced after SCI and, for the most part, these studies have been 
performed using directed searches (primarily against myelin proteins, gangliosides and 
glycoproteins) limiting their diagnostic and prognostic potential for neuropathic pain.[10-19] 
While neuroinflammation is recognized as an ongoing process after SCI, autoantibody 
discovery after human SCI has not been thoroughly explored.[20, 21]    Ongoing 
inflammation due to an autoimmune reaction to CNS antigens may contribute to 
neuropathic pain.  
Hypothesis: proteins from the injured spinal cord released by SCI trigger autoantibody 
production that can lead to the development of neuropathic pain. Two specific aims are 
outlined to test the above hypothesis. 
Specific Aim 1: To test whether SCI elicits an autoantibody response and identify the 
antigen(s) that triggers this response in human SCI subjects. 
Specific Aim 2: To statistically compare whether the presence of autoantibodies to specific 
antigen(s) correlates with the development of neuropathic pain in human SCI subjects.  
  Inflammatory processes such as astrogliosis, abnormal cytokine production 
and activation of complement are known to occur after SCI and have been associated with 
neuropathic pain.[22-26] Mouse models have identified autoantibodies produced after SCI 
to CNS antigens.[27] However, the presence of autoantibodies to CNS proteins in human 
SCI has not been well documented, nor have the antigens predictive of neuropathic pain 
been established.  Western blot-based approaches were utilized to explore the presence of 
autoantibodies in human plasma following SCI.  Investigations were performed to test for an 
association between the presence of the autoantibodies and neuropathic pain.  Using this 
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unbiased screening, newly enhanced immunoreactivity to collapsin response mediator 
protein 2 (CRMP2) and glial fibrillary acidic protein (GFAP), both CNS antigens, was 
detected in patients’ plasma after SCI.  Additionally, complement components C3 and C5 
were increased in patients’ plasma after SCI. These data suggest that release of CRMP2 
and GFAP after SCI may trigger an autoimmune response that contributes to neuropathic 
pain.   
 Further studies were conducted to verify the antigen specificity.  The time course of 
circulating GFAP autoantibodies (GFAPab), CRMP2 autoantibodies (CRMP2ab) and 
complement C3 and C5 levels in SCI patients and whether the presence of GFAPab, 
CRMP2ab, C3 or C5 correlated with subsequent development of neuropathic pain was 
evaluated.  Plasma complement C3 levels at 6.4 ± 1 days and GFAPab at 16 ± 7 days were 
correlated; C3 and CRMP2ab levels at 16 ± 7 days were correlated.  Analysis identified an 
association between the presence of GFAPab at 16 ± 7days post-SCI and the development 
of neuropathic pain within 6 months post-SCI.   Combining the GFAPab plus CRMP2ab into 
a panel determined that the presence of these autoantibodies increased the odds of 
developing neuropathic pain 9.5 times compared to those without GFAPab and CRMP2ab 
(95% CI, 2.08-43.50, p=0.006). When controlling for age, gender, body mass index, 
complete injury, and cervical level, the presence of GFAPab and/or CRMP2ab remained a 
significant factor in predicting neuropathic pain within 6 months of SCI (OR 15.3, 95% CI 
1.9 to 125, p=0.01). 
Significance: These data suggest the autoimmune response to GFAP and CRMP2 is a 
contributor to chronic pain following SCI in humans.  If these results are confirmed, 
GFAPab and CRMP2ab may be used as a predictor of neuropathic pain. Treatments aimed 
at the removal of GFAPab early post-injury may be able to prevent the development of 
neuropathic pain.  This suggests screening for autoantibody production may initiate new 
strategies for preventive therapies. 
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Chapter 1.  Introduction 
 
1.1. Description and course of spinal cord injury 
 Approximately 17,500 SCI occur annually in the U.S.[28]  The World Health 
Organization estimates that the worldwide incidence of SCI is up to 500,000/year.  
Compared to those without injury, people with SCI are 2 to 5 times more likely to 
experience premature death.[29]  Approximately 80% of injuries occur in males.  The 
average age at time of SCI is 42 years; 59% of injuries result in tetraplegia (45.8% 
incomplete tetraplegia, 13.2% complete tetraplegia), 40.6% paraplegia (20.9% incomplete 
paraplegia,19.7% complete paraplegia) and 0.4% are neurologically normal by hospital 
discharge.[28] The leading causes of SCI are motor vehicle accidents, falls, assault and 
sports-related injuries. 
 Spinal cord injury can be segregated into two stages, 1) the primary injury from the 
initial mechanical insult causing damage to the spinal cord resulting in cell death and the 
activation of the inflammatory response; and, 2) the secondary injury caused by the 
vascular and immune responses associated with a persistently permeable BSCB. Loss of 
function occurs as a result of loss of conduction of sensory and motor signals across the 
lesion site.  Damage to axons of spinal sensory neurons or dorsal nerve roots causes 
interference of ability of afferent signals to reach the brain, and damage to axons of motor 
neurons or ventral nerve roots inhibits efferent signals from reaching muscles.      
 
 1.2. Level and classification of injury (complete or incomplete) 
 SCI level of injury is classified according to the most caudal spinal cord segment 
(cervical, thoracic, lumbar, or sacral) that is functionally normal.  Injury to the cervical spinal 
cord results in tetraplegia.  Tetraplegia manifests as malfunction of arms, legs, thoracic and 
pelvic region.  Paraplegia refers to loss of function of thoracic, lumbar or sacral spinal cord 
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segments as a result of spinal cord damage.  The specific spinal segment injured dictates 
the level of function.  Paraplegia includes preserved upper extremity function.   
 SCI degree of neurological impairment is classified as complete or incomplete.  A 
complete SCI is one in which no motor or sensory function exists below the level of the 
lesion. An incomplete injury is one in which some motor or sensory function exists below 
the lesion.    The most accepted tool used to classify subjects’ injury is the International 
Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) formerly referred 
to as the American Spinal Cord Injury Association (ASIA) exam which was based on the 
Frankel Classification.[30]  The exam captures bilateral upper and lower extremity motor 
function based on myotome, and sensory function by dermatome location.  Muscle grade is 
from 0 (total paralysis) to 5 (active movement against full resistance). Sensory points are 
graded as 0 (absent), 1 (impaired) or 2 (normal).  In order to be motor incomplete, the SCI 
subject must have sacral sparing and either voluntary anal sphincter contraction or motor 
function preserved for at least three levels below the motor level. In addition to classifying 
the degree of impairment the ISNCSCI assigns motor and sensory levels at the most 
caudal segment of the spinal cord where the patient is bilaterally normal. Of note, this is 
not necessarily the same as the level of the lesion as it refers to normal function.  
Generally, patients’ receive a summary ISNCSCI score based on the spinal segment and 
degree of completeness.  For instance, a person who has normal motor function and is 
able to fully extend their wrist against normal resistance (extensor carpi radialis longus and 
brevis, C6) and has normal sensory function to the thumb and index finger, but no function 
below that level (complete, A) would be defined as a “C6 A”.  Not all SCI are neatly 
classified and a patient’s exam may change over the course of the injury, in part related to 
edema/swelling.   
 Classification is useful as a gauge to measure patients’ improvement or decline in 
function, to identify sensory aberrations, to anticipate lifestyle modifications, rehabilitation 
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capability and secondary complications.  Patients have varying degrees of recovery related 
to the neurological level of injury and degree of impairment.  For instance, someone with a 
cervical complete injury has less chance of recovery of function and independence, and 
more complications than someone with a thoracic incomplete injury.[31] The rate of motor 
recovery is highest during the first 3 months and plateaus around 6 months post-SCI.[32]  
Ninety-four percent of patients with complete injuries remained complete 1 year to 5 years 
post-SCI and, at most, 2% of those with motor incomplete injuries improved 
neurologically.[32]  
 Two recent studies have been performed evaluating the ability of early magnetic 
resonance imaging (MRI) biomarker measurements for predicting short term neurological 
outcome after cervical and thoracic SCI. Using a data-driven tool, nonlinear principal 
component analysis to detect statistical patterns, neurological impairment was predicted 
using MRI biomarker measurements demonstrating that the Brain and Spinal Injury Center 
(BASIC) score (lesion/no lesion) was predictive for short term outcome (ISNCSCI score at 
hospital discharge) for both cervical SCI patients when correcting  for interactions from 
surgical decompression and spinal cord compression, and thoracic SCI patients.[33, 34] 
This type of objective biomarker measurements from imaging or other biological sources 
are helpful in classifying injury and in evaluating response to existing and experimental 
treatments. 
 
 1.3. Acute and chronic spinal cord injury 
 Damage to the cord begins at the time of trauma and the pathology is progressive.  
There is no precise demarcation between the acute and chronic phases of injury.[35] The 
distinction is often contextual.  Generally, the acute hospital stay when a patient is being 
stabilized is considered acute.  By the time a patient has lived with an injury for 6 months 
the injury is considered in the chronic phase of recovery.[36, 37] During the acute phase of 
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injury care focuses on stabilization to prevent further injury and medical management to 
prevent secondary complications.  Rehabilitation to maximize remaining function is initiated 
as the patient recovers. Secondary conditions associated with SCI and their overall health 
status affect the injured person’s ability to participate in rehabilitation.    
 
1.4. Secondary conditions associated with spinal cord injury 
 People with SCI have considerable morbidity including pain (nociceptive and 
neuropathic), depression, infections, skin breakdown, deep vein thrombosis, spasticity, 
contractures, autonomic dysreflexia, bone demineralization, muscle atrophy, bowel, 
bladder and sexual dysfunction in addition to loss of motor and sensory function.[38, 39]  
These secondary morbidities contribute to diminished quality of life and reduced life 
expectancy.[40-42]  The scope of this work focuses primarily on neuropathic pain resulting 
after SCI. 
 
1.5. Innate and adaptive response 
 
 The innate immune response is the initial, non-specific immune response which 
defends the host against pathogens, eliminates dead or damaged cells and initiates tissue 
repair.  This non-specific immune response initiated immediately after SCI causes 
vasodilation, edema, cytokine and chemokine production and an influx of leukocytes and 
polymorphonuclear cells as the body works to repair damaged tissue.[43] The adaptive 
immune response is antigen-specific and therefore requires time to respond.  The innate 
response is efficient in recognizing specific patterns.  For instance, the innate system uses 
Pattern Recognition Receptors (PRR) that recognize motifs found on the surface of 
bacteria and other pathogens to identify them for destruction.  The innate system also 
recognizes damage-associated molecular patterns (DAMPS) found on cellular debris and 
8 
 
initiates its removal.[44] The innate immune response activates the complement system to 
enhance antibodies’ and phagocytes’ ability to clear cellular debris and pathogens.[9, 45]  
The opsonization (coating) of pathogens by complement facilitates their uptake by 
phagocytic antigen presenting cells expressing complement receptors.  This readies the 
antigen for T cells.  Conventional dendritic cells take up antigen in tissue, process it to 
generate a peptide antigen that can activate T cells and induce an adaptive immune 
response.[46, 47] After SCI, these antigens could be fragments of CNS proteins.  There 
are two types of antigen-specific lymphocytes, T cells and B cells.  B cells are produced in 
the bone marrow, have B cell receptors on their surface that are specific for antigens, and 
produce antibodies.  
 The adaptive immune response is induced as T cells and B cells receive antigen 
stimulation; T cells differentiate into T effector cells (helper (Th) and cytotoxic (Tc)) and B 
cells differentiate into antibody-secreting plasma cells. Activated antigen presenting cells 
(dendritic cells) present antigen and prime T cells in peripheral lymph nodes or, as in SCI 
with severe inflammation, naïve T cells can be activated within the CNS. [48]  Disruption of 
gut microbiota is also involved with priming T cells, activation of B cells and autoimmune 
responses.[49, 50] T cells are activated and stimulated to release cytokines. CD4+ T cells 
secrete cytokines in the CNS; Th1 secrete IFN-γ and Th17 secrete IL-17, IL-21 and IL-
22.[48] CD8+ T cells secrete TNF-α, IFN-γ.[51] The autoimmune disease systemic lupus 
erythematosus (SLE) is associated with antigen presentation by dendritic cells in 
association with CD4+ T cells; additionally, CD8+ T cell deficient mice are resistant to the 
development of SLE showing T cells can contribute to autoantibody production with 
cytokine production.[51]   
 Mature B cells are released into the circulation and lymphatic system from the bone 
marrow as naïve B cells.  Upon receiving stimulation from antigen in the presence of Th 
cells in lymph nodes a germinal center reaction results in clonal expansion, B cell class 
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switching, somatic mutation and the production of 1) activated memory B cells that are 
long-lived and 2) plasma cells that secrete antigen-specific antibodies.[48]  
 
   1.6. Autoantibody 
 
 Antibodies bind specifically to the antigen to generate the immune response and to 
recruit cells to destroy the antigen once it is bound by the antibody.  Autoantibodies are 
antibodies directed against self-antigens. During typical lymphocyte differentiation, some 
lymphocytes develop that have affinity for self-antigens.  These lymphocytes are removed 
or have such low affinity to self-antigens that they are of little significance.  A state of self-
tolerance exists where the immune system does not attack normal self-tissues.  
Autoimmunity occurs when this system malfunctions.[52] Autoimmune disease results from 
mounting of an immune response to a self-antigen(s).  For instance, multiple sclerosis is 
the result of auto-reactive T cells against CNS antigens causing the formation of sclerotic 
plaques and destruction of myelin sheaths resulting in muscle weakness and ataxia.[53, 
54]  Pathology occurs when there is a sustained reaction and myelin is destroyed.[55]  
Methods of tolerance include the sequestration of antigens where they are not accessible 
to the immune system.  Trauma that increases the permeability of the BSCB and tissue 
damage allowing previously sequestered antigens to become accessible abrogates this 
sequestration.  The release of CNS antigens can activate ignorant latent T  and B cells.  
Autoantibodies may be produced by B cells when self-tolerance malfunctions and the body 
destroys otherwise normal tissue that the immune system perceives as foreign.[56]  
 Autoantibody binding triggers B and T cell reactions such as the release of 
inflammatory mediators (e.g., IL-1β, IL-6, TNFα, lymphotoxin) that excite nociceptors, or 
cause a conformational change or change in expression of receptors or channels, or 
induce nerve cell damage resulting in sensitization of nociceptors inducing neuropathic 
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pain.[57-61]  However, there is controversy about whether autoantibodies produced after 
SCI are neuroprotective or neurotoxic.  For example, enhancing T-lymphocyte response to 
antigens at the injury site has been shown to improve neuronal survival in an optic nerve 
injury model.[62] Additionally, intravitreal injection of glutamate or ferrous ions (free 
radicals) to nude mice possessing no mature T cells produced significant retinal ganglion 
cell loss that was not seen in wild type mice demonstrating neuroprotection from T 
cells.[63] A murine retinal ganglion cell study attributed credit to T cells for protection 
against thrombin-induced toxicity because of T cells’ ability to transcribe thrombin  inhibitor 
anti-thrombin III.[64] It was previously demonstrated that after crush injury, retinas of rats 
treated with the thrombin inhibitor NAPAP (N-α-(2-naphthylsulphonylglycyl)-4-(D,L)-
amidinophenylalanine piperidide acetate salt) had more intact retinal ganglion cells 
compared to vehicle treated rats.[65]  
 Efforts to utilize the immune response in order to induce neuroprotection after SCI 
are under study.  Nogo is an axonal growth inhibitor protein.   Anti-Nogo-A antibodies 
infused intrathecally have facilitated axon regeneration in rats and monkeys.[66]  It has 
been proposed that the anti-Nogo-A antibody induces T cell mediated neuroprotection.[67]  
A safety and feasibility clinical trial of humanized anti-Nogo-A antibody (Novartis 
Pharmaceuticals) was recently conducted in 52 acute SCI patients; the results are 
pending.[68]    
 Alternatively, antibodies created in response to myelin damage at the site of injury 
are believed to result in secondary damage.[6]  Myelin basic protein (MBP) is a major 
structural protein in myelin.  MBP-reactive T cells propagate the inflammatory process by 
producing cytokines. Chronic SCI patients have been shown to have high levels of MBP-
reactive T cells.[69]  GM1 ganglioside-specific autoantibodies, as well as cytokines IL-2 
and TNFα, which promote axonal dysfunction and demyelination, were elevated in chronic 
SCI patients.[19]   
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1.7. Neuropathic Pain after Spinal Cord Injury 
 Pain serves a protective function in that it signals the body to prevent or notifies the 
body of tissue injury.  Virtually all patients experience pain due to trauma after an SCI.  
However, neuropathic pain is a distinct type of pathological pain that persists after wound 
healing.  Prevalence rates of neuropathic pain after SCI range from 26% to 96% of 
patients.[3]  Using more consistent definitions of neuropathic pain the estimated range is 
narrowed to 40% - 70% of SCI patients. [2, 70, 71]    Once neuropathic pain occurs it tends 
to become chronic.  
 Neuropathic pain is defined as “pain caused by a lesion or disease of the 
somatosensory system”.[70, 72, 73] The current definition was derived from the 
International Association for the Study of Pain (IASP) that defined neuropathic pain as 
“pain arising as a direct consequence of a lesion or disease affecting the somatosensory 
system”.[74] The IASP proposed a uniform classification system to define pain: nociceptive 
(musculoskeletal and visceral) and neuropathic (at level and below level of injury).  The 
International Spinal Cord Injury Pain Classification system offers a tiered system of 
classification of pain types.[70] In addition to necessitating a CNS lesion, these neuropathic 
pain definitions include characteristics requiring that 1) sensory deficits exist within the pain 
distribution; 2) allodynia and/or hyperalgesia exist within the pain distribution and 3) the 
patient verifies that neuropathic pain descriptors (e.g., hot-burning, tingling, pins and 
needles, etc.) depict their pain. In contrast, musculoskeletal pain is characterized as a dull 
aching pain that gets worse with movement, and is often related to overuse injuries (i.e. 
transfers relying on only arm and shoulder muscles).   
  Pain limits physical function and ability to rehabilitate, infringes on work and social 
activities, and reduces quality of life. Approximately 75% of SCI patients with neuropathic 
pain described it as a sharp, shooting continuous pain that is stimulus-independent; it is 
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associated with allodynia (normally non-painful stimuli evoking pain), hyperalgesia 
(increased sensitivity to noxious stimuli), and paresthesia (pins and needles sensation).[2] 
The factors that are associated with, or causal of, the development of chronic neuropathic 
pain in SCI have not been fully determined.   
 Neuropathic pain and spasticity (exaggerated muscle tone with increased tendon 
reflexes and clonus) are both aftereffects of maladaptive neuronal plasticity resulting from 
injury, but musculoskeletal pain due to spasticity differs from neuropathic pain and is 
differentiated through careful assessment.[75] Multiple factors including psychological, pain 
location, pain descriptors and onset, injury characteristics, physical condition  and 
environment must be taken into account when evaluating pain.[75]  Distinguishing the type 
of pain experienced after SCI (neuropathic, nociceptive, or other) is important in 
determining the appropriate treatment. Unfortunately, neuropathic pain is frequently 
refractory to existing treatments.[76-78] Gabapentin and pregabalin, commonly used 
medications for SCI neuropathic pain,  provide partial relief.[79, 80] In addition to 
unsatisfactory pain relief, existing treatments have undesirable side effects.[81] For 
example, these medications are known to cause drowsiness, weakness, fatigue, cognitive 
issues, constipation, dry mouth and headache.  It is difficult to predict which SCI patient is 
at risk for developing neuropathic pain. Notwithstanding the above definition of neuropathic 
pain there is no universally accepted objective test for diagnosing neuropathic pain, and a 
clinical diagnosis of neuropathic pain remains the standard on which most tools are 
based.[70, 82-84] There are ongoing international efforts for standardizing the definition 
and grading of neuropathic pain.[70, 77, 83, 84] 
 
1.8. Pain Pathways 
 Pain is sensed by specialized sensory receptors (nociceptors) that transmit signals 
from noxious stimuli along A delta (Aδ) and C fibers to the dorsal horn of the spinal cord.  
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Thermoreception is also transmitted through Aδ and C fibers. There are three types of 
primary afferent nerve fibers, Aδ, C and Aα/β fibers.  Aα/β fibers are large diameter 
myelinated fibers that have a low threshold for activation and conduct signal rapidly and 
transmit non-noxious stimuli/mechanoreception.[85]  Aδ fibers transmit sharp, fast pain.  
They are small diameter myelinated fibers.  C fibers are unmyelinated and small and 
therefore slow conducting.  They carry dull, long lasting pain and are responsible for 
perceiving burning pain.  Most primary afferent fibers enter the spinal cord through dorsal 
roots at their level of origin or 1-2 segments above or below, although some unmyelinated 
afferent fibers enter the spinal cord though ventral roots.[85] Generally, C fibers terminate 
in laminae 1-2 and Aδ fibers in laminae 1, 2, 5 and 6. [85]  The major pathways that 
transmit pain signals are the spinothalamic tract and the spinoreticular tract. Secondary 
afferent fibers decussate close to the level of entry and ascend on the contralateral 
spinothalamic tract to the thalamus to third order neurons which end in the somatosensory 
cortex.  The spinoreticular tract is implicated in the emotional component of pain; it also 
ascends on the contralateral side and after reaching the reticular formation of the 
brainstem goes to the thalamus and hypothalamus and then to the cortex. There are 
descending pathways that inhibit pain transmission, these are central to Melzack and 
Wall’s gate control theory of pain sensation, and the ascending/descending pain 
transmission system.[86, 87] The gate control theory proposes that non-noxious sensory 
input from Aα/β fibers activates inhibitory neurons which inhibit pain transmission (input 
from the C or Aδ fibers). The gate is opened or closed depending on the balance of the 
large (Aα/β) and small (C or Aδ) fiber input; prolonged high-intensity stimulation disturbs 
the balance which results in removal of presynaptic inhibition of sensory inputs and opens 
the gate. The gate control theory proposes that peripheral sensory and central inputs 
cause brain activity to reach a threshold evoking pain.[87] The ascending/descending pain 
transmission system is made up of areas that have high concentrations of opioid receptors 
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and endogenous opioids; descending pathways project to the dorsal horn using 
noradrenaline and serotonin to inhibit pain.  The system includes the upper brain stem 
periaqueductal gray matter, the locus coeruleus the nucleus raphe magnus and nucleus 
reticularis gigantocellularis.[88]  Pain perception and processing occurs in multiple areas of 
the brain including the thalamus, the somatosensory, insular, anterior cingulate, and 
prefrontal cortex.  Multiple mechanisms are involved in the development and maintenance 
of neuropathic pain.   
 
1.9. Mechanisms involved in neuropathic pain 
 
 Injury to the spinal cord results in damage and disruption of the pathways that 
transmit signals from peripheral sensory receptors to the dorsal horn of the spinal cord and 
then ascend to the brain.  Studies in animals have identified multiple mechanisms 
contributing to the development or maintenance of neuropathic pain, however these 
mechanisms are not fully understood.[89] Neuropathic pain mechanisms can be 
interrelated. These include increased spontaneous activity of pain nociceptive neurons, 
sprouting of C and Aδ fibers, altered expression of ion channels on neurons in the pain 
pathway, removal of inhibitory inputs, altered release and reuptake of the excitatory 
neurotransmitter glutamate, altered expression of excitatory neurotransmitter receptors, 
increased efficacy of “silent synapses” or newly formed synaptic circuits and synaptic 
reorganization, and increased firing of dorsal root ganglion neurons.[90-101]  These 
mechanisms do not occur in isolation, and central components of developing neuropathic 
pain include neuronal hyperexcitability and inflammation.[102, 103]   
 Peripheral sensitization (enhanced response to stimuli by the nociceptor) and 
central sensitization (enhanced response to painful stimuli in the spinal cord dorsal cord 
neurons) can occur after SCI.[104] Previously silent nociceptive neurons become 
responsive after a prolonged period of stimulation, and nociceptive neurons are exposed to 
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excitatory neurotransmitters including substance P and calcitonin gene-related peptide 
creating peripheral sensitization and pain.[105-109]  Peripheral sensitization causes 
increased frequency of nerve impulses leading to hyperexcitability from prolonged release 
of glutamate in the dorsal horn and subsequent central sensitization and pain.[104]  
 Neuronal hyperactivity, defined as enhanced spontaneous neuronal excitability or 
enhanced neuronal responses to sensory stimuli resulting in pain hypersensitivity, is 
essential for the development and maintenance of neuropathic pain. [110] In a study of 15 
people with complete thoracic SCI at-level hypersensitivity to cold, touch and pinprick was 
associated with neuropathic pain.[111] After SCI multiple alterations can occur causing 
neuronal hyperexcitability in the dorsal horn resulting in neuropathic pain.[104] Using a 
sensorimotor test to evaluate mechanical allodynia in rodents, correlations have been 
found between neuronal hyperactivity and neuropathic pain  as demonstrated by 1) 
decreased threshold for paw withdrawal with simultaneous increased firing of the dorsal 
horn sensory neurons and 2) increase in ion channel expression with neuropathic pain 
behaviors.[110]    
 Inflammation in the spinal cord which leads to secondary tissue damage is an 
important contributor to neuropathic pain.[112, 113]  CNS glial cells (microglia, astrocytes 
and oligodendrocytes) are involved in the initiation and continuation of neuropathic pain.  
For instance, blocking glial activation in rats prevented neuronal and glial activation of a 
phosphorylated MAPK (p38 MAPK) and reduced neuronal hyperexcitability and 
mechanical allodynia.[104, 114]  Glial cell activation has also been identified in human 
spinal cord tissue.  A study of post-mortem human spinal cords including 11 SCI and 2 
traumatic brain injury (TBI) control spinal cords evaluated spinal cord tissue obtained from 
people who died 30 minutes to 5 days post-SCI.  Activated microglia, IL-1β, IL-6 and 
TNFα, all associated with inflammation, were found near the lesion and in the spinal cord 
as early as 30 minutes post-SCI, but no expression was found in the spinal cords of people 
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who died secondary to TBI without SCI.[115]  Serum levels of IL-6, and TNFα were 
elevated in people with SCI and these cytokines were further elevated in people with pain 
or who had active infection.[16] The presence of inflammatory mediators and the fact that 
blocking them alleviates pain provides support for inflammation as a mechanism for 
neuropathic pain. 
 Activated astrocytes and microglia release pro-inflammatory cytokines, 
neurotransmitters, and reactive oxygen species (ROS).  This results in increased blood-
spinal cord barrier (BSCB) permeability, and abnormal function of ion channels and 
receptors.  Activation of voltage-gated calcium channels and NMDA receptors result in an 
increase in intracellular calcium ions, this leads to activation of multiple downstream kinase 
pathways (e.g., calcium-calmodulin-dependent kinase II, protein kinase C, protein kinase 
A) which perpetuate neuronal hyperexcitability  of dorsal horn sensory neurons.[110]  
 Glial cells, including microglia and astrocytes are involved in hyperexcitability and 
neuropathic pain.  Glial cells maintain gamma-aminobutyric acid (GABA) and glutamate 
concentrations in the spinal cord contributing to both release and uptake in order to 
maintain extracellular concentrations.[89] GABA is a neurotransmitter that acts on 
inhibitory interneurons; loss of GABA inhibition results in hyperexcitability in dorsal horn 
neurons and neuropathic pain.[89, 116]  Glutamate, an excitatory neurotransmitter, 
contributes to sensitization.  After painful stimuli, intracellular calcium concentration 
increases in astrocytes which in turn cause an increase in calcium-dependent glutamate. 
High intracellular calcium concentrations activate phospholipase A2.[104]  Arachidonic 
acid, prostaglandins and leukotrienes are produced when phospholipase A2 hydrolyzes the 
cell membrane. Calcium-independent phospholipase A2 produces reactive nitrogen 
species, MAPK, and ROS.[104]  ROS cause the release of glutamate via the Transient 
receptor potential vanilloid 1 (TRPV1) and TRPA1 channels  which are also involved with 
neuropathic pain.[104, 113]  Glutamate release increases local glutamate receptors and 
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ion channels which in turn increases the release of cytokines and ROS and activation of 
glial cells and kinase cascades leading to pain.[89]   
 
1.10. Autoantibody mediated pain 
 Autoantibodies to CNS proteins can elicit pain via multiple mechanisms.  
Complement binding of the Fc region of autoantibodies can produce inflammation, when 
this inflammation causes nerve damage neuropathic pain can occur.[45, 57, 117]  For 
instance, complement-induced response ultimately leads to neuronal damage and can 
cause neuropathic pain as is found in Guillain-Barre syndrome.[57]  Autoantibodies binding 
to nociceptors may damage the nerve cell or change its function resulting in neuropathic 
pain.[57] Sensitized nociceptors may become hypersensitive to noxious and/or non-
noxious stimuli or become spontaneously active.  Neuropathic pain mediated through Fab-
region binding can have multiple effects by blocking the binding sites, causing a 
conformational change, or activating the antigen.[57]  The binding of the antigen by the 
antibody may potentiate the inflammatory response and/or prevent the glial scar from 
forming properly perpetuating a permeable BSCB and neuropathic pain.[25]  
 Autoantibodies produced after SCI could work through any of these means and 
result in the development of neuropathic pain.  Currently, there are no diagnostic tools 
available to predict who will develop chronic neuropathic pain after SCI.  Therefore, this 
research sought to identify autoantibodies after SCI that may predict the development of 
neuropathic pain.  
 
1.11. Knowledge Gaps. 
 Although both experimental and clinical studies have observed immune responses 
after SCI, it has not been investigated if human SCI elicits an autoantibody response.  As a 
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part of this thesis research the following questions were investigated in human SCI 
subjects: 
1.  Does human SCI elicit an autoantibody response? 
2.  What is the antigen(s) that triggers autoantibody production? 
3. Does the circulating level of identified autoantibodies correlate with the development or 
presence of neuropathic pain? 
 
1.12. Study Impact 
 The identification of autoantibodies produced after SCI may lead to new treatment 
targets or new prognostic indicators.   
 
Hypothesis: proteins from the injured spinal cord released by SCI trigger autoantibody 
production that can lead to the development of neuropathic pain.  
 
Aim 1: To test whether SCI elicits an autoantibody response and identify the antigen(s) 
that triggers this response in human SCI subjects. 
 
Aim 2: To statistically compare whether the presence of autoantibodies to specific 
antigen(s) correlates with the development of neuropathic pain in human SCI subjects.  
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Chapter 2.  General Methods 
2.1. Reagents, antibodies and proteins 
Methods Table 1.  List of reagents or kits 
 
Reagent or Kit Provider Catalog Number 
CDP-Star Reagent for alkaline 
phosphatase 
Biolabs, Ipswich, MA 
 
C0712 
Albumin from Bovine Serum  Sigma Aldrich A7906-100G and A3059-
50G 
microBCA assay kit Thermo Scientific, 
Rockford, IL 
23235 
Melon Gel IgG Spin 
Purification kit (Antibody 
purification) 
Thermo Scientific, 
Rockford, IL 
45206 
Pierce Protein A IgG Plus 
Orientation (protein A affinity 
columns) 
Thermo Scientific, 
Rockford, IL 
44893 
Complement C3 ELISA abcam  ab108822 
Complement C5 ELISA abcam ab125963 
Precision Plus Protein 
Standards 
BioRad 161-0363 
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Methods Table 2.  Antibodies used, provider and catalog number. 
 
Antibody Provider Catalog Number 
Primary Antibodies 
Custom rabbit anti-GFAP antibody Custom – Dash lab NA 
Anti-CRMP2 (Rabbit) Sigma Aldrich C2993 
Anti-CRMP2 antibody(Rabbit) abcam Ab36201 Rb,  
Lot GR212945-1 
Anti-CRMP2  antibody (Rabbit) ThermoFisher 
Scientific 
PA5-29728 
Secondary Antibodies 
Goat anti-human IgG (H+L) 
secondary antibody, Alexa Fluor 
488 conjugate 
Invitrogen by 
Thermo Fisher 
Scientific 
A-11013 
Goat anti-human IgG (H+L) 
seconday antibody, Alexa Fluor 
568 conjugate 
Invitrogen by 
Thermo Fisher 
Scientific 
A-21090 
Alkaline phosphatase goat anti-
rabbit IgG antibody 
Vector AP-1000 anti-R,  
Lot YO222 
HRP goat anti-human IgG 
antibody (peroxidase) 
Vector PI-3000,  
Lot ZA0709 
Pierce Antibody Goat  Anti-Rabbit 
IgG (H+L) Horseradish Peroxidase 
Pierce Thermo 
Scientific 
Prod #31460,  
Lot OG 1886-49 
Anti-rabbit horseradish peroxidase 
secondary antibody for Wes 
Protein Simple DM-001,  
Lot number 26571 
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Methods Table 3.  Purified Recombinant Proteins, Provider and Catalog number  
Protein Provider Catalog 
Number 
Predicted 
Molecular 
Weight 
(kDa) 
Reference peptide 
sequence 
Purified recombinant protein 
of human glial fibrillary acidic 
protein (GFAP), transcript 
variant 1 
 
OriGene TP304548 49.7 NP_002046 
Purified recombinant protein 
of homo sapiens 
dihydropyrimidinase-like 2 
(DPYSL2)           (CRMP2) 
 
OriGene TP309080 62.1 NP_001377 
Recombinant protein of 
human calreticulin 
(CALR) 
OriGene TP303222 46.4 NP_004334 
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2.2.  Study Subjects 
 The protocol for the use of adult human subjects was reviewed and approved by the 
University of Texas Committee for the Protection of Human Subjects.  All SCI subjects 
enrolled were over 18 years of age and had a traumatic, non-penetrating SCI with a 
neurologic deficit.  Acute SCI subjects were enrolled within 2 days of SCI.  Chronic SCI 
subjects were enrolled at greater than one year post-injury.  Subjects were excluded if they 
had a known medical condition that accounted for neuropathic pain (e.g., diabetic 
neuropathy, renal insufficiency, HIV-associated, ethanol-associated neuropathy) or 
diagnosis of cancer within the previous 5 years.  In addition, chronic SCI subjects were 
excluded if they had a known infection within 30 days of blood sampling. Blood samples 
were obtained after informed consent and were de-identified to provide confidentiality. 
Plasma from healthy volunteers was used as reference controls.  Plasma from these 
groups of patients was used for autoantibody screening, validation and association with 
neuropathic pain studies (Figure 1).  Demographic and clinical data were collected. 
Patients’ neurological levels of injury were classified according to the ISNCSCI Scale.[30] 
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Figure 1.  Flow chart of plasma used for autoantibody screening, validation and association 
with neuropathic pain studies. 
 
 
 
 
 
Flow chart of subjects and samples used for autoantibody screening; T1= Time 1 
(within 2 days after SCI); T2=Time 2 (8-30 days after SCI). 
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A. ISNCSCI 
  
 The ISNCSCI is a standardized method of classifying sensory and motor impairment 
in spinal injury for research and clinical practice.[30]  Subjects enrolled in this study were 
ISNCSCI A-D defined as,  
“A = Complete. No sensory or motor function is preserved in the sacral segments 
S4-S5. 
B = Sensory Incomplete. Sensory but not motor function is preserved below the 
neurological level and includes the sacral segments S4-S5 AND no motor function is 
preserved more than three levels below the motor level on either side of the body. 
C = Motor Incomplete. Motor function is preserved below the neurological level, and 
more than half of key muscle functions below the single neurological level of injury 
have a muscle grade less than 3. 
D = Incomplete. Motor function is preserved below the neurological level, and at 
least half of key muscles below the neurological level have a muscle grade greater 
than or equal to 3.”[30]   
American Spinal Injury Association: International Standards for Neurological Classification of Spinal Cord Injury 
 
 B.  Classification of Neuropathic Pain 
 
 The definition of neuropathic pain was based on the clinical diagnosis and 
documentation of neuropathic pain.  In order for a subject to be classified as having 
neuropathic pain there must have been documentation of pain in the medical record which 
included the descriptor neuropathic.  The IASP has proposed a uniform classification 
system to define pain: nociceptive (musculoskeletal and visceral) and neuropathic (at level 
and below level of injury).[118]  In accordance with the IASP and other recommendations, 
pain documented as “acute pain due to trauma” was not considered neuropathic pain nor 
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was nociceptive pain described as musculoskeletal, visceral or headache considered 
neuropathic.[119] Treatment with gabapentin or pregabalin, commonly used medications for 
neuropathic pain, was used as confirmation of the neuropathic categorization.   All of the 
chronic  and 18 of the acute subjects completed the Leeds assessment of neuropathic 
symptoms and signs (S-LANSS) pain scale and the Short-Form McGill Pain Questionnaire 
as additional validation of their pain classification.[120-122]  The S-LANSS scale has been 
validated against clinical judgement.[121]  These scores were corroborated with the 
clinician’s assessment of pain.  The S-LANSS self-assessment form was administered in a 
standardized manner.  Subjects were instructed to consider their pain within the last week 
and to focus on the most severe pain.  The instrument includes a numeric visual analog 
scale for rating pain intensity and diagram on which the subject indicates where the 
neuropathic pain exists.  Descriptors on the S-LANSS and in the McGill Pain Questionnaire 
include words commonly associated with neuropathic pain (e.g., pins and needles, electric 
shock, burning). The pain onset, duration, aggravating or mitigating factors and whether or 
not the patient had spasticity was also documented.  
 
2.3. Plasma Samples  
 
 For the initial screening for autoantibodies, blood samples were collected in EDTA 
tubes (BD, Franklin Lakes, NJ USA) from 18 adult, acute, traumatic SCI patients at two time 
points: 1) within 2 days of injury (Time 1, T1); and, 2) within 8-30 days of injury (Time 2, 
T2).  A study has demonstrated that IgG titers peaked 14-33 days after brain injury [123], 
therefore, it was anticipated that autoantibodies related to injury would not be present close 
to time of injury and would emerge within the Time 2 period.  Blood cells were removed by 
centrifugation (4°C, 800 X g for 10 minutes), plasma was collected, and platelet-poor 
plasma prepared by centrifugation (4°C, 10,000 X g) for 10 min.  Samples were aliquoted 
and frozen at -80oC until assayed.  
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 To confirm the presence of autoantibodies to a specific CNS protein, plasma was 
collected and processed in the same manner as described above for acute and chronic SCI 
patients and healthy volunteers.  Autoantibody confirmatory studies were performed on 
plasma obtained from 38 adult, acute, traumatic SCI patients at four time points post-injury: 
1.2 ± 0.7, 6.4 ± 1, 16 ± 7 and 96 ± 54 days post-injury. Thirteen of these subjects provided 
the sample at 96 ± 54 days post-SCI.   The 80 chronic SCI subjects (> 1 year post-SCI) and 
20 healthy volunteers provided a one-time blood sample.  
  
2.4. Preparation of Human Cadaver CNS Homogenate  
 It is not possible or humane to obtain CNS tissue samples from individual patients to 
test for IgG reactivity to self-proteins.  For the purpose of this study, human cadaver CNS 
tissue was used as a substitute for the patient’s own tissue and antibodies produced in 
response to this tissue were classified as autoantibodies.   Human cadaver CNS tissue 
samples (from one individual who died from complications of Alzheimer’s disease (AD)) and 
three individuals without confirmed AD were obtained from the UT-Health Willed Body 
Program and were frozen at -80°C until ready for use. The mean time from time of death to 
tissue extraction was 16 hours.  Cadaver tissue was collected from an 1) elderly male with 
a medical history of AD, cluster headaches, and concussion in 1965 after being hit by a car 
while riding a bike. 2) A 75 year old female with possible history of dementia, post-mortem 
interval from time of death until tissue extraction was less than 24hrs. 3) A 75yo male with 
history of cardiac bypass, post-mortem interval was approximately 14 hours until tissue 
procurement; and  4) A 67 year old female with post-mortem interval of 12 hours.  The 
subject appeared to be of low to normal body weight, no medical history was provided. 
  CNS tissue from the four cadavers listed above was used for 1- and 2-
Dimensional (1-D and 2-D) gel studies.  The rationale for use of multiple sources of CNS 
tissue was to assure that anti-mortem factors from any one cadaver and/or post-mortem 
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time did not dictate study results.[124]  For instance, glial cells and specifically, astrocytes 
have been associated with Alzheimer’s disease (AD). [125] Post-translational changes, 
including glycosylation, phosphorylation and increased GFAP expression have been 
reported in the AD brain. [126] Increased CRMP2 phosphorylation is present in the AD 
brain.[127] As the initial cadaver donor had AD, to assure that reactivity to the CNS 
homogenate was not specific to post-translational changes with one specific homogenate 
donor, testing was performed using different donors who did not have AD. Experiments on 
both 1-D and 2-D gels were repeated with brain homogenate from 4 different cadaver 
donors, only one of which had a reported clinical diagnosis of AD.  The latter 3 cadaver 
brains were perfused with PBS prior to CNS tissue procurement.  Cadaver CNS tissue was 
snap frozen in liquid nitrogen which causes rapid, temporary inactivation of all reactions that 
occur in extracted tissue.[128] Neural tissue is sensitive to protein degradation (for instance 
degradation fragments) which could impact CRMP2 or GFAP proteins; however, no 
degradation was seen in post-mortem interval analysis of GFAP.[124, 128]   
 CNS tissue samples were homogenized in a buffer consisting of 
radioimmunoprecipitation assay buffer (RIPA) containing protease (1mM PMSF in DMSO; 
10 µg/ml leupeptin hemisulfate) and phosphatase (1 mM NaF; 0.2 mM Na pyrophosphate, 
100 nM okadaic acid in DMSO).  Protein concentration was estimated using a microBCA 
assay kit (Thermo Scientific) and tested on western blot as described below. Results from 
samples from spine tissue were replicated in brain tissue.  Because brain tissue was more 
accessible the western blot experiments discussed below were conducted using brain 
tissue homogenates (total human CNS protein).   
 
2.5. Protein quantitation  
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 A microBCA assay kit (Thermo Scientific) was used to quantify protein 
concentrations in CNS protein/brain homogenate samples.  Bicinchoninic acid (BCA) was 
used as the detection reagent of Cu++.  Cu++ is formed when Cu2+ is reduced by protein 
in an alkaline setting.  A standard curve with 6 serial dilutions was made in duplicate using 
bovine serum albumin (BSA).  Two hundred microliters of the protein assay mix of reagents 
MA, MB, MC (combined in the ratio of 25:24:1) were applied to each well.  Standards, plain 
buffer, and unknowns were applied to a 96 well plate and allowed to incubate for 45 
minutes.  The results were read on a plate reader at 562nm.   Secondary measurements 
were made with a Beckman coulter spectrophotometer set at 280nm wavelength.   
   
2.6. Western Blot   
 Preliminary western blot studies were performed on a subset of plasma samples.  
Precision plus protein standards (BioRad) were used as molecular weight standard 
markers. Total human CNS protein (10 µg) was resolved on 4-12% gradient sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gels (Novex, Life 
Technologies, USA) and transferred to Immobilon-P membrane (Millipore).  Membranes 
were blocked overnight at 4°C in a Tris-buffered saline solution containing 1% Tween-20 
(TBST), 5% bovine serum albumin (BSA) and 1%milk. Blots were incubated for one hour at 
room temperature in primary antibody (human plasma (1:1000) or rabbit anti-GFAP 
(1:6000) or rabbit anti-CRMP2 (1:1000)) that was diluted in a 5%BSA, 1%milk solution 
(1:6000), washed with TBST, incubated for one hour at room temperature in secondary 
antibody (anti-human or anti-rabbit alkaline phosphatase antibody 1:20,000 (Vector) as 
appropriate in TBST containing 2%BSA and 1%milk), and again washed in TBST.  
Membranes were developed with CDP-Star Reagent for alkaline phosphatase (BioLabs, 
Ipswich, MA).   
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 Membranes were tested with and without primary antibody to distinguish between 
the primary and secondary antibodies immunoreactivity.  Plasma samples from subjects 
that were determined to be positive or negative on the initial western blot screening were 
re-screened to confirm immunoreactivity patterns using both CNS homogenate and purified 
human recombinant GFAP (GFAP, OriGene TP304548) or purified human recombinant 
CRMP2 (CRMP2, OriGene TP309080).  A custom-made anti-GFAP antibody or a 
commercial anti-CRMP2 antibody was used as a positive control.    
  
2.7. 2-Dimensional gel Electrophoresis  
 The first sets of 2-D gels were performed with Immobiline DryStrip gels, pH 3-
11(immobilized pH gradient, IPG) (GE Healthcare Life Sciences, Pittsburgh, PA).  For the 
first dimension of the gel the IPG gels were rehydrated overnight. Enough CNS protein 
sample was prepared for 135 µl per IPG gel.  This consisted of 50µl of 4µg/ul (200µg) CNS 
homogenate, 80µl Destreak buffer (GE Healthcare Life Sciences; containing urea, 
thiorurea, CHAPS and Destreak reagent), and 1.3µl (1%) ampholytes.  Each of 4 lanes of 
the gel hydration chamber was loaded with 125µl of CNS protein in buffer. The IPG strip 
was carefully placed on top of the sample assuring to keep the sample under the strip and 
avoid trapping any air. About 3ml of mineral oil cover fluid was applied on top of the IPG 
and assuring to place cover fluid at each end of the IPG to keep the sample under the gel. 
Then the IPG gels and samples were covered and allowed to rehydrate at room 
temperature overnight (Figure 2A).   
 The IPG gels were rinsed with deionized water and placed in the IEF chambers and 
covered with oil, again allowing no air bubbles.  The IEF chambers containing the IPG gels 
were positioned so that the positive end (acidic) of the IPG strip was placed toward the 
anodic electrode (+) and the negative end of the strip was placed toward the cathodic 
electrode (-) (Figure 2B). The top was placed on the Ettan IPGphor II machine and a step 
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gradient step protocol was run (1: 300v for 1hr, 300vhr at 15°C; 2: 1000v for 0:46hr, 500vhr; 
3: 1000v for 0:30 hr, 500vhr; 4: 5000v for 1 hr; 5: 500 v for 1 hr; 6 100v for 11 hr, 1100vhr) 
(Figure 2C).  Starting with a low voltage reduces protein aggregation. During the isoelectric 
focusing the blue dye migrates toward the anode, Figure 2D shows the dye has cleared.   
 Once the step gradient protocol was completed, the IPG strips were rinsed briefly in 
deionized water and placed in 15ml conical tubes containing equilibration buffer (6M urea, 
30% glycerol, 2%SDS, 1M Tris(pH6.8), 65mM DTT, and bromophenol blue as a tracking 
dye) with the first tube including DTT reagent (0.14g/14ml) as a reducing agent for 30 
minutes on a rocker followed by a second tube with lodoacetamide 2.5% (0.35g/14ml 
equilibration buffer) to fix and equilibrate the sample (30 min on a rocker). Following this the 
IPG gel was placed in the sample well on an 8% acrylamide gel (with the positive end/low 
pI proteins on the side near the molecular weight markers). The second dimension 
separation was performed with NuPAGE MES SDS running buffer and MES SDS (Figure 
2E).  
 Two gels were placed in GelCode Blue for 1-8 hours then stored in 10% acetic acid.  
Two gels were transferred to Immobilon-P membranes using NuPage transfer buffer with 
15% methanol. Transfer was started at 30V then run for 90 minutes at 150mAmps.  After 
transfer membranes were blocked with 5% BSA and 1% milk for 12 hours on a rocker.   
Membranes were then incubated with purified IgG from Time 1 (T1) or Time 2 (T2) plasma 
in 5%BSA, 1% milk (1:500) for 3 hours. After rinsing in TBST (5 times), membranes were 
incubated for 1hr in alkaline phosphatase secondary antibody in 2% BSA, 1% milk 
(1:20,000).  Membranes were rinsed again and placed in CDP-Star reagent buffer and 
developed.  The film was marked to assure proper alignment of the membrane-generated 
spots with spots on the GelCode blue stained gel.  New spots found in T2 were identified 
and extracted from the corresponding gel for protein identification.    
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Figure 2.  2-Dimensional Gel Electrophoresis  
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2.8. Large Scale 2-Dimension Gel Electrophoresis 
 Large scale 2-D gels (20 x 22 cm) were used in order to spread out immunoreactive 
spots and improve the precision of spot selection for protein identification using liquid 
chromatography-mass spectrometry (LC-MS/MS).  Large scale 2-D gels were prepared in 
duplicate, one for Coomassie staining and one for western analysis according to a protocol 
provided by Kendrick Laboratories (Madison, WI). [129, 130] Brain homogenate containing 
phosphatase and protease inhibitors and SDS boiling buffer was treated with Omnicleave 
and heated in a boiling water bath for 5 minutes.  Protein concentration was ascertained 
using the BCA Assay. Two-dimensional electrophoresis was performed using the carrier 
ampholine method of isoelectric focusing. [129, 130] Brain sample (250µg) was loaded on 
the first dimension gel.   Each sample included an internal standard (tropomyosin (33,000)) 
and molecular weight markers (myosin (220,000), phosphorylase A (94,000), catalase 
(60,000), actin (43,000), carbonic anhydrase (29,000), and lysozyme (14,000) (Sigma 
Chemical Co., St. Louis, MO and EMD Millipore, Billerica, MA) as reference points for 
orientation for later spot identification on the Coomassie stained 10% acrylamide gels 
(second dimension gel).  SDS second dimension gel electrophoresis was carried out for 5 
hours at 25 mA/gel. Duplicate gels were then transferred onto PVDF membranes using the 
same molecular marker proteins as reference points.  
 To identify cross-reacting self-antigens, sections from two Coomassie-stained sister 
2-D membranes between approximately 30-75 kDa were cut and imaged. Then the 
membranes were blocked, and probed with T1 or T2 plasma from samples found to 
produce new immunoreactivity using T2 plasma on screening western blots.  Concentrating 
on the 30-75 kDa section of the 2-D membrane allowed conservation of precious plasma 
sample.  Protein spots on the 2-D T2 membrane with new or enhanced immunoreactivity 
were identified.  The scanned membrane images, tropomyosin marker and standards were 
used as guides, and calipers were used to measure the precise locations of areas of 
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enhanced T2 membrane immunoreactivity.  Clear transparency film was placed on top of 
the membrane and the Coomassie-stained companion gel.  The spots were marked on the 
membrane transparency and this was matched to the gel and identified spots were circled 
and numbered. Prior to excising spots, the locations were validated with the caliper 
measurements.  A photograph was taken of the numbered spots.  The gel was wiped with 
100% methanol and the spots were carefully cut out around the edges using a sharp, fresh 
scalpel.  Samples were speared with the tip of the scalpel and placed in sterile Eppendorph 
tubes and capped immediately.  Next 200µl of ultrapure water per spot was added to the 
Eppendorph tubes.  This was allowed to sit for 20 minutes prior to vortexing.  The vortexing 
removed the plastic film from the gel.  The water was aspirated and the gel was moved to a 
fresh Eppendorph tube labeled with the spot number. These spots were sent for LC-MS/MS 
identification.      
 
2.9. LC-MS/MS and protein identification 
 LC-MS/MS was performed by the Darie Laboratory at Clarkson University according 
to published protocols.[131, 132]  In brief, gel spots were washed rehydrated and trypsin 
digested.  The peptide mixture was analyzed by reversed phase liquid chromatography 
(LC) and MS (LC-MS/MS) using a NanoAcuity UPLC (Micromass/Waters, Milford, MA) 
coupled to a Q-TOF Ultima API MS (Micromass/Waters, Milford, MA), as previously 
described.[131-135] A Mascot and PLGS database search provided a list of proteins for 
each gel spot. The MS/MS spectra for the proteins identified by either one peptide or a 
Mascot score lower than 25 were verified to eliminate false positives. 
 
2.10. Statistical analysis 
 Statistical analysis was performed using SigmaPlot 11.0 (Systat Software, Inc.).   
Descriptive data for subject groups was summarized as means and standard deviations 
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(SD).  Data was tested for normality using the Kolmogoroff-Smirnov test.  For data that did 
not pass the normality test, the Mann-Whitney Rank-Sum Test was used and the data are 
presented as medians ± SE.  Kruskal-Wallis One Way Repeated Measures ANOVA 
followed by Dunn’s Method for multiple comparisons was used when comparing the three 
time points for acute SCI data. Spearman Rank Order Correlation was used to assess for 
correlation between the continuous non-parametric GFAPab immunoreactivity or CRMP2ab 
immunoreactivity and plasma complement C3 and C5 levels.  Two Way Repeated 
Measures ANOVA followed by Holm-Sidak method for all pairwise multiple comparison was 
used for comparing the C3 and C5 levels over time by pain group. Chi-square test was 
performed to determine the relationship between the presence of multiple autoantibodies 
and the development of neuropathic pain.  Multiple logistic regression was performed to 
assess the relationship between the presence of multiple autoantibodies and neuropathic 
pain while controlling for other variables.  Significance was defined as p < 0.05.  
 
2.11. Method to Screen for autoantibody detection 
Figure 3.  Flow chart of methods for autoantibody detection 
 
 
 A. Patient samples used for autoantibody screening. 
 Patients were enrolled prospectively and classified according to their level of injury 
and presence or absence of neuropathic pain (pain group).  The first autoantibody 
screening experiments (Figure 3) performed were on the first consecutive 18 acute SCI 
subjects enrolled to determine whether new immunoreactivity could be identified 
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subsequent to SCI (Table 4). It is not possible to collect patient spinal cord tissue, nor is it 
possible to test pre-injury samples from human SCI subjects to establish a baseline.  
Therefore, a baseline sample <48 hours following injury (T1) served as the comparator to a 
sample obtained 8-30 days post-injury (T2).  Demographics on these acute SCI subjects 
are presented in Table 4.   Subjects were primarily male (94%) with an average age of 
38.1±14.6 years, 78% had complete or sensory incomplete injury (ISNCSCI A or B) and 
78% were cervical neurological level injuries.   
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Table 4. Demographics of Subjects Used in Screening Studies. 
Subject No. 
(n=18) 
Age Gender Mechanism of Injury ISNCSCI Neurological 
Level of 
Injury 
1 61 Male Bicycle A C4 
2 37 Male Motor vehicle collision A T3 
3 37 Male Fall C T12 
4 26 Male Fall C C5 
5 20 Male Motor vehicle collision A T6 
6 36 Female Motor vehicle collision A C4 
7 18 Male Motor vehicle collision A C7 
8 57 Male Motor vehicle collision A C5 
9 69 Male Fall C C5 
10 39 Male Bicycle A C4  
11 26 Male Diving A C6 
12 21 Male Motor vehicle collision B T9 
13 30 Male Motor vehicle collision A C5 
14 52 Male Assault A C4 
15 35 Male Car fell on his neck C C2 
16 48 Male Motor vehicle collision A C3 
17 30 Male Motor vehicle collision B C5 
18 44 Male Motor vehicle collision A C4 
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B.  Western blots for autoantibody screening  
 Western blots for autoantibody screening were performed as described in Chapter 
2.7. Total CNS protein homogenate (10 µg) was separated on 4-12% SDS-PAGE gels and 
transferred to Immobilon-P membranes.  Western blots were performed on samples from 
18 subjects at T1 and T2 to identify new immunoreactivity at T2 that was not present in T1. 
These results of these western blots were dichotomized as positive or negative for new 
immunoreactivity based on visual inspection.  Additionally, similarities in molecular weight 
of new immunoreactive bands between different patients’ T2 plasma samples were 
assessed.  A pattern of new immunoreactive bands ranging in size between 35-50kDa was 
found in 4/18 (22%) subjects (Figure 4).[136]  
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Figure 4.  Representative western blot probed with human SCI patients’ plasma obtained at 
T1 and T2. 
 
   
 
 
 
 
 
  
Figure 4.  Representative western blot probed with human SCI patients’ plasma 
obtained at T1 and T2.  The protein source for the gel was human cadaver 
CNS homogenate. To reduce IgG contribution from the donor cadaver, the 
cadaver was perfused with PBS prior to tissue extraction. A) a subject without 
change in immunoreactivity between T1 and T2, B) a subject with increased 
immunoreactivity between 35-50kDa at T2 compared to T1, and C) 
immunoreactive patterns resulting from IgG present in the cadaver 
homogenate, present when no primary was used.  Bands at 50 and 25kDa are 
heavy chain (hc) and light chain (lc) immunoglobulin G (IgG).  The new 
immunoreactivity between 35-50kDa was present in 4 of 18 subjects tested. 
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2.12 Method to identify antigens for autoantibodies  
 
 
Figure 5.  Flow diagram of experiments conducted to identify target antigens 
 
 
 
 Multiple techniques were tried to isolate the protein antigen.  For instance, IgG 
purification was performed and affinity columns were created using recombinant protein A 
to covalently crosslink the antibody in the plasma sample.  CNS homogenate was 
incubated in the column and glycine elution was performed (Appendix).  The amount of 
antigen eluted from the column was found to be insufficient and, therefore, a new approach, 
2-D gel electrophoresis was tested (Figure 5). 
  
 A. 2-D gels electrophoresis to separate human cadaver CNS protein  
 2-D gel electrophoresis as described in section 2.7 was used to separate human 
cadaver CNS protein homogenate by isoelectric focusing and molecular weight. 2-D gels 
were run in duplicate, one for each western blotting and Coomassie staining.  Membranes 
from the 2-D gels were probed with T1 or T2 SCI subject plasma known positive for new 
immunoreactivity at T2. This was repeated using 3 different cadaver donors and two 
different SCI subjects’ plasma.  New or enhanced immunoreactivity was found at T2 in the 
area between 35-70kDa. (Figure 6). 
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Figure 6. 2-D Gel with human CNS protein and membranes probed with SCI patients’ 
plasma 
 
 
 
 
  
 
 
 
  
Figure 6.  2-D gel electrophoresis was used to separate human cadaver CNS homogenate by 
isoelectric point (pI) and molecular weight. A) GelCode Blue stained gel showing spots which 
are proteins that have been separated by pI and molecular weight.  B and C) Membranes 
derived from a corresponding 2-D gels; B was probed with T1 SCI patient plasma, C was 
probed with T2 SCI patient plasma.  This SCI subject was known to be positive for new 
immunoreactivity in the 37-50kDa range at T2.  New immunoreactivity can be seen in 
membrane C (arrows). 
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 B.  Excision of protein spots from 2-D gels 
 
 Protein spots of interest were identified using 2-D gels and western blot analysis 
and excised as described in Methods 2.8.  Large 2-D gels and corresponding membranes 
were prepared in order to further separate the spots.  Numerous membranes were probed 
with two SCI patients’ T1 and T2 plasma.  Areas of enhanced immunoreactivity at T2 were 
identified.  Spots showing new immunoreactivity were carefully excised from the 
corresponding Coomassie-stained 2-D gels and prepared for analysis by LC-MS/MS. An 
example of membranes from a SCI subject’s T1 and T2 plasma and locations of spots 
excised from the Coomassie-stained 2-D gel is shown in Figure 7.  
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Figure 7. Large scale 2-D membranes and Coomassie stained gel showing spots 
selected for LC-MS/MS. 
     
 
 
 
 
 
 
  
Figure 7. Large scale 2-D membranes and Coomassie stained gel showing spots selected 
for LC-MS/MS. 
2-D gel membranes probed with T1 (A) and T2 (B) patient plasma showing enhanced 
immunoreactivity at T2 compared to T1 from one of the four patients that previously 
demonstrated increased immunoreactivity at T2 on 1-D gel membranes.  Spots circled in 
blue were identified for sequencing.  They were located and cut out of the corresponding 
Coomassie stained gel (C) and sent for identification by LC-MS/MS.   Glial fibrillary acidic 
protein (GFAP) and collapsin response mediator protein 2 (CRMP2) were the predominant 
proteins identified. 
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C.  LC-MS/MS protein identification 
 
 Excised proteins were subjected to LC-MS/MS and identified as described in 
Chapter 2.9. 
 Dihydropyrimidinase-related protein 2 isoform 2 also known as collapsin response 
mediator protein 2 (CRMP2) and glial fibrillary acidic protein (GFAP) and were the most 
commonly identified proteins on the spots analyzed.  CRMP2 was found in 11 spots and 
GFAP was found in 7 spots when probed with different SCI patients’ plasma.  The mass 
spectrometry results for these proteins are presented in Table 5. The Mascot score 
provided in Table 5 column three is the calculated probability (P) that the peptide match 
between the experimental data and the database sequence is a random event (reported as 
-10Log(P)). Peptides found above a pre-defined significance threshold are separated from 
random scores.  Generally, a higher Mascot Score is a higher probability of a correct match; 
the score is separated out from the distribution of random scores indicating the match is not 
a random event. All of the reported identified peptides have matches above the significance 
threshold. As noted in section 2.9, Mascot scores lower than 25 were verified to eliminate 
false positives. Of 22 spots evaluated there were 886 unique peptides mapped; 490/886 
(55%) and 175/886 (19.8%) showed peptides that mapped to CRMP2 or GFAP 
respectively.  The remaining peptides may have resulted from contamination of nearby 
proteins or they could be additional candidates.  For example, a minority of peptides that 
mapped to β-actin were present in two spots.  However, when the blot was re-probed with 
antibodies specific to β-actin, the immunoreactive signal did not co-localize with the location 
of these spots, but rather an abundant adjacent spot. Multiple GFAP isoforms and their 
post-translational modifications and have been shown in a staircase-like pattern in brain 
tissue similar to what is found on the 2-D gels.[126, 137] CRMP2 protein and post-
translational modifications have also been seen with multiple spots in other studies as 
CRMP2 is a highly phosphorylated protein.[138]  
44 
 
 
Table 5. LC-MS/MS Findings  
Number of 
Spots 
identified 
    Protein Identified Ranges 
of 
Mascot 
Scores 
Range of 
Number of 
unique 
peptides  
found per spot 
NCBI Accession 
Number (gi 
number GenInfo 
Identifier) 
11 dihydropyrimidinase-related 
protein 2 isoform 2  
[Homo sapiens] 
 
50 - 1005 9-109 giǀ4503377 
7 glial fibrillary acidic protein 
isoform 1 [Homo sapiens] 
 
142-1362 8-41 giǀ4503979 
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Chapter 3.  Human SCI increases autoantibodies to 
CRMP2  
3.1. Introduction  
A.  Collapsin Response Mediator Protein 2 (CRMP2) 
 
 The cytosolic protein collapsin response mediator protein 2 (CRMP2) is also known 
as dihydropyrimidinase-related protein 2 (DPYSL2, DRP-2) or turned-on-after-division-64 
(TOAD-64).[139]  CRMP2 is a member of the CRMP family of phosphoproteins. All of the 
CRMPs (1, 2, 3, 4 and 5) are highly expressed in development with CRMP2 being the most 
abundant CRMP at maturity.[139] In adults CRMP2 is expressed in neurons and 
oligodendrocytes in the spinal cord and brain, and it has also been found in monocytes and 
lymphocytes.[138, 140] CRMP2 has multiple known binding partners with which it affects 
neurite growth, polarity, guidance, neurotransmitter release and calcium balance.[139]  
CRMP2 activity is regulated through kinase-induced phosphorylation.  CRMP2’s 
phosphorylation by cyclin-dependent kinase 5 (Cdk5) and glycogen synthase kinase-3β 
(GSK3β) is necessary for the semaphorin 3A (sema3A)-induced growth cone collapse 
which operates through microtubule reorganization or destabilization.[141, 142]  
 Along with sema3A, CRMP2 participates in axon guidance exerting an inhibitor role. 
Sema3A is an axonal growth inhibitor which is expressed in fibroblasts and glia in the glial 
scar 1 day to 4 weeks after SCI.[143]  Kaneko et al. used a specific sema3A inhibitor 
derived from fungus (SM-216289) in spinally transected rats to determine whether 
neutralizing sema3A permits axon regrowth after SCI.  SM-216289 inhibits growth cone 
collapse and supports neurite lengthening.[143]  The sema3A inhibitor was delivered to 
rats via an osmotic mini-pump for 4 weeks after transection.  More axonal regeneration 
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within the lesion site in the sema3A inhibitor treated rats was observed compared to control 
rats; some of these regenerated axons were from Schwann cells (PNS) that had migrated.  
Calcitonin gene related peptide (CGRP)-positive fibers were increased in the sema3A 
inhibited group compared to vehicle control group which was interpreted as sprouting of 
unmyelinated C fibers which are associated with pain.  However, no allodynia was reported 
in these rats.[143] The effect of sema3A inhibition resulted in sprouting.   
 A separate study utilized a CRMP2-specific binding drug, Lanthionine ketamine 
(100mg/kg/d IP for 4 weeks) in a thoracic 7 level SCI incomplete transection mouse model.  
Fibrous scar tissue was measured by immunohistochemistry of Collagen IV fibrous tissue 
within the glial scar and axonal sprouting was detected using 5-HT.  Lanthionine ketamine 
treated SCI mice had smaller areas of fibrous scar tissue and more axonal sprouting in the 
serotoninergic raphespinal tract than vehicle treated SCI mice.[144] The intent of both the 
sema3A inhibitor study and the Lanthionine ketamine study was to promote axonal 
regeneration through the glial scar; however CRMP2 and sema3A’s effect glial scar 
formation, axon extension and axon guidance was also demonstrated.  The glial scar is 
thought to be important for containing the injury site acutely after SCI and protecting intact 
tissue from damage.  (Please see section 4.1.A for additional discussion on the glial scar.)  
 CRMP2 promotes neurite growth and modification of cell structure through 
interactions with tubulin, actin and neurofilaments.[139, 145]    CRMP2 expression was co-
localized with cytoskeletal protein βIII-tubulin in the white matter and marginal layer of the 
spinal cord in a study of developing chick spinal cords demonstrating CRMP2’s 
involvement in axon elongation and cytoskeletal structure modification.[141] The 
expression patterns of CRMP2 on transverse sections of chick spinal cords were 
compared at developmental stages permissive for regeneration (E11) and non-permissive 
for regeneration (E15) in SCI crush injured versus sham operated chick spinal cords.  After 
injury there was a change in CRMP2 expression from white matter to gray matter, but there 
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was not a difference in level of CRMP2 protein expression.[141]  The CRMP2 redistribution 
demonstrated CRMP2 movement from axons to the cell body as a response to injury.  
  Cell culture studies of human T cells identified CRMP2 in T cells and determined 
that CRMP2 is involved with T cell migration and conformational changes.[140] In order for 
T cells to migrate they must first become polarized. During T cell polarization CRMP2 
relocates to the trailing edge (uropod) of T cells with vimentin (an intermediate filament 
protein) where it is involved in motility through adhesive functions and cytoskeletal 
rearrangement.[140] Semaphorins are involved in lymphocyte migration by steering and 
facilitating or impeding cell motility.[140] CRMP2 is downstream of sema3A and transduces 
sema3A guidance signals in addition to CRMP2’s participation in cell migration.[140]  
CRMP2 presence in the uropod depends on the activated status of the T cell. The 
presence of CRMP2 is important in directing T cells to the injury site. For example, blood 
from patients who were infected with retrovirus HTLV-1 associated with neuroinflammation 
had higher CRMP2 levels in activated T cells compared to healthy donor blood or HTLV-1 
infected asymptomatic carriers.[140] Flow cytometry analysis of the HTLV-1 patients’ 
peripheral blood mononuclear cells (PBMC) identified CRMP2 in CD4+ and CD8+ T cells 
and CD14+ monocytes/macrophages.[140]   
 CRMP2 phosphorylation is increased after SCI and increased phosphorylation of 
CRMP2 has been associated with poorer outcome.[141, 146] Chondroitin sulfate 
proteoglycans (CSPG) are also increased after SCI and CSPG inhibits axonal growth 
through GSK3β activation.[147]  Inhibition of CRMP2 phosphorylation reduces CSPG-
induced inhibition of axonal growth, improves microtubule stabilization and increases 
sensitivity to brain derived neurotrophic factor (BDNF).[146] BDNF is supportive of axonal 
growth.  Nagai et al., using a near-complete dorsal transection SCI mouse model, 
observed an increase in pCRMP2T509 (CRMP2 phosphorylation site of GSK3β) after SCI 
in CRMP2+/+ mice, but CRMP2 protein expression had not changed. Phosphorylation at 
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T509 was inhibited in CRMP2KI/KI mice. The SCI CRMP2KI/KI mice had better locomotor 
recovery, regained nociceptive function and increased growth-associated protein 43 
(GAP43) protein levels at the lesion site compared to CRMP2+/+ mice related to the 
CRMP2 phosphorylation inhibition provided by the knock-in model.[146]  Dorsal horn 
CGRP-positive (nociceptive) and 5-HT-positive (locomotor circuitry) fibers were present at 
an increased density in CRMP2KI/KI mice and the inhibition of the phosphorylation of 
CRMP2 in these mice also resulted in less immunoreactivity to GFAP (suggesting a 
reduced inflammatory response) and a more compact glial scar.[146] These studies 
illustrate that CRMP2 and its phosphorylation impacts axon sprouting, the glial scar and 
inflammatory responses[146].  
 
 B. CRMP2 and neuropathic pain 
  Aberrant nociceptive fiber sprouting could lead to neuropathic pain.[148-150]  
Nerve growth factor (NGF) enhances nociception and induces axonal elongation and 
sprouting.[145, 151] A study that used dissociated sensory neurons from chick dorsal root 
ganglia demonstrated that neutralizing CRMP2 potentiated NGF-induced neurite 
outgrowth.[145] Investigators neutralized CRMP2 activity with anti-CRMP2, or with a 
dominant-negative form of CRMP2, in the presence of NGF which resulted in more DRG 
with neurites and lengthened neurites.[145] Additionally, CRMP2 antibodies triturated into 
DRG neurons blocked sema3A-induced growth cone collapse suggesting that CRMP2 is 
involved as a negative regulator of NGF-induced neurite growth.[145] Through inhibition of 
CRMP2, sprouting was induced; CRMP2 functionally inhibits sprouting.   
 NGF mRNA expression in adult rat spinal cord was shown to be elevated up to 4 
days after injury indicating conditions for NGF-induced neurite growth after SCI.[152]  
CGRP immunoreactivity (nociceptive) is shown to increase in deeper lamina III and IV in 
spinally hemi-sectioned rats; however the administration of anti-NGF in this model reduced 
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CGRP expression in lamina I and II and prevented projection of CGRP into lamina III and 
IV suggesting anti-NGF inhibited sprouting of primary pain afferents.[151]     
 These studies support the possibility that after SCI an autoantibody to CRMP2 could 
contribute to blocking sema3A-induced growth cone collapse and/or increase the number 
of cells with neurites and the length of neurites in the DRG. These neurites, that would 
normally extend only to lamina I and II, in the presence of autoantibody to CRMP2 may 
project into deeper lamina. This sprouting of sensory neurons into deeper lamina related to 
the presence of an autoantibody to CRMP2 could lead to neuropathic pain.[150] 
 CRMP2 is a regulator of N-type voltage-gated calcium channel activity. The binding 
of CRMP2 to N-type voltage-gated calcium channels in a Cdk5-phosphorylation dependent 
manner amplifies calcium currents and increases neurotransmitter release in sensory 
neurons.[146, 153]   Inhibition of this interaction or inhibition of the phosphorylation of 
CRMP2 reduces transmission of pain signals, possibly because of CRMP2’s regulation of 
voltage-gated channels.[154] However, it is possible that an autoantibody to CRMP2 could 
interfere with the CRMP2-N-type voltage gated calcium channel regulation balance.  The 
abnormal calcium influx into N-type voltage-gated calcium channels has been suggested to 
be related to neuronal excitability and pain.[154]   
 The hypothesis is that an autoantibody to CRMP2 contributes to the development of 
neuropathic pain.  The potential for a relationship between the development of neuropathic 
pain and the presence of CRMP2ab in SCI patient plasma may result in clinically important 
findings.  Therefore, correlative experiments with human plasma samples were performed 
to validate findings of CRMP2 as a potential antigen for the production of autoantibodies 
involved in the development of neuropathic pain.   
 
3.2. Methods. 
 
A. Fluorescent western blots on 2-D gel membranes    
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 Fluorescent western blotting was performed to determine whether there are 
overlapping areas of immunoreactivity produced by T2 SCI patient plasma and a 
commercial anti-CRMP2 on 2-D gel membranes. A section of a 2-D gel membrane at the 
same molecular weight and isoelectric point range that was used to identify CRMP2 as a 
potential antigen was selected.  This membrane was probed with T2 SCI plasma and a 
commercial anti-CRMP2 antibody.  Some overlapping immunoreactivity between the patient 
plasma and anti-CRMP2 was expected if CRMP2 is a valid antigen.   
 The membrane was cut and scanned, wet with methanol, destained and blocked (in 
filtered PBST with 5%BSA, 1% milk) for 2 hours.  The membrane was incubated overnight 
on a rocker at 4°C in plasma T2 primary (1:500 in filtered PBST with 5% BSA, 1% milk).  
The membrane was then incubated in anti-CRMP2 raised in rabbit (1:1000, in filtered PBST 
with 5%BSA, 1% milk) for 8 hours.  After washing in PBST the membrane was incubated 
with Alexa Fluor 488 (green) goat-anti-human IgG secondary (1:500) and Alexa Fluor 568 
(red) goat-anti-rabbit IgG secondary (1:500) for 1 hour.  This was followed by washing.  To 
read the fluorescent signal, the membrane was placed protein side down on the Typhoon 
Trio scanner.  The emission settings used for 50um scans were 5265P Fluor Cy Alexa 
Fluor, 488, PMT 375 and 610 BP30 green, 532, deep purple spyro ruby, PMT 375.   
  
B.  SCI plasma immunoreactivity to purified recombinant CRMP2 
 Western blots were performed as described in Chapter 2.7 to validate plasma 
immunoreactivity to CRMP2.  SCI patient plasma samples known to be positive at T2 for 
the presence of autoantibodies found in the initial screening western blots were used to 
probe purified recombinant protein of human CRMP2.  In this experiment 8% acrylamide 
gels were used in order to increase the separation of proteins between 37-75kDa.  Purified 
recombinant CRMP2 (0.25µg/well) was used as the antigen that was probed with patient T2 
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plasma (1:500) or anti-CRMP2 (1:1000) followed by alkaline phosphatase secondary 
(1:50,000) and developed with West Pico.   
 
C.  CRMP2 immunodepletion of brain homogenate. 
Figure 8. Flow chart of Immunodepletion of brain homogenate.  
 
 
 The goal of the immunodepletion was to have CRMP2-poor brain homogenate to 
use for western blot (Figure 8). Protein A agarose resin (Pierce) was used to remove the 
CRMP2 from brain tissue homogenate. The IgG from the brain tissue was depleted first to 
assure that donor brain tissue IgG was not contributing to immunoreactivity. 50µl of Protein 
A agarose resin was centrifuged, washed with 1ml PBST and centrifuged again to remove 
the 1ml wash.  Brain supernatant (0.7µg/ul protein per microBCA) was added to 25µl resin 
beads.  A second aliquot of 25µl resin beads was combined with 25µl anti-CRMP2 plus 
261µl of 2%BSA in PBST to bring samples to an equivalent volume.  Both were allowed to 
incubate overnight in the cold room on an agitator.  After incubation these samples were 
centrifuged for 5 min at 500Xg, and each of the supernatants were divided in half.  The 
CRMP2 beads were washed twice in 1ml PBST.  Half of the IgG-depleted brain supernatant 
was combined with the anti-CRMP2 beads to deplete the CRMP2 from this sample. The 
supernatant and beads were allowed to incubate for 8 hours.  Dot blots with anti-CRMP2 
were used to confirm depletion of CRMP2 from the sample.   
 The IgG-depleted brain or the CRMP2-depleted brain supernatants (5µg 
protein/well) were run on an 8% acrylamide gel and proteins were transferred to an 
immobilon-P membrane.  The membrane was probed with patient T2 plasma (1:500) or 
anti-CRMP2 (1:1000) followed by alkaline phosphatase secondary (1:50,000) and 
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developed with West Pico.   These Western blots were run to determine whether the 
immunoreactivity produced by patient plasma that was shown to be immunoreactive to 
purified CRMP2 decreased when probing the CRMP2-depleted brain sample.   
 
D. Capillary electrophoresis–immunoassay   
 After identifying patient plasma samples containing anti-CRMP2 immunoreactivity 
using western blots, the specificity of immunoreactivity was verified using a commercial 
anti-CRMP2 antibody and purified recombinant human CRMP2 protein with a capillary-
electrophoresis immunoassay.  All subject samples were then tested on this capillary-
electrophoresis immunoassay. Purified recombinant protein CRMP2 (36ng/µl) was 
denatured with SDS-containing buffers and florescent standards and subsequently loaded 
into capillaries for separation by size.  Ultraviolet light was used to immobilize the proteins 
to the capillary wall where they were probed with plasma primary (1:100) and anti-human 
HRP secondary 1:500 (Vector).  Separation was run for 25 minutes at 375 volts, antibody 
diluent incubation time was 5 minutes, primary antibody incubation time was 30 minutes, 
secondary antibody incubation time was 30 minutes and detection used multi-image 
analysis of 5 exposures (1, 2, 5, 15 and 30 seconds). Chemiluminescence (produced by 
luminol and peroxide) was acquired by a charge-coupled device camera and the image was 
measured and peaks were detected by the system software (Compass for SW, 
ProteinSimple, V3.0.9). System parameters were set with a peak threshold of 10, width of 9 
and a Gaussian fit for area calculation.  Each assay included positive control capillaries of 
the commercial anti-CRMP2 antibody (1:1000) and an anti-rabbit secondary, a negative 
control of no primary antibody (antibody diluent only), and a known positive human plasma 
sample (identified through 1-D and 2-D gel testing).  All time points for an individual subject 
were assayed by capillary electrophoresis -immunoassay on the same capillary array to 
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minimize between-assay variability for a subject.  All immunoassays were performed on the 
same instrument. 
 The area under the curve (AUC) and the signal to noise ratio (S/N) were calculated 
with the assay software (Compass for SW, ProteinSimple, V3.0.9). Existence of a curve 
was confirmed by visual inspection. The measurements of AUC, in arbitrary units, were 
used for comparison between groups. 
 
E. Determination of specificity of autoantibodies   
 To verify antigen-binding specificity, competition studies were performed on the 
diluted plasma (1:100) samples that were analyzed for reactivity to CRMP2 protein using 
the capillary electrophoresis-immunoassay.  Plasma samples were incubated overnight at 
4°C either with 360ng purified CRMP2 protein/10µl of plasma or a competing protein of a 
similar molecular weight that contained the same tag (Myc-DDK) used for purification (glial 
fibrillary acidic protein, GFAP or calreticulin, CALR) of an equimolar amount.  
Immunoreactive signals to CRMP2 obtained with the pre-absorbed samples (CRMP2, 
GFAP or CALR) were compared to immunoreactive samples from the plasma sample that 
was not pre-absorbed.  Anti-CRMP2-specific immunoreactivity should be diminished if there 
is cross-reactivity with the CRMP2-pre-absorbed sample.  Immunoreactivity from samples 
deemed anti-CRMP2-specific had to have a decrease in AUC.  Immunoreactivity that had a 
similar decrease when pre-absorbed with GFAP and/or CALR was deemed non-specific.  
The presence of plasma anti-CRMP2 (CRMP2ab) was considered positive if 1) the AUC 
was above the level of background noise and 2) the AUC decreased greater than 30% 
when pre-absorbed with the CRMP2 protein, but not the pre-absorbed competing 
protein(s).  
 BLAST (National Center for Biotechnology Information, U.S. National Library of 
Medicine) searches for homology between CRMP2 and GFAP or CALR were performed. 
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The BLAST search for CRMP2 and GFAP resulted in 3 matches, one of which had 6 
sequential amino acids.  The BLAST search comparing peptide sequences for CRMP2 and 
CALR identified two areas with overlapping peptide sequences, one had 8/20 the other 
8/28 identical peptides, at most there were only 3 sequential amino acids. 
 
 F.  Analysis of CRMP2ab levels by pain group   
 Patients were classified as positive or negative for neuropathic pain based on a 
clinical diagnosis of neuropathic pain as describe in Section 2.3.  Acute SCI subjects were 
divided into those classified as positive for neuropathic pain within 6 months post-SCI 
versus those who did not have evidence of neuropathic pain by that time.  Chronic SCI 
subjects were classified according to their pain status at the time of sampling.  A 
comparison of the S-LANSS scores (as described in Chapter 2.3B) between pain groups 
was performed as a corroboration of the clinical diagnosis of neuropathic pain. The Mann-
Whitney Rank-Sum Test was used to determine whether there was a difference in the 
levels of CRMP2ab at 16 ± 7 days in those with versus without neuropathic pain within 6 
months of SCI. 
  
3.3 Results 
A.  Fluorescent staining validates CRMP2 as a source of 
immunoreactivity   
 Probing the membrane with T2 plasma followed by anti-CRMP2 utilizing anti-human 
or anti-rabbit specific secondary antibody with fluorescent tags confirmed co-localization of 
SCI plasma and CRMP2 immunoreactivity (Figure 9).  For further confirmation, calipers 
were used to make precise measurements of co-localized spot locations and spots from 
corresponding gels were cut and sent for repeat LC-MS/MS identification.  The repeat LC-
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MS/MS results confirmed the original CRMP2 findings.  These findings implicate CRMP2 as 
a potential antigenic target of an autoimmune response after SCI.  
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Figure 9. CRMP2 Verification, Co-localization of Immunoreactivity.
 
 
Figure 9. CRMP2 Verification, Co-localization of immunoreactivity.   
Coomassie stained membrane after transfer from a 2-D gel containing CNS proteins (A).  The 
membrane was probed with T2 SCI patient plasma known to be immunoreactive and Alexa 
Fluor 488 (green) goat-anti-human IgG secondary (B).  The same membrane was also 
probed with anti-CRMP2 (rabbit) and Alexa Fluor 568 (red) goat-anti-rabbit IgG secondary 
(C).  Arrows show co-localization of some of the fluorescent green and red spots (D). 
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B. Western blotting confirms T2 SCI plasma immunoreactivity to 
purified recombinant CRMP2. 
 Representative results are shown in Figure 10.  The SCI plasma sample shown 
below is immunoreactive to CRMP2 at T2. The commercial anti-CRMP2 positive control 
developed a broad single band at the same molecular weight location.  These results are 
consistent with the findings from the LC-MS/MS showing SCI patient plasma 
immunoreactivity to CRMP2.   
  
            Figure 10.  Western blot showing patient plasma at T2 with banding pattern consistent with 
 positive immunoreactivity to CRMP2 protein. 
 
 
 
 
 
 
 
  
Figure 10.  Western blot showing SCI patient plasma at T2 with banding pattern 
consistent with positive immunoreactivity to CRMP2 protein. Lane 1 shows Patient T2 
plasma probed against purified recombinant CRMP2 protein.  Lane 2 is a commercial 
anti-CRMP2 antibody.  These results are consistent with the LC-MS/MS results that 
identified CRMP2 as a potential antigen.   
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 C.  Immunodepletion of brain tissue demonstrates a decrease in T2 
plasma immunoreactivity at the molecular weight of CRMP2. 
  Immunoreactivity decreased in the CRMP2-depleted brain at the molecular weight 
level of CRMP2 bands.  Representative results are shown in Figure 11.    
 
Figure 11. Decreased Immunoreactivity of T2 Patient Plasma on CRMP2-depeleted 
 brain sample. 
           
Figure 11.  Decreased immunoreactivity of T2 patient plasma on CRMP2-
depleted brain sample. 
Protein A agarose resin beads were used to deplete brain homogenate of IgG 
and then further deplete the homogenate of CRMP2. Lane 1 shows 
immunoreactivity of a T2 SCI patient sample against IgG-depleted brain.  On 
Lane 2 the same plasma was used to probe the brain sample that was depleted 
of CRMP2.  The reduced immunoreactivity from patient plasma in Lane 2 
suggests this patient plasma is immunopositive to CRMP2. 
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D. Capillary electrophoresis immunoassay is effective at measuring the 
SCI plasma for immunoreactivity to CRMP2 
 The previous experiments confirm that some SCI subjects produce immunoreactivity 
to the CRMP2 antigen that was identified through 2-D electrophoresis and LC-MS/MS.  In 
order to estimate the percent of the acute SCI subjects who are positive for CRMP2ab 
purified recombinant CRMP2 protein was used as the sample on a capillary electrophoresis 
–immunoassay.  Increasing dilutions of plasma and amounts of protein were tested to 
determine loading amounts.  An illustration of the difference of immunoreactivity to CRMP2 
from the same plasma sample at dilutions of 1:50 or 1:100 is shown in Figure 12. Plasma 
dilutions of 1:100, and CRMP2 protein at 36 ng/µl were used for these studies.  
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Figure 12. Example of assay for CRMP2 plasma dilutions and protein volume 
 
 
Figure 12. Preliminary capillary electrophoresis immunoassays were performed to determine the 
amount of protein and the dilution of plasma antibody to use for subsequent testing.  The image on 
the left shows immunoreactivity from one plasma sample of one patient that was diluted either 
1:50 or 1:100 used to probe CRMP2 protein 36 or 72 ng/µl. The image on the right shows the 
corresponding areas under the curve (AUC).   Plasma dilutions of 1:100, and CRMP2 protein at 36 
ng/µl was selected for subsequent studies. 
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 The level of immunoreactivity produced by acute SCI patient plasma in response to 
CRMP2 protein was measured in serially collected plasma samples as the timing of 
production of autoantibodies was expected to have some variability in different patients.  
The 16 ± 7 day sample time point produced the peak immunoreactivity.  Figure 13 shows 
an image of the immunoreactivity on the capillary electrophoresis immunoassay of samples 
at three time points from a SCI patient that was also immunopositive to CRMP2 on 
acrylamide gels.   
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Figure 13.  Capillary electrophoresis immunoassay of patient plasma on CRMP2 protein.  
 
 
Figure 13.  Capillary electrophoresis immunoassay of patient plasma on CRMP2 
protein.  
A) Immunoassay: Lanes 1-3 probed with patient plasma (1:100) at 3 time points on 
36ng/µl of CRMP2.  Lane 4 shows no immunoreactivity using no primary and anti-
human HRP (1:500) secondary.  The positive control commercial anti-CRMP2 (1:1000) 
is in Lane 5. B) Corresponding graph of immunoreactivity of SCI plasma.  The green 
color identifies the area measured to calculate AUC of CRMP2ab.  
A B 
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E.  Specificity of Immunoreactivity 
E.1 Subjects used in antigen-binding specificity and subsequent studies 
 Acute, chronic and healthy volunteers were evaluated to test for the presence of 
CRMP2ab.  A total of 138 subjects (20 healthy volunteers, 38 acute SCI and 80 chronic 
SCI) were consented and enrolled for their participation in this study.  The demographics of 
these subjects are reported in Table 6.  On average, the acute SCI patients were 1.2 days 
post-injury, whereas the chronic SCI patients were 15 years from injury.  The primary cause 
of injury in the majority of SCI patients was motor vehicle accidents (MVA). The acute and 
chronic SCI groups included primarily cervical injuries and over half of each SCI group was 
ISNCSCI A or B impairment level (A: complete loss of function; or B:  sensory, but no motor 
function was preserved below the level of the injury).   
 Acute SCI subjects were divided into those classified as positive for neuropathic 
pain within 6 months post-SCI versus those who did not have evidence of neuropathic pain 
by that time.  Chronic SCI subjects were classified according to their pain status at the time 
of sampling.  In both acute and chronic SCI groups, all subjects with an S-LANSS score of 
greater than 12 had a clinical diagnosis of neuropathic pain.  The chronic subjects with 
neuropathic pain had a significantly higher S-LANSS score than those without neuropathic 
pain (T=741, median 9 vs. 0, p<0.001), but there was no difference on the McGill pain 
score.  S-LANSS scores were available for 18 acute SCI subjects at 6 months, when 
combining these scores with the chronic subjects’ scores, the combined S-LANSS scores 
were significantly different between those with a clinical diagnosis of neuropathic pain and 
those without neuropathic pain (T=1091, median 9 vs. 0, p<0.001) corroborating the clinical 
diagnoses of neuropathic pain (Figure 14). The affective descriptors (tiring-exhausting, 
sickening, fearful, and punishing-cruel) on the McGill pain score were significantly higher for 
the acute SCI patients with neuropathic pain compared to those without neuropathic pain 
(mean 3.5 ± 3.2 vs 0.2 ± 0.4, p<0.04).  Of the 38 acute SCI subjects, 23 (60.5%) were 
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diagnosed as having neuropathic pain by the 6 month time point while 15 (39.5%) had no 
evidence of neuropathic pain. Key demographics of the acute SCI subjects by pain group 
are shown in Table 7.    
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Table 6. Demographics of subjects used for capillary-immunoassay studies  
 
ACUTE SCI 
SUBJECTS 
(N=38) 
CHRONIC SCI 
SUBJECTS (N=80) 
HEALTHY 
VOLUNTEERS (N=20) 
GENDER, COUNT (PERCENT) 
      MALE 34 (89) 59 (74) 16 (80) 
      FEMALE 4 (11) 21 (26) 4 (20) 
AGE, AVERAGE YRS(SD)  43.5 (17.7) 44.1 (14.0) 35 (13.2) 
AGE, RANGE  YEARS 18-82 19-76 20-62 
RACE, COUNT (PERCENT) 
     WHITE 32 (84) 66 (82) 11 (55) 
     ASIAN 0 (0) 3 (4) 6 (30) 
     BLACK 5 (13) 11 (14) 3 (15) 
     OTHER 1 (3) 0 (0) 0 (0) 
ETHNICITY 
      
     HISPANIC 6 (16) 19 (24) 0 (0) 
     NOT HISPANIC 32 (84) 61 (76) 20 (100) 
MECHANISM OF INJURY, COUNT (PERCENT) N/A 
     MVA 23 (60) 47 (59) 
  
     FALL 10 (26) 19 (24) 
  
     SPORTS-RELATED 4 (11) 10 (13) 
  
     ASSAULT 1 (3) 4 (5) 
  
TIME POST-SCI AT ENROLLMENT N/A 
     AVERAGE (SD) 1.2 DAYS 15.3 (12.3) YEARS 
  
     RANGE 0.1-2.7 DAYS 1- 41 YEARS 
  
  LEVEL OF INJURY 
 CERVICAL  31 (82) 47 (60) 
 
THORACIC 6 (16) 22 (28) 
 
LUMBAR 1 (2) 4 (5) 
 
UNKNOWN  7 (9) 
 
 
ISNCSCI Impairment Scale 
     A 23 (60) 28 (35) 
 
     B 3 (8) 21 (26) 
 
     C 8 (21) 11 (14) 
 
     D 4 (11) 12 (15) 
 
     N/A    8 (10) 
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Figure 14. Box plot of S-LANSS Pain scores by pain group for Acute SCI 
and Chronic SCI patients.  Acute SCI patients were classified as having 
neuropathic pain within 6 months of injury and chronic subjects were 
classified based on their pain state at the time of the visit (on average 15 
years post-injury).  Neuropathic pain classification was based on the 
clinical diagnosis of neuropathic pain and the S-LANSS score reported by 
patients supports the classification.[121] (T=1091, median 9 vs. 0, 
p<0.001) 
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Table 7.  Demographics of acute SCI by pain group 
 
Neuropathic Pain (n=23) No Neuropathic  
Pain (n=15) 
P* 
Age (years, median) 36 47 0.69 
BMI  
(kg/m2, median) 
26.5 27.8 0.94 
Male gender 19 15 0.14 
Complete (ISNCSCI A) 14 9 1.0 
Cervical Level Injury  15 14 0.06 
*Mann-Whitney rank sum test for variables not normally distributed.  Fisher’s exact test was used for 
variables with small expected cell number.  No significant results were found for any variables. 
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E.2 Specificity of Immunoreactivity to CRMP2 
 Specificity of immunoreactivity to CRMP2 was determined by pre-absorption of the 
plasma with purified CRMP2 or a non-specific protein (i.e. GFAP or CALR) which contained 
the same tag (Myc-DDK) used for purification.   Only samples with immunoreactivity that 
was blocked by the pre-incubation with CRMP2, but not GFAP or CALR, were considered 
positive for CRMP2ab (Figure 15).  Samples that demonstrated reduced immunoreactivity 
to both blocking (CRMP2) and competing (GFAP or CALR) proteins were considered 
nonspecific and therefore not counted as CRMP2ab positive (Figure 16). Only those 
samples that 1) had immunoreactivity above baseline, 2)  decreased > 30% when pre-
blocked with CRMP2 and 3) did not decrease when pre-absorbed with GFAP or CALR were 
deemed as having specific immunoreactivity to CRMP2 and were classified as CRMP2ab 
positive.    
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Figure 15.  SCI patient plasma immunoreactivity specific for CRMP2.  
 
 
 
 
 
Figure 15.  SCI patient plasma immunoreactivity specific 
for CRMP2.   A) Image showing SCI plasma 
immunoreactivity to CRMP2 (lane 1), plasma pre-
blocked with CRMP2 (lane 2), plasma pre-blocked with 
competing protein (GFAP) (lane 3), no primary showing 
no immunoreactivity (lane 4), anti-CRMP2 positive 
control (lane 5).  Immunoreactivity from plasma is not 
seen in lane 2 that was pre-blocked with CRMP2, but it 
is present in the plasma that was pre-blocked with GFAP 
showing the plasma antibody in this sample is specific 
for CRMP2. B) AUC of plasma, pre-blocked plasma and 
competed plasma. C) Graphic representation of 
immunoreactivity change with blocking. 
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 Figure 16. CRMP2 Blocking and Competing Studies – SCI patient non-specific for CRMP2.  
         
Figure 16.  CRMP2 Blocking and Competing Studies – SCI 
patient non-specific for CRMP2.  SCI plasma was incubated 
overnight in standard block (1:100) or equimolar amounts of 
CRMP2, GFAP or CALR protein.  These samples were then 
used to probe CRMP2 protein.  A) Lane 1 shows plasma 
immunoreactivity to CRMP2, Lane 2 the plasma was pre-
blocked with CRMP2 and immunoreactivity was reduced as 
expected.  Lane 3 the plasma was pre-blocked with GFAP 
and Lane 4 the plasma was pre-blocked with CALR.  Pre-
blocking with these competing proteins also reduced 
immunoreactivity indicating this response is non-specific.  B) 
AUC of the immunoreactivity, C) Graphic representation of 
immunoreactivity change with blocking. 
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 The Grubbs’ test was performed to determine whether any samples in either group 
were outliers.  One healthy volunteer was found to be a significnat outlier (Z=2.71, p<0.05) 
and was removed from analysis. Results indicated 8/35 (23%) SCI subjects and 1/19 
healthy controls (5%) were CRMP2ab positive.  However, the difference in the median 
levels of CRMP2ab was not significantly different between SCI subjects at the 16 ± 7 peak 
time point and healthy controls (T=461.0, p=0.09). CRMP2ab was detected in chronic SCI 
subjects, however because the peak acute timepoint did not reach significance the antigen 
verification studies were halted. 
 
F. No statistically significant difference in the levels of CRMP2ab at 16 ± 
7 days in acute SCI patients who developed neuropathic pain versus those 
who did not. 
The results of the CRMP2 antigen verification and competition studies above 
identified 8 of 35 (23%) subjects had immunoreactivity that was specific for CRMP2 protein 
at 16 ± 7 days after SCI.  (Three subjects with immunoreactivity did not block with CRMP2 
and were omitted; the 6 day sample was used for the one subject who did not have a 
sample at 16 ± 7 days.) There was no difference in median CRMP2ab levels of those with 
and without neuropathic pain (T = 231.000, p = 0.08) (Figure 17). Sample size calculations 
based on data from theses acute SCI subjects indicate that a total of 64 subjects would be 
needed to detect a significant difference at an 80% power with an alpha of 0.05. 
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  Figure 17. CRMP2ab levels at 16 ± 7 days after SCI were not statistically 
different between those who developed neuropathic pain (n=20) compared to 
those who did not develop neuropathic pain (n=15) within 6 months after SCI 
(T=231.000, p=0.08).   
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3.4. Discussion 
A. Key findings  
Eight of thirty-five (23%) subjects were identified as CRMP2ab positive after SCI.    
There was no difference in median CRMP2ab levels of those with and without neuropathic 
pain (T = 231.000, p = 0.08).  Although this did not reach significance, it could be due to 
limited number of positive patients. Sample size calculations based on data from theses 
acute SCI subjects indicate that a total of 64 subjects would be needed to detect a 
significant difference at an 80% power with an alpha of 0.05. 
 B. Spots observed    
 Of the 22 spots sent for evaluation, 11 were positive for CRMP2.  Of the spots 
matched to CRMP2, the molecular weight and species were correct.  Figure 8 above, 
reveals spots that are likely different isoforms and post-translational modifications of 
CRMP2.  There are multiple isoforms of CRMP2 including 75kDa CRMP2A and 62-66kDa 
CRMP2B variants that are commonly observed in adult CNS tissue.[139]  One of the spots 
showed 59% coverage and the coverage included peptides in the N (glutamine 8, Q8) and 
C terminals (lysine 465, K465) supporting that it was identifying CRMP2, not homologous 
parts of other isoforms.  CRMP2 has been identified as a potential antigen causing human 
plasma immunoreactivity previously on 2-D gels as a 62kDa protein with two 
phosphorylated isoforms at 64kDa and 66kDa.[155] Additionally, 55kDa CRMP2 breakdown 
products have been previously identified.[156]  Spots that are more negatively charged 
(more phosphorylated) migrate to the left/acidic side of the 2-D gel.[141] Cyclin-dependent 
kinase 5 (CDK5) phosphorylates CRMP2.[157] In a chick SCI crush injury study CDK5 was 
inhibited with roscovitine in explanted cells. Using βIII-tubulin staining neurite sprouting and 
cell migration was detected, and in some cells there was an increase in phosphorylation at 
S522 mediated by CDK5.  Two known sites of phosphorylation of CRMP2 are at threonine-
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514 (70 and 78kDa) and serine-522 (62 and 70 kDa); phosphorylation at both residues was 
shown at 70 and 78kDa in chick spinal cord.[141]   
 C.  Mechanism(s) by how CRMP2 autoantibody may contribute to neuropathic 
pain  
 CRMP2 autoantibody may contribute to neuropathic pain by fostering the sprouting 
of pain fibers.  Aberrant sprouting of afferent fibers occurs after SCI.  Calcitonin gene 
related peptide (CGFP) in the dorsal horn is a nociceptive neurotransmitter.[150] After SCI 
neurite spouting measured by increased density of growth associated protein-43 (GAP-43) 
co-localized with α-CGRP indicating nociceptive primary afferent sprouting in laminae 
where these primary afferents are not normally found.[150] In human postmortem subjects 
immunohistochemistry and immunocytochemistry for CGRP were performed on thoracic 
spinal cord tissue comparing 4 chronic SCI spinal cords below the level of the lesion and 5 
intact control spinal cords.  Confirming rodent studies, CGRP-containing fibers were found 
in both groups in lamina I and II, but in the human SCI tissue, fibers were denser and 
extended into deeper laminas III-V, VII and X.[158] Previous experimental rat studies 
demonstrated CGRP nociceptive sprouting was associated with hyperalgesia and 
allodynia.[151] 
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Chapter 4.  Human SCI elicits an autoantibody response to 
GFAP 
4.1. Introduction 
A. Astrocytes 
  Astrocytes are the most abundant of central nervous system (CNS) glial 
cells.[159]  Astrocytes provide structural support for neurons and facilitate the uptake of 
neural transmitters and maintenance of the blood-spinal cord barrier (BSCB).   Astrocytes 
also control the migration of immune-mediating leukocytes into and out of the injured spinal 
cord.[160]  Astrocytes can exert chemical signals that recruit leukocytes into the spinal 
cord parenchyma (pro-inflammatory) or restrict their entry (anti-inflammatory effect).[160] 
For instance, vascular endothelial growth factor A (VEGFa), derived from astrocytes, 
induces permeability of the BSCB and entry of leukocytes.[161]  
 Astrocytes are intricately involved in the BSCB providing chemical support for 
endothelial cells and maintaining the ion balance.[160]  After trauma to the spinal cord, 
astrocytes are activated by cytokines and growth factors (e.g., IL-1, IL-6, TGFα, TGF-1, 
bFGF) becoming reactive.[160]  Two types of reactive astrocytes have been identified, A1 
and A2.  A1 astrocytes are generally considered neurotoxic generating a pathological 
response whereas A2 astrocytes stimulate neuronal survival and healing of injured 
tissue.[162] Reactive astrocytes surround the injured area creating a glial scar.  
 The glial scar is thought to be protective by sequestering the damaged area and 
promoting cleanup of myelin and cellular debris, but the glial scar prevents axon 
regeneration across the scar, inhibiting recovery.[163, 164] After SCI astrocytes 
hypertrophy and form a mesh-like barrier around the lesion core.[165] Confining the 
inflammatory cells within the glial scar protects intact cells from macrophage-induced 
damage.[166] The reactive astrocytes forming the glial scar recruit inflammatory mediators 
76 
 
(chemokines, cytokines, growth factors, prostaglandin, nitric oxide) and perform a barrier 
function, restricting the spread of inflammation to uninjured tissue (Figure 18).[160] 
Consistent with this, reactive astrocytes that were experimentally ablated near the injury 
site by the antiviral ganciclovir in transgenic herpes simplex virus mouse stab and crush 
injury models demonstrated markedly worse tissue damage, demyelination, increased 
leukocyte infiltration and poorer motor function compared to control injured mice.[167, 168]  
GFAP is essential for astrocytes’ glial scar formation.[169]  
 Astrocytes are involved with autoimmune pathology. For example, the disruption of 
astrocyte functions by binding of complement and autoantibodies that bind to aquaporin 4 
(AQP4) on astrocyte membranes is causal of neuromyelitis optica (NMO), a demyelinating 
disease of the eye which leads to loss of vision.[160] The AQP4-autoantibodies result in 
complement-mediated astrocyte damage, blood-brain barrier breakdown, increased 
inflammation and enlarged tissue damage.[160] Furthermore, in NMO astrocyte-associated 
damage of the optic nerve and spinal cord can cause pain.[170] 
 Gliopathy, defined as “the dysfunctional and maladaptive response of glial cells to 
neural injury” is proposed to be the result of the sudden increase in extracellular glutamate 
concentration resulting in excitotoxicity, sensitization of neurons and glia and includes 
increase of pro-inflammatory cytokines and immune cell infiltration.[171] Gliopathy results 
in ongoing inflammation and neuropathic pain.[171] 
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Figure 18. Model of spinal cord injury showing reactive astrocytes creating a 
glial scar. 
 
 
  Figure 18.  Model of spinal cord injury showing reactive astrocytes creating a 
glial scar.   
A spinal cord injury causes damage to neurons resulting in dystrophic growth 
cones, degenerating axons and cellular debris.  
After trauma to the spinal cord, astrocytes are activated by cytokines and growth 
factors becoming reactive astrocytes in response to the trauma.  Reactive 
astrocytes surround the area of injury creating a glial scar. The glial scar is 
protective by sequestering the damaged area and promoting clean up, but also 
inhibits axons ability to regenerate across its inhospitable territory.[166] The 
model shows activated astrocytes surrounding the injury site.   
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B.  The Role of GFAP 
  GFAP knock-out mouse models have shown reduced glial scar formation in GFAP 
knock-out mice.[169, 172] This weakened glial scar may contribute to a persistently 
permeable BSCB, or it may promote axonal growth across the lesion.[172]   
 DNA microarray analysis on rat spinal cord after SCI found upregulated genes 
associated with inflammation and astrocyte activation in rats with SCI and chronic pain 
compared to SCI rats without chronic pain.[25] GFAP mRNA and protein expression were 
elevated in SCI and further increased (more than 2-fold) in SCI rats with chronic pain. The 
increase in GFAP expression started as early as 4 hours after injury and persisted for 9 
months in chronic pain SCI rats.  Activation of astrocytes and the accompanying pro-
inflammatory state is associated with chronic pain. The authors propose that persistent 
astrocyte hypertrophy leads to (and/or results from) the breakdown of the BSCB and entry 
of inflammatory cells into the injured cord, ultimately contributing to the onset and 
maintenance of neuropathic pain.[25]   
  
C.  GFAP is released after CNS injury 
 GFAP protein is known to be released after SCI and TBI and is proposed to be a 
biomarker for CNS injury.[173-176]  The release of GFAP, a CNS antigen, after SCI could 
disrupt the state of immune tolerance and result in autoantibody production. The process of 
the development of autoantibodies after SCI (a “sterile injury”) is proposed to be similar to 
immune response to pathogen associated molecular patterns (PAMPs) in bacterial 
exposure; however, after a sterile injury development of autoantibodies is in response to 
damage associated molecular patterns (DAMPs).[177, 178] Circulating B cells are 
recruited by the dying cells, B cells can bind the released self-antigen (GFAP) and the B 
cell can be activated by a T cell that is specific for a self-peptide. These B cells differentiate 
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into plasma cells secreting autoantibody, the autoantibody further stimulates the 
inflammatory response inducing more cell damage and activating more autoreactive B 
cells, producing more autoantibody until the damaged cells are cleared.[179] Deficiencies 
in the clearance of apoptotic and dying cells after SCI may contribute to loss of B cell 
tolerance and result in autoantibody production.[180]  
 After injury, inflammation is induced in recognition of damage associated molecular 
patterns (DAMPs) on the released CNS antigen(s) (e.g., GFAP and CRMP2) that are 
detected by pattern-recognition receptors (PRRs) (similar to the mechanism used by 
pathogens and PAMPs).[178] Classes of PRRs include Toll-like receptors, NOD-like 
receptors, anti-viral RIG-I-like receptors, C-type-lectin receptors with their carbohydrate-
binding domain and absence in melanoma 2-like receptors (the latter PRR having 
involvement in immune responses to bacteria and DNA viruses); PRRs mediate the 
DAMP-associated inflammatory response.[180] After tissue damage, PRRs activate 
signaling pathways mitogen-activated protein kinase (MAPK), nuclear factor-kB (NF-kB), 
and type 1 interferon (IFN-1) which increase pro-inflammatory cytokines (e.g., IL-1, TNF) 
and chemokines.[181] IL-1α and IL-33 are released in their precursor, biologically active 
form from cells during necrosis leading to the recruitment of neutrophils and alarmins which 
alert immune cells.[181]  Uric acid is an example of a pro-inflammatory DAMP that 
contributes to inflammation.[182] Post-trauma necrotic cell death resulting in the loss of cell 
membrane integrity results in the release of multiple pro-inflammatory endogenous DAMPs 
including high-mobility group box 1 (HMBG1), heat shock proteins, S100 proteins, heparin 
sulfate, DNA, RNA and others.[181, 183]  
 Heat shock proteins, S100, uric acid, HMGb1 and heparin sulfate activate Toll-like 
receptors expressed on the membranes of dendritic cells and lymphocytes.[181] Dendritic 
cells are activated by necrotic cells releasing heat shock protein 70, IL-1α, HMGB-1 which 
induce Toll-like receptor-IL-1 signaling.[184] Dendritic cells then present the auto-antigen 
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resulting in the potential for formation of autoantibodies.  The development of 
autoantibodies has been demonstrated in a sterile injury mouse model of myocardial 
infarction which results in ischemia and tissue necrosis causing release of intracellular 
contents that cause sterile inflammation.[185] The mouse myocardial infarction model 
proved that dendritic cells presented the self-antigen to autoreactive CD4+ T cells which 
assumed an autoreactive T-helper cell phenotype, Th1/Th17, promoting autoantibody 
production.[184]   
 DAMPs can bind to an antibody and activate complement through antibody binding 
to lipids on the necrotic cell surface, or to released antigen.[177]  Complement is also 
activated by proteases released from damaged tissue.[186]  The complement cascade 
results in the activation of inflammatory anaphylatoxins C3a and C5a.[187, 188] Mice 
deficient in C3 have a reduced immune response compared to wild type mice.[177] 
However, even in the absence of complement, in the context of  cell death B cells and 
antibodies contribute to inflammation, possibly through uric acid promoting inflammation or 
through antibody binding Fc receptors on leukocytes.[177] PAR2 receptor expressed on 
leukocytes can induce inflammation and it can be activated by proteases released from 
necrotic cells; consistent with this, PAR2 deficient mice had reduced inflammatory 
response compared to wild type mice in a cell death-induced model.[177] The PRRs that 
activate the Toll-like receptor pathway (e.g.,TLR7 with IFN-1) cause the activation of B 
cells and production of autoantibodies.[189, 190] GFAP that is released after injury could 
similarly cause the activation of B cells and the production of autoantibody.  
 Increased GFAP expression after CNS injury accompanies astrocyte hypertrophy 
and activation. Activation of astrocytes leads to the secretion of inflammatory mediators 
(IL-1β, IL-6 and TNF-α) and expression of inducible nitric oxide synthase which propagates 
the inflammatory state and may potentiate SCI-induced chronic pain.[25]  
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 The development of an autoantibody that binds to GFAP may contribute to 
prolonged BSCB breakdown, continued passage of inflammatory mediators across the 
BSCB and potentiate pain.  The hypothesis is that autoantibodies to GFAP will be present 
after SCI and will be associated with neuropathic pain. The following experiments were 
performed to validate the potential of GFAP to be an antigen to which some SCI patient 
plasma is immunopositive and assess the relationship to neuropathic pain.   
 
4.2. Methods 
 A.  Spot excision and LC-MS/MS 
 Immunoreactive spots from 2-D gels were identified and excised from Coomassie 
stained gels as described in Chapter 2.13B   Proteins were subjected to LC-MS/MS and 
identified as described in Chapter 2.13C. 
B.  Validation of GFAP antigen, Immunodepletion and western blots 
 
Figure 19. Flow chart of GFAP immunodepletion of brain homogenate 
 
  
 Immunodepletion was performed to prepare IgG-poor and GFAP-poor brain 
homogenate as described in Chapter 3.2 C; 25µl anti-GFAP was used in these experiments 
to create the beads to deplete GFAP from brain homogenate (Figure 19).   
 To further validate that the T2 patient samples produced immunoreactivity to GFAP, 
western blots were performed as described in Chapter 2.7.  These western blots were from 
8% acrylamide gels containing purified recombinant GFAP (5µg/well) (OriGene).  
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 C.  Capillary electrophoresis immunoassay and antigen verification 
 Western analysis and verification of antigen specificity was carried out as described 
in Chapter 3.2 D and E.  The capillary electrophoresis immunoassay parameters were the 
same except GFAP protein (160ng/µl) and plasma dilutions of 1:50 were used and a 
custom anti-GFAP antibody (1:20,000) was the positive control.  Those plasma samples 
that were immunopositive to GFAP were considered as having autoantibodies reactive to 
GFAP (GFAPab) if they met the criteria of 1) having immunoreactivity above baseline, 2) 
decrease by >30% when pre-blocked with GFAP protein, and 3) immunoreactivity did not 
decrease when blocked with a competing protein. Subject samples used in these studies 
are described in Chapter 3.2 E.1 and Tables 6 and 7. 
 
 D.  Receiver Operator Characteristic (ROC) curve analysis 
 A ROC curve was generated to determine the sensitivity (true positive rate) and 
specificity (1- specificity is the false positive rate) of GFAPab at predicting neuropathic pain 
within 6 months of SCI at different thresholds. The area under the curve (AUC) generated 
from the ROC curve provides an index of how useful GFAPab is at predicting neuropathic 
pain.[191] An AUC of 0.5 has no discriminatory ability; generally, an AUC > 80 is good, 70 
to 80 is fair, and < 70 is considered a poor predictor.[191]  
 To estimate the ng/mL of GFAPab present in human plasma a standard curve was 
created with the custom anti-GFAP antibody that had a known concentration.  The GFAP 
sample (160ng/mL) was probed with the custom anti-GFAP antibody (1mg/mL) at 
increasing dilutions (1:25,000 to 1:3200,000).  A standard curve of the anti-GFAP AUC 
immunoreactivity relative to anti-GFAP ng/mL was generated (Figure 20).  This curve was 
used to estimate the concentration of GFAPab (ng/mL) in plasma from the AUC 
measurement that was predictive of future development of neuropathic pain.  The 
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concentration of GFAPab that provided the highest sensitivity and specificity was selected 
as the threshold value. 
Figure 20 Extrapolation of GFAPab threshold in ng/mL based on GFAPab AUC 
  
Figure 20.  Extrapolation of GFAPab threshold in ng/mL.  The GFAP protein sample 
(160ng/mL) was probed with a custom anti-GFAP antibody (concentration of 1mg/mL) 
at increasing dilutions (1:25,000 to 1:3200,000) (lanes 1-8).  Two SCI plasma samples 
(1:50 (lanes 9-10) and no primary (lane 11) were included as controls.  A standard 
curve of the anti-GFAP AUC immunoreactivity relative to anti-GFAP ng/mL was 
generated (shown above right).  The white circle indicates the threshold level of 
GFAPab in patient plasma at 16±7 days that would be predictive of development of 
neuropathic pain within 6 months of injury.   
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E. Measuring the odds of developing of neuropathic pain when GFAPab 
and/or CRMP2ab are present at 16 ± 7 days. 
 The presence of the two autoantibodies on the the development of neuropathic pain 
was analyzed using a chi-square test and an odds ratio was calculated. Multiple logistic 
regression was performed while controlling for age, gender, body mass index, complete 
injury, and cervical level to evaluate the probability of the GFAPab and/or CRMP2ab 
predicting neuropathic pain. Statistical analysis was performed as described in Chapter 
2.11.  
 
4.3. Results 
 
 A.   Spots excised identified as GFAP. 
 Seven of the spots sent for LC-MS/MS analysis were positive for GFAP (Chapter 
2.13B).  The species was correct. Results of peptide matches showed good coverage.  For 
example, on one spot the sequence coverage was 66.8%.  For that spot, the first matched 
peptide started with serine 8 (S8) in the N terminal region and the last matched peptide 
ended with Lysine 399 (K399) which is  in the C terminal region; additionally there were 
multiple peptides matched in the rod domain.[192]  Consistent with GFAP, these spots 
ranged in molecular weight from 38 to 50kDa and pI of between pH 5 to 6.  The original 2-D 
gel membrane that was used to identify spots for LC-MS/MS analysis was stripped and re-
probed with a custom anti-GFAP antibody.  There was overlapping reactivity between the 
index SCI patient immunoreactivity and the immunoreactivity produced by the custom anti-
GFAP antibody.  This suggested that the patient IgG immunoreactivity and the anti-GFAP 
antibody had some commonality.   
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 B. Validation of immunoreactivity to GFAP. 
 The brain homogenate and GFAP-depleted homogenate were probed on a western 
blot with T2 patient plasma known to be positive for immunoreactivity at 38-50kDa.  Brain 
homogenate sample depleted of GFAP had less immunoreactivity between 38-50kDa than 
the non-GFAP depleted sample.  Western blots probed with SCI patient T2 plasma and 
custom anti-GFAP demonstrates immunoreactivity to GFAP at 50kDa (Figure 21).  These 
results are consistent with the findings from the LC-MS/MS showing SCI patient plasma 
immunoreactivity to GFAP.  
 
 
 
                         
 
 
 
 
 
  
Figure 21.  Representative lanes from a Western blot showing T2 with banding 
patterns consistent with positive immunoreactivity to GFAP protein. Lane 1 
shows a SCI patient T2 plasma probed against purified recombinant GFAP 
protein.  Lane 2 is a custom anti-GFAP antibody generated by the Dash 
Laboratory.  These results are consistent with the LC-MS/MS results that 
identified GFAP as a potential antigen.   
Figure 21. SCI Patient Plasma Immunoreactive to Purified Recombinant GFAP Protein 
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C.  Capillary electrophoresis immunoassay and antigen verification validates 
the presence of GFAPab. 
C.1 GFAPab is specific 
 The previous experiments suggest that the GFAP antigen, identified through 2-D 
electrophoresis and LC-MS/MS, produces immunoreactivity at T2 in some SCI patients.  In 
order to estimate the proportion of the SCI subjects who are positive for GFAPab purified 
recombinant human GFAP protein was used as the sample on a capillary electrophoresis–
immunoassay to measure the level of immunoreactivity produced by SCI patient plasma.   
Initial studies determined the plasma dilution and amount of protein to use for the assay.  
Figure 22 illustrates a SCI patient plasma’s immunoreactivity to increasing amounts of 
GFAP (10, 20, 40, 80, 160 ng) and lack of immunoreactivity to a second protein (CRMP2) in 
the same amounts.  Indiscriminant binding was not seen in this subject.  
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Figure 22 Immunoreactivity of a SCI plasma sample specific for GFAP in response to 
increasing amounts of GFAP protein and CRMP2 protein. 
                
 
 
 
 
 
 
 
 
 
Figure 22 Immunoreactivity of a SCI plasma sample specific for GFAP in response to increasing 
amounts of GFAP protein and CRMP2 protein. 
A) Purified recombinant GFAP protein was loaded in increasing amounts on lanes 1-4 (20, 40, 80, 160 
ng), purified recombinant CRMP2 protein was loaded in lanes 5-8.  Lanes were probed with human 
plasma (1:50) from a known GFAPab-positive subject and secondary anti-human HRP IgG.  
Immunoreactivity is seen in the GFAP lanes, but not in the CRMP2 lanes.  This subject shows 
specificity for GFAP.  For this subject the amount of GFAP is the limiting factor as indicated by the 
decreasing GFAPab area under the curve at lower amounts of protein.  
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 To verify antigen-binding specificity, competition studies were performed using 
diluted plasma (1:50) by the capillary electrophoresis-immunoassay.  Samples were 
incubated overnight at 4°C either with or without 1600ng/10µl of the GFAP protein or an 
equimolar amount of a competing protein labeled with the same Myc-DDK tags (purified 
CRMP-2) to allow comparison between pre-absorbed samples with the same sample that 
underwent standard incubation.   Figure 23 is a representative subject showing 
decreased immunoreactivity to GFAP after pre-incubation with GFAP.  An immunoreactive 
area can be seen, corresponding to the molecular weight of GFAP. Immunoreactivity was 
reduced when pre-absorbed with GFAP whereas the pre-incubation with CRMP2 had no 
demonstrable effects on the immunoreactivity to GFAP protein. These results are 
consistent with the LC-MS/MS findings of GFAP as an antigen, and suggest the 
immunoreactivity to GFAP protein is specific.   
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Figure 23.  SCI patient plasma immunoreactivity specific for GFAP.  
 
    
Figure 23.  SCI patient plasma immunoreactivity specific for 
GFAP. A) Image showing SCI plasma immunoreactivity to 
GFAP protein (lane 1), plasma pre-blocked with GFAP 
(lane 2), plasma pre-blocked with competing protein 
(CRMP2) (lane 3), no primary showing no immunoreactivity 
(lane 4), anti-GFAP positive control (lane 5). 
Immunoreactivity from plasma is not seen in lane 2 that 
was pre-blocked with GFAP, but it is present in the plasma 
that was pre-blocked with CRMP2 showing the plasma 
antibody in this sample is specific for GFAP. B) AUC of 
plasma, pre-blocked plasma and competed plasma. C) 
Graphic representation of immunoreactivity change with 
pre-incubation of sample. 
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C2. GFAPab present in plasma samples 
  There was no statistically significant difference between GFAPab-positive 
and GFAPab-negative SCI patients based on sex, age, weight, complete/incomplete, or 
cervical/other level of injury.  
  For acute SCI patients, plasma samples collected 1.2 ± 0.7, 6.4 ± 1, 16 ± 7 and 96 ± 
54 days after injury were assayed.  Figure 24 presents the time course for GFAPab levels 
following SCI.  There was a significant change in GFAPab over time (F(3,37) = 3.42, p=0.02), 
with peak levels detected at the 16 day time point.  For the 96 day sampling period, only 13 
samples were available for testing.  When assessed for the presence or absence of 
GFAPab at the 16 day time point, 21 of 38 (55%) acute SCI were found to be 
immunopositive.  By comparison, 4 of 19 (21%) healthy volunteers were positive for 
GFAPab.  The GFAPab levels measured at the 16 day time point were found to be 
significantly increased by comparison to those measured in healthy volunteers (T=401.5, 
medians 26,377 vs 0; p=0.005) (Figure 25).   
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Figure 25. SCI patient plasma levels of GFAPab are significantly different from 
those of healthy volunteer controls. (T=401.5, medians 26,377 vs 0; p=0.005) 
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 Samples from chronic SCI patients (1-41 years post-injury, mean of 15 years) were 
assayed for the levels of GFAPab.  Of the 80 chronic SCI patients assayed, 34 (42.5%) 
were found to be immunopositive for GFAPab.  When compared to the healthy volunteers, 
chronic SCI GFAPab levels were not significantly different (T=758, medians 0 vs 0, 
p=0.052; Figure 26).   Sample size calculations based on data from theses chronic SCI and 
healthy volunteer subjects shows that 23,091 subjects would be needed to detect a 
significant difference at an 80% power with an alpha of 0.05. 
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Figure 26. Chronic SCI patient plasma levels of GFAPab compared to healthy volunteer 
controls.  (T=758, medians 0 vs 0, p=0.052; Figure 27).   Sample size calculations based on 
data from theses chronic SCI and healthy volunteer subjects shows that 23,091 subjects 
would be needed to detect a significant difference at an 80% power with an alpha of 0.05. 
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 C3. GFAPab in chronic SCI patients does not have diagnostic value for 
neuropathic pain.   
 Neuropathic pain was diagnosed in 46 (57.5%) chronic SCI subjects and they were 
classified as positive for neuropathic pain, whereas 34 (42.5%) of the chronic SCI patients 
were classified as not having neuropathic pain.  GFAPab levels at the time of pain 
assessment could not distinguish between chronic subjects with or without neuropathic pain 
(T=1507, medians 0 vs 7898.5; p=0.16).  When evaluated using a receiver operating 
characteristic (ROC) curve, chronic SCI GFAPab was found to have no diagnostic value 
(AUC = 0.42) in identifying chronic patients with neuropathic pain.   
 D. ROC curve analysis shows GFAPab levels distinguish acute patients 
who develop neuropathic pain versus those who do not.    
 In acute SCI patients, neuropathic pain was defined by a clinical diagnosis within 6 
months of injury.  Figure 27 shows GFAPab levels over time by pain group.  Using the 
GFAPab levels measured at the 16 day time point, acute SCI subjects with neuropathic 
pain within 6 months had higher GFAPab levels than those without neuropathic pain 
(T=219, p=0.02) (Figure 28).  There was a positive correlation between the presence of 
GFAPab at 16 ± 7 days and the development of neuropathic pain (r=0.46, p=0.003). 
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Figure 28.  GFAPab level is significantly higher at 16±7 days post-SCI in patients 
who develop neuropathic pain within 6 months of SCI; T=219, p=0.02. 
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 ROC analysis shows that GFAPab levels have a predictive value of 0.71 (95% CI, 
0.53-0.89 p=0.03) for the development of neuropathic pain within 6 months after injury 
(Figure 29 A).  Using a cut-off of 36 ng/mL (AUC=10,208) at 16 ± 7 days post-SCI, GFAPab 
had 74% sensitivity and 73% specificity for predicting neuropathic pain within 6 months of 
SCI (95% CI, 0.52-0.9 for sensitivity, 0.45-0.92 for specificity)( Figure 29 B).  
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Figure 29. Receiver operator characteristic analysis of predictive value of GFAPab for the 
development of neuropathic pain within 6 months of spinal cord injury. 
 
A) Receiver operator 
characteristic analysis 
shows that GFAPab levels 
have a predictive value of 
0.71 (95% CI, 0.53-0.89 
p=0.03) for the 
development of 
neuropathic pain within 6 
months after injury. 
   
B) Using a cut-off of 36 
ng/mL (AUC=10,208) at 
16±7 days post-SCI had 
74% sensitivity and 73% 
specificity for predicting 
neuropathic pain within 6 
months of SCI (95% CI, 
0.52-0.9 for sensitivity, 
0.45-0.92 for specificity). 
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E.  Predictive utility of GFAPab and CRMP2ab for the development of 
neuropathic pain after SCI. 
 These experiments identified two autoantibodies that are present in circulationg 
plasma of people with SCI.  The peak immunoreactivity for the longitudinally collected 
samples was detected at 16 ± 7 days.  Recognizing that no one autoantibody is likely to be 
the sole predictor of the development of neuropathic pain, the effect of the presence of the 
two autoantibodies on the the development of neuropathic pain was analyzed (Figure 30).  
A chi-square test was performed and a significant relationship was found between the 
presence of autoantibodies and the development of neuropathic pain, X2 (1, N=38)=7.47, 
p=0.006.  The presence of either or both antibodies at  16 ± 7 days post-SCI significantly 
increases the odds of developing neuropathic pain within 6 months by 9.5 times among 
those with SCI (95% CI, 2.08-43.50, p=0.006). When controlling for age, gender, body 
mass index, complete injury, and cervical level, the presence of GFAPab and/or CRMP2ab 
remains a significant factor in predicting neuropathic pain within 6 months with an odds ratio 
of 15.3 (95% CI 1.9 to 125, p=0.01). 
 
 
 
 
 
 
Figure 30.  Panel of autoantibodies. 
There were 24/38 (63%) of SCI subjects positive for one or both autoantibodies.   A significant 
relationship was found between the presence of autoantibodies and the development of 
neuropathic pain, X2 (1, N=38)=7.47, p=0.006.  The presence of GFAPab and/or CRMP2ab 
increased the odds of developing neuropathic pain within 6 months of injury by 9.5 times. 
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4.4.  Discussion 
A.  Key findings 
 1.  GFAPab was present in 21/38 (55%) of acute SCI subjects, 34/80 (43%) chronic 
SCI subjects and 4/19 (21%) of healthy control volunteers.   
 2.  The level of GFAPab in the acute SCI subjects was significantly higher than that 
of healthy volunteers and chronic SCI subjects with the 16 ± 7 day sample showing peak 
levels.   
 3.  GFAPab levels in chronic SCI subjects were not significantly higher than 
GFAPab levels of healthy volunteers (T=758, p=0.052).  It is possible that the timing of the 
acquisition of the sample, an average of 15 years after SCI, influenced the level of the 
GFAPab present in the plasma.   
 4.  In chronic SCI patients, 46/80 (58%) had neuropathic pain at the time of 
sampling (1-41 years post-SCI).  No difference in the levels of GFAPab could be detected 
in the chronic SCI patients with neuropathic pain compared to those without neuropathic 
pain.   
 5.  There were significantly higher levels of GFAPab in the 16±7 day plasma of 
acute SCI patients who developed neuropathic pain (23/38, 60.5%) compared to those who 
did not develop neuropathic pain (15/38, 39.5%) within 6 months of injury and there was a 
positive correlation between the presence of GFAPab and the development of neuropathic 
pain.  
 6.  When combining the presence of GFAPab with CRMP2ab at 16 days post-SCI 
the odds of developing neuropathic pain within 6 months was significantly higher (OR 9.5, 
95% CI 2.08 to 43.50, p=0.006). This remained significant after controlling for age, gender, 
body mass index, complete injury, and cervical level (OR 15.3 95% CI 1.9 to 125, p=0.01). 
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B.  There was more than one GFAP spot identified on 2-D gels   
 Seven of the spots sent for LC-MS/MS analysis were positive for GFAPab.  These 
spots ranged in molecular weight from 38 to 50kDa and pI of between pH 5 to 6. 
Consistent with the LC-MS/MS findings (Methods 2.13 C), GFAP and its breakdown 
products have molecular mass of approximately 38-51kDa and a basal pI of pH 5.4. [192]  
The human CNS expresses 8 highly homologous GFAP isoforms (α, γ, δ/ε, κ, ∆135, ∆164, 
∆exon6, ∆exon7).[169, 193]  It is possible that the range of immunoreactivity seen in SCI 
patient samples represents recognition of different homologous isoforms.  A recent study 
identified 22 of 451 (5%) patients with neurological autoimmune disease as having 
antibodies to GFAPα, 14 of these 22 patients were also immunopositive for GFAPδ.[194]  
 Ishida et al. performed 2-D western blotting analysis comparing immunostaining of 
patients with autoimmune dementia to vascular dementia patients and to a standard anti-
GFAP antibody.  A broad range of pIs existed in the patients’ immunoreactivity, and the 
patients with autoimmune dementia had more alkaline (high) pIs than those of the 
commercial antibody or of vascular dementia patients’ immunoreactivity.[195] The 
differences in pIs are related to the degree of phosphorylation, with higher phosphorylation, 
GFAP becomes more acidic.[195] Different patients may form autoantibodies to different 
post-translational modifications of GFAP.  The Ishida et al. commercial anti-GFAP, the 
custom anti-GFAP and SCI patients in the present study showed immunoreactivity at the 
size of intact GFAP as well as to degradation products of lower molecular weights. The 
Ishida et al. patients’ immunoreactivity ranged between 40-58kDa, similarly the spots 
identified as GFAP evaluated on patients in the present study ranged from 38 to 50kDa. 
Truncated GFAP at 38-48kDa in addition to the intact 50kDa protein on western blot has 
been reported and it was suggesting the immunoreactivity recognized GFAP that had 
undergone postmortem proteolysis in the CNS homogenate.[192] Calpain cleavage of 
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GFAP to 38kDa was reported in a TBI study which proposed that the 38kDa fragment was 
the primary autoantigen inducing an autoimmune response.[196] 
 
 C.  Some healthy volunteers have GFAPab 
 Four healthy volunteers were found to have detectable GFAPab.    All healthy 
volunteers represented themselves as healthy.  A history of prior TBI and/or concussion 
was not recorded at the time of sample collection; therefore it is unclear if the levels of 
GFAPab seen in these patients were due to a previous, undocumented CNS injury, 
neurosurgical procedure or an ongoing inflammatory disease state.  
 A study of TBI patients who had autoantibodies to GFAP found 64.2% (34/53) of 
their TBI subjects 10 days post-injury and 15.2% (15/96) of healthy controls were positive 
for GFAP autoantibodies.[196] The TBI patients’ serum GFAP level at 1 day after injury and 
GFAP autoantibodies 4 to 10 days post injury was correlated (p=0.048).[196] GFAP 
autoantibodies have also been identified in patients with neoplasms (breast, ovarian and 
brain (GBM) cancer and thymoma).[194] Additionally, GFAP autoantibodies were reported 
in diabetes type I and type II. [197, 198] There was no relationship found with GFAPab or 
neuropathic pain in chronic or acute SCI coupled with a diagnosis of diabetes in the present 
study; however, there were only one acute SCI and 5 chronic SCI subjects with diabetes.  It 
is not known if any of the SCI subjects or healthy volunteers developed diabetes after the 
study ended.  Diabetes studies evaluating the correlation of the presence of GFAPab with 
the development of diabetic neuropathy and neuropathic pain are unreported in the 
literature.  
 
 D.  Potential role of GFAP autoantibodies in developing neuropathic 
pain 
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 SCI causes a breakdown of the BSCB that allows for the infiltration of circulating 
cells and molecules into the injured cord, and also allows the efflux of cellular debris and 
proteins.[199, 200]   Consistent with this, it has been previously reported that the astrocytic 
protein GFAP can be detected in the plasma of SCI patients.[201, 202] However, there 
was no correlation between neuropathic pain at 6 months  and CSF GFAP protein levels at 
24 hours.[202] 
 The peak levels of GFAPab occurred at 16 ± 7 days after SCI.  It is possible that the 
early availability of GFAPab contributes to the development of neuropathic pain and that 
once its action has transpired, it may no longer be required to maintain neuropathic pain.  
Alternatively, GFAPab could contribute to a continuously permeable BSCB.    The presence 
of antibody fostering ongoing inflammation could lead to a perpetually permeable BSCB 
and promote neuropathic pain.[25] 
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Chapter 5.  Complement Components C3 and C5 
 
5.1. Introduction 
 A. What is complement? 
 The complement system includes over 40 proteins that function together to defend 
the host against pathogens and infection through a coordinated cascade of processes that 
opsonize pathogens, clear host cells after apoptosis, clear immune complexes and 
enhance antibody response.[187]  Complement is made primarily in the liver and circulates 
in blood in its inactive form.  After SCI, activation of complement is initiated by the trauma 
to the tissue.  In this context, complement activation is involved in clearing apoptotic cells 
and neuronal or glial cell fragments.[23] Activated components can be found at the injury 
site as well as in systemic circulation.[45]  
 There are three main complement pathways (classical, lectin and alternative) that 
converge at complement component C3.  The classical pathway is initiated by the binding 
of complement C1q to immune complexes or to pathogen-associated molecular patterns 
(PAMPs) on pathogen surfaces which initiates a conformational change that activates C1r 
and C1s leading to cleavage of C2 and C4 resulting in C4b-C2a (the C3 convertase).[203] 
The lectin pathway detects PAMPS or damage-associated molecular patterns (DAMPs, on 
damaged host cell surfaces) through mannose-binding lectin (MBL) or ficolins which 
causes the mannose-binding lectin-associated serine proteases (MASPs) to activate C2 
and C4 resulting in the formation of C3 convertase.[203] The alternative pathway is 
activated spontaneously through C3 hydrolysis. With C3 hydrolysis, C3b binds to 
complement factor B (FB) forming C3b-B which, when activated, is processed by 
complement factor D (FD) resulting in alternative pathway C3 convertase (C3b-Bb).[203] 
(Complement can also be activated through the coagulation cascade.[204])  
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 The cleavage of C3 by C3 convertases leads to activation of C3a, opsonization and 
clearance of pathogens, and activation of C5. C5 is the target component which is cleaved 
by the C5 convertase complexes leading to C5a release and the initiation of the membrane 
attack complex (MAC) pathway which culminates in cell lysis and death. Normally, 
complement regulatory molecules present on host cells (e.g., membrane cofactor protein, 
or complement receptor 1) and plasma regulators (factor H) protect the host cells against 
complement activation against host cells.[187] (Figure 31, adapted from[187, 203, 205]). 
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Figure 31  Model of Complement Cascade 
  
Figure 31.  Model of the complement cascade.  The complement cascade is an important host 
defense mechanism against infection and disease.  There are three main activation pathways of the 
complement cascade, the classical, lectin and alternative pathways.  The pathways have different 
initiators of activation; however they converge at complement C3.  The cleavage of C3 by C3 
convertases leads to activation of C3a, opsonization and clearance of pathogens, and activation of 
C5. C5 is the target component which is cleaved by the C5 convertase complexes leading to C5a 
release and the initiation of the MAC pathway which culminates in cell lysis and death. (MBL, 
mannose binding lectin; MASP, mannose-binding lectin-associated serine proteases; FB, 
complement factor B; FD, complement factor D; MAC, membrane attack complex.) 
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 Complement anaphylatoxins C3a and C5a are chemotactic mediators that lead to 
the activation of immune cells.[203] C3a and C5a stimulate polymorphonuclear cells (e.g., 
neutrophils, eosinophils, and mast cells) to release histamine and arachidonic acid 
metabolites (prostaglandins, leukotrienes and lipoxins), all of which are critical in events 
occurring during tissue damage.  The histamine release causes vasodilation, enhanced 
vascular permeability and endothelial activation; prostaglandins contribute to vasodilation, 
pain and fever; leukotrienes also increase vascular permeability, chemotaxis and leukocyte 
adhesion and activation; lipoxins act as antagonists to leukotrienes.[206]   The increased 
vascular permeability and leukocyte and endothelial activation contribute to increased 
blood-spinal cord (BSCB) permeability after SCI.   
Complement activation contributes to inflammation as part of the innate immune 
response and provides a bridge to the adaptive immune system through interactions with 
B- and T cells.[203, 207, 208] Complement C1q activates complement by binding to the Fc 
portion of surface-bound antibodies and immune complexes.[205] Complement C3 binds to 
circulating B- and T-lymphocytes and dendritic cells.  Complement also produces pro-
inflammatory effects through complement anaphylatoxins (C3a and C5a). [188, 209, 210]  
The combined presentation of complement receptors and B cell antigens enhances the 
activation of B cells.[211] Complement clears the immune complexes of B cell produced 
pathogen-specific antibodies and the pathogen antigen.[187] 
 
B.  Complement activation and neuropathic pain 
 Increased complement component concentrations have been associated with 
neuropathic pain, related in part to the pro-inflammatory effects of complement discussed 
previously.   Chronic constriction of the sciatic nerve in a rat model demonstrated 
increased C3 mRNA expression in the spinal dorsal horn as measured by RT-PCR that 
was correlated with hyperalgesia (r=0.899, p<0.0001).[23] The levels of dorsal horn C3 
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mRNA increased over the 7 days evaluated and these increases corresponded with the 
development of hyperalgesia. C3 immunoreactivity was also increased by 2-fold and C3 
concentration in spinal cord homogenate was up to 3.5-fold higher in the injured rats 
compared to sham controls. The level of circulating C3 was 300-fold greater than the CSF 
C3 level, suggesting that a breech in the BSCB allowed complement components to 
penetrate the BSCB, thus elevating the concentration of complement in the cord. GFAP (a 
marker for activated astrocytes) was also increased in the spinal cord in the injured rats 
with hyperalgesia.[23]   
 After SCI a positive feedback cycle is created from the elevated levels of 
complement accumulated at the injury site that stimulates the release of inflammatory 
mediators which then further activate the complement cascade.[187]  The activated 
complement perpetuates increased vascular permeability, leukocyte recruitment and 
activation, pain and sustained tissue damage.    
 Using three distinct peripheral nerve injury models (chronic constriction injury, 
sciatic inflammatory neuropathy, intrathecal injection of HIV-1) Twining et al. administered 
an intrathecal complement inhibitor (soluble human complement receptor type 1) that 
blocked C3a, C5a and the formation of the MAC.  Use of the complement inhibitor 
correlated well with the elimination of the mechanical allodynia that was induced in all three 
different peripheral injury models.[212]  Griffin et al. performed a gene chip screen on RNA 
from dorsal horn in peripheral neuropathic pain rat models and identified an increase of 
genes expressing complement proteins (C1qb, C1qg, C4 and C3).[213] The relationships 
of complement components C5, C5a, C5b and C6 to pain sensitivity were evaluated.  C5a 
was injected into the intrathecal space of uninjured rats which induced cold pain sensitivity; 
additionally, a C5a receptor antagonist injected into the intrathecal space of peripheral 
nerve injured rats resulted in decreased cold hypersensitivity.[213] C5-deficient mice with 
peripheral nerve injury had decreased pain sensitivity, whereas C6-deficient rats with 
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peripheral nerve injury (C6 is downstream of C5b) had no change in pain sensitivity leading 
to the conclusion that in this model C5a mediates neuropathic pain. [213]     
 Overall, these experimental models show a strong relationship of complement 
components C3 and C5 mediating the development of trauma-induced neuropathic 
pain.[23, 210, 212, 213]  Data presented here indicate that after SCI some patients 
develop CRMP2ab and GFAPab and that there is an association between GFAPab at 
16±7 days and neuropathic pain within 6 months of SCI.  Complement and complement 
breakdown may be contributing to the association seen between the GFAPab and the 
development of neuropathic pain after SCI.  Supporting this, impaired clearance of antigen-
antibody complexes from deficiencies in complement increases the risk of developing an 
immune complex-mediated disease such as in systemic lupus erythematosus (SLE).[214, 
215] Complement activation after SCI is expected.  The physical damage to the cells is the 
cause of complement activation and complement infiltrates to the injury site.[216]  
Therefore, analyses were performed to test whether SCI results in a reduction in the 
circulating levels of complement C3 or C5 in human patients reflecting complement 
migration of C3 or C5 to the site of injury.   
 The overriding hypothesis is that complement components and their subsequent 
cascade related components contribute to the association between the GFAPab and the 
development of neuropathic pain.  However, as results below show, a reduction in 
complement after the initial complement activation was not observed in the present study.   
 
5.2. Methods 
 
A.  Plasma collection and patient classification 
111 
 
 Plasma from consented acute SCI patients was collected as described in Method 
2.3.  Patients were classified according to the presence or absence of neuropathic pain as 
described in Method 2.2. 
 
B.  Enzyme-linked immunosorbent assay (ELISA) 
 Complement C3 and C5 levels were evaluated in the acute SCI plasma samples to 
determine whether there was an association with plasma levels of these proteins with the 
presence of GFAPab, CRMP2ab or the development of neuropathic pain.  To evaluate 
levels of complement C3 and C5, enzyme-linked immunosorbent assays (ELISA) were 
performed according to the manufacturer’s instructions (abcam ab108822 and ab125963).  
Plasma previously collected in EDTA tubes and frozen at -80◦C was diluted 1:800 for 
complement C3 and 1:20,000 for complement C5 assay.  Each plasma sample was 
assayed in duplicate on 96-well plates.  For the C3 assay plasma or standard were 
incubated for 2 hours with biotin followed by washing, then streptavidin-peroxidase 
conjugate was added to each well, incubated for 30 minutes and washed. For the C5 
sandwich ELISA, sample or standard was added to each well and allowed to incubate for 2 
hours.  The plate was washed and then biotin was added and allowed to incubate for one 
hour.  This was followed by washing; streptavidin-peroxidase conjugate was added to each 
well, incubated for 30 minutes and washed.  After the last wash for both assays, 
tetramethylbenzidine (TMB) was added followed by the stop solution and the absorbance 
was read at 450nm with a correction at 540nm.  The calculation of unknown concentrations 
from the standard curve was performed using Systat Software, Inc. SigmaPlot for Windows 
(San Jose, CA). The minimum detectable threshold of the Complement C3 assay is 
0.2µg/mL and normal plasma levels range from 900 to 1900 µg/mL.[217, 218]  The assay 
minimum detectable threshold of Complement C5 is 0.1ng/mL and normal plasma levels 
are 65µg/mL(abcam).[219, 220] 
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Statistical analysis was performed as described in Chapter 2.11.  
 
5.3. Results 
A.  Complement C3 or C5 are activated after SCI  
 Plasma levels of complement C3 and C5 were measured using ELISAs. Median 
values for complement C3 were 472.3 µg/ml for healthy volunteers and 673µg/mL, 901.3 
µg/mL and 970.9 µg/mL for 1.2, 6.4 and 16 days post-SCI, respectively.  There was a 
significant increase in the C3 levels between 1.2 days and C3 levels at 6.5 and 16 days 
(F(2,37)=34.1, P<0.001). The levels of C3 at 1.2 days compared to healthy volunteers was 
not significantly different (T=77, p=0.056). At the 6.4 and 16 day time point, C3 was 
significantly elevated compared to healthy volunteers (6.4 day: T= 32, p<0.001; 16 day: 
T=33, p<0.001). 
 Median values for complement C5 were 96 µg/mL for healthy volunteers and 
130µg/mL, 188µg/mL and 189.8 µg/mL for 1.2, 6.4 and 16 days post-SCI, respectively.  
There was a significant increase in C5 levels between 1.2 days and C5 levels at 6.5 and 16 
days after SCI (F(2,37)=36.7, p<0.001).  The levels of C5 at 1.2 day compared to healthy 
volunteer samples was not significantly different (T=76, p=0.052).  C5 was significantly 
higher at the 6.4 and 16 day time points compared to healthy volunteer levels (6.4 day: 
T=35, p<0.001; 16 days T=35, p<0.001) (Figure 32).  
 
B.  A correlation is observed between the levels of complement C3 but not C5 
with the levels of GFAPab and CRMP2ab. 
 Assessments were made to test whether there is a correlation between the levels of 
C3 or C5 and the levels of GFAPab or CRMP2ab at each time point.  There is a positive 
correlation between the 6.4 day levels of complement C3 and GFAPab levels at 16 days 
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(r(34)=0.34, p=0.04), but not any other time point.  There is a positive correlation between 
levels of C3 and CRMP2ab at 16 days (r(31) = 0.41, p=0.02), but not at any other time 
point.  
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Figure 32.  Complement C3 and C5 levels in SCI patient plasma over time compared 
to healthy volunteer control levels. C3 and C5 are significantly elevated at the 6 and 
16 day time points. C3: (F(2,37)=34.1, P<0.001); C5: (F(2,37)=36.7, p<0.001) 
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C.  An association is not found between complement C3 or C5 with the 
development of neuropathic pain  
 Complement C3 or C5 levels are not different between those who developed 
neuropathic pain compared to those who did not (Figure 33).  There is not a significant 
difference in levels of C3 by pain group F(1,35)=0.48, p=0.49 and there is not a statistically 
significant interaction between pain group and time F(2,35)=0.004, p=1.  For C5 levels, 
there is also no significant difference in C5 levels by pain group F(1,35)=0.49, p=0.49, and 
there is not a statistically significant interaction between pain group and time F(2,35)=0.58, 
p=0.57. 
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  Figure 33.  Complement C3 and C5 levels did not differ by pain group. There is not a 
significant difference in levels of C3 by pain group F(1,35)=0.48, p=0.49 and there is not  
a statistically significant interaction between pain group and time F(2,35)=0.004, p=1.  
For C5 levels, there is also no significant difference in C5 levels by pain group 
F(1,35)=0.49, p=0.49, and there is not a statistically significant interaction between pain 
group and time F(2,35)=0.58, p=0.57. 
 
117 
 
 5.4 Discussion 
A.  Key Findings  
 Plasma levels of complement C3 and C5 were increased after SCI through the 16 
day time point.  Complement C3 and C5 levels did not differ by pain group. 
 
B. Elevation of complement C3 and C5 after SCI. 
 Contrary to the hypothesis, circulating complement levels did not decrease, but 
rather increased over time after injury.  It was hypothesized that circulating C3 and C5 
levels would decrease as they migrated to the injury site. Alternatively, the upregulation of 
C3 and C5 may be the result of ongoing inflammation. 
 Anderson et al. evaluated the deposition of complement components C1q, C4, 
Factor B (binds C3b) and MAC (C5b-9) in the spinal cords of SCI rats experiencing mild or 
severe contusion injuries compared to laminectomy-only rats at 1, 7 and 42 days post-
SCI.[216]  These time points are similar to the time points assessed in the acute SCI 
human subjects’ circulating plasma.  The Anderson et al. study discovered complement 
components C1q, C4, FB, C5b-9 activated and peaked within one day, and complement 
remained immunoreactive in the injured spinal cord for 6 weeks post-SCI.  There was 
uniform magnitude of complement component staining both rostral and caudal of the lesion 
epicenter (>20mm) in SCI rats, but no immunoreactivity in the laminectomy controls.  
Changes due to BSCB permeability in the lateral or ventral white matter were not observed 
until 14 days, yet the complement immunoreactivity was present in gray and white matter at 
all levels of the spinal cord within one day, thus the authors concluded that BSCB 
permeability was not the only source of complement migration and that local complement 
synthesis was likely to have been enhanced by inflammatory mediators.[216]  In addition to 
circulating blood complement permeating the BSCB and complement being produced 
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locally in spinal cord astrocytes, microglia and neurons, complement is found in 
polymorphonuclear leukocytes (PMN). C1q, C3, and C5b-9 were associated with PMN 
infiltration near the epicenter of the spinal cord.[221] PMN were detected at two hours, 
peaked at 24 hours and could still be detected by flow cytometry analysis 6 months after 
SCI. Three days after SCI at least 70% of PMNs infiltrating the spinal cord were associated 
with C1q or C3 and 95% were associated with C5b-9.[221] A study of 34 acute trauma 
victims that evaluated circulating C3a and C3 levels at multiple time points up to 7 days 
post-injury found an association with higher circulating C3a levels and non-survival only at 
the sample taken within 37 minutes after injury (p=0.008) and the C3a/C3 ratio was higher 
in non-survivors than survivors at about 1 hour post-injury (p=0.033).[222] The level of 
activation, not the duration of activation was related to non-survival.  The acute trauma 
study indicated that complement activation occured almost immediately after injury and 
peaked early. Based on the timing of peak complement levels in the above studies, it is 
possible that a dip in circulating complement would have been missed with the three time 
points measured here. Alternatively, the local production may have supplemented 
circulating levels to sustain complement levels.  
 
C.  No association found between complement C3 and C5 levels and 
neuropathic pain. 
 The circulating C3 and C5 levels in SCI human subjects were elevated during the 30 
days measured; however, there is no association with the presence of neuropathic pain 
within 6 months.  It is possible that the timing of the complement measurements were too 
remote from the later determination of neuropathic pain and that if complement was 
measured at 6 months in the neuropathic pain patients it may have been elevated 
compared to those without pain.  
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Chapter 6. General Discussion 
 
A. Summary of findings 
  The primary finding from this investigation is that SCI patients who developed 
CRMP2ab and/or GFAPab at 16 days had 9.5 times greater odds of developing 
neuropathic pain than patients who did not develop these autoantibodies.   Additional 
findings include:  1) 34/80 (43%) of chronic SCI patients had GFAPab. 2) Autoantibody 
levels peaked at 16 ± 7 days and returned to healthy volunteer levels by 96 ± 54 days after 
SCI. 3) At 16 ± 7 days after SCI 8/35 (23%) patients developed CRMP2ab and 21/38 
(55%) patients developed GFAPab. 4) The presence of GFAPab at 16 ± 7 days after SCI is 
a predictor of the development of neuropathic pain.  5) C3 and C5 remained elevated 
through 16 ± 7 days after SCI.  
 Inflammation has been identified as a contributing factor to the development of 
neuropathic pain after SCI.[102, 113, 223] After SCI, inflammation is initiated by the 
physical injury and the local immune response. Trauma results in cell damage which 
triggers an innate immune response to activate the complement system.[216]  Complement 
enhances the ability of antibodies and phagocytes to clear cellular debris and pathogens, 
and it promotes inflammation as C3a and C5a are activated.[187]  C3a and C5a 
anaphylatoxins stimulate neutrophils, eosinophils, and mast cells to release histamine and 
arachidonic acid metabolites (prostaglandins, leukotrienes).[187]  Histamine promotes 
vasodilation, enhanced vascular permeability and endothelial activation; prostaglandins 
produce vasodilation, pain and fever; leukotrienes promote vascular permeability, 
chemotaxis, leukocyte adhesion and activation. The increase vascular permeability, 
leukocyte and endothelial activation augmented by the mechanical damage from the injury 
results in a permeable BSCB. [187] Increased permeability of the BSCB promotes the 
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activation of resident CNS immune cells. Cellular debris is transported to lymphoid organs 
for processing by immune dendritic cells enabling lymphocyte activation and the opportunity 
to generate autoantibodies.[214] Supporting this, B cells were present in the area of the 
lesions after SCI in mice and are also found in the CNS in humans with multiple sclerosis, 
an autoimmune disease.[9, 224] Astrocytes and infiltrating monocytes supply factors (B 
cell-activating factor (BAFF), and proliferation-inducing ligand (APRIL)) that are required for 
B cell functions (survival, differentiation, and germinal formation) and contribute to clonal 
expansion of B cells in situ.[225] This creates a favorable environment for autoantibody 
production.[225] 
 Autoantibodies that develop as part of the immune response after SCI have been 
identified as contributing to enhanced tissue damage and poor outcome.[9]  B cells have 
been demonstrated to be causative of SCI pathology through 1) improved functional, 
behavioral and tissue recovery from SCI in B cell knockout mice compared to wild type 
mice; and 2) that B cell-mediated neurotoxicity is cause by SCI rodent IgG as injection of 
SCI IgG into uninjured mice resulted in SCI-like pathology.[5, 9] Until now, the identities of 
autoantibodies associated with the development of neuropathic pain in human SCI have not 
been identified.  The hypothesis is that proteins from the injured spinal cord released by 
SCI trigger autoantibody production, which can lead to the development of NP.  GFAP and 
CRPM2 are two antigens identified as inducing immunoreactivity from SCI patient plasma 
samples.   
 
SCI patients who developed CRMP2ab and/or GFAPab had 9.5 times greater odds of 
developing neuropathic pain than patients who did not develop these 
autoantibodies. 
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 Antibodies found in human blood vary between individuals based on their lifetime of 
variable exposures to pathogens, autoantigens, and other antigens.  Autoimmune diseases 
have been characterized by the presence of patterns of autoantibodies.  A panel of 
autoantibodies is likely to be more powerful than a single autoantibody to supplement or 
predict the clinical diagnosis of neuropathic pain after SCI.  GFAPab and CRMP2ab are 
two autoantibodies that combined show a 9.5 times increased odds of developing 
neuropathic pain after SCI and when controlling for injury factors. The injuries being 
complete and/or at the cervical level were not associated with the development of the two 
autoantibodies.   
 Systemic lupus erythematous (SLE) is a chronic autoimmune disease affecting 
multiple organs including the skin, heart, lungs, kidneys, joints, and nervous system.  SLE 
is an example of an autoimmune disease that is diagnosed based on clinical findings that 
are supplemented with results from evaluations of panels of autoantibodies including 
antinuclear antibodies, anti-double stranded DNA and other autoantibodies.   Antinuclear 
antibodies are approximately 90% sensitive, but not very specific for SLE whereas anti-
double stranded DNA is over 95% specific.[226]  The panel of autoantibodies for SLE 
balances sensitivity and specificity to enhance the ability to distinguish SLE from other 
autoimmune conditions.  When the panel of autoantibodies is combined it provides data on 
which to determine the presence of disease.  For neuropathic pain after SCI, additional 
autoantibodies may improve the sensitivity and specificity in order to distinguish who will 
develop neuropathic pain.  If the current findings are validated this panel of autoantibodies 
could be used as a biomarker for early diagnosis.   
 
Forty-three percent of chronic SCI patients have GFAPab 
 The presence of circulating GFAPab was found in 43% of chronic SCI patients.  
ISNCSCI scores, age, sex and weight were comparable for both autoantibody- positive and 
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negative chronic SCI patients indicating the populations were similar.  However, it is 
unclear why only a portion of chronic SCI patients generated GFAPab while others did not.  
It is possible that the autoantibody negative patients may not have been exposed to 
plasma GFAP levels sufficient to mount an immune response (either as primary or 
secondary exposure). When evaluating the levels of GFAPab in chronic SCI a difference in 
the levels of GFAPab between the pain groups was not detected. The chronic patients 
ranged from 1 to 41 years post-SCI.  It is possible that the autoantibody-negative patients 
produced antibodies at other times. For example, blood levels of IgG antibodies in humans 
after receiving a tetanus toxoid boost increased by a factor of 80 between days 5-8 after 
injection then decreased after about 2 months reflecting production of short-lived plasma 
cells.[227] Short-lived plasma cells have an approximate half-life of human IgG of about 20 
days, and long-lived plasma cells have a half-life of about 40 days.[227]  Memory B cells 
can be antigen-dependent resulting in extensive proliferation and differentiation toward 
short-lived plasma cells, or polyclonal responding to  polyclonal activators where all 
memory B cells respond undergoing continuous proliferation and differentiation maintaining 
a steady state.[227] The chronic subjects enrolled in this study were excluded if they had 
known ongoing inflammation (e.g., infection, cancer, skin breakdown, deep vein 
thrombosis), and they were on average 15 years post-SCI.  These exclusion criteria may 
have reduced the ability to measure both short term serological memory (antigen-
dependent) and long-term serological memory (antigen-independent polyclonal activation 
and differentiation of memory B cells).[227] It is possible that their GFAPab levels were 
below the assay’s limit of detection at the time that their sample was acquired, years after 
autoantigen exposure.   
 The number of active memory cells is influenced by stimulation from cytokines (e.g., 
IL-2, IL-10, IL-21).[228-230]  Antigen-specific immune responses directed at other non-
cross reacting antigens impact the level of these cytokines, which then effects the volume 
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of active memory cells.[231] IL-2, IL-10, anti-CD40 and IL-21 induce plasma cell 
differentiation from memory B cells, and levels of these cytokines are higher in times of 
active inflammation.[230, 232-235] Chronic SCI subjects were excluded if there was a 
known, active ongoing inflammatory process.  It is possible that excluding those subjects 
created a subject selection bias reducing the percentage of chronic SCI with perceptible 
GFAPab levels.   
 
Autoantibody levels peaked at 16 ± 7 days and returned to healthy volunteer levels 
by 96 ± 54 days after SCI. 
  On exposure to an antigen lymphocytes with the antigen-specific receptor are 
activated and proliferate.  Over a period of about 5 days B lymphocytes go through clonal 
expansion where they differentiate into effector cells.[179]  The differentiated plasma B 
cells secrete antibody into the circulating blood as a response in order to clear the 
antigen.[236] Most plasma B cells die after the antigen is eliminated, but some of these 
antigen-specific B cells remain as memory cells and can be activated quickly.[237] For SCI 
subjects, the GFAPab secreted through activation of the memory B cells would require 
antigen stimulus to progress though the clonal expansion process.[227, 236]  The peak 
levels of antibody detected in these samples were found to be at the 16 ± 7 day time point.  
These peak levels were generally higher than those observed in samples collected during 
the chronic stage of injury.   Of exception, four of the chronic SCI subjects with levels of 
GFAPab that were more comparable to that seen acutely after SCI had evidence of 
disruption of the BSCB (e.g., recent placement of intrathecal pumps), suggesting a re-
exposure to antigen may be responsible for the increased GFAPab levels observed in 
these patients.[227]  Three of these four patients had neuropathic pain.  
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At 16 ± 7 days after SCI 8/35 (23%) patients developed CRMP2ab and 21/38 (55%) 
patients developed GFAPab. 
 Although the exact time course of GFAP release in humans after SCI has not been 
established, GFAP levels can be detected in the serum of traumatic brain injury patients 
within hours of the injury, returning to baseline by 3 days post injury.[174]  In rat cortical and 
hippocampal brain tissue after controlled cortical impact CRMP2 decreased from 6 hours to 
3 days, returning to normal levels by 5 days; the CRMP-2 55kDa breakdown products 
showed a corresponding increase over this time period.[156]  Circulating levels of CRMP2 
were not provided, but this breakdown of CRMP2 indicates that substrate could be 
available for autoantibody production after injury.  Samples were not available for most 
patients within the very early time post-SCI in order to measure early release of GFAP or 
CRMP2. 
 After SCI astrocytes become reactive astrocytes.  These reactive astrocytes have 
increased size, increased GFAP expression and increased number.[238]  Recent analyses 
of rat tissue, CSF and serum showed release of GFAP protein and its breakdown products 
after SCI that was measurable at 4 hours, 24 hours, and 7 days post-SCI. Elevated GFAP/ 
breakdown product levels persisted at the injury site and in the serum longer than in the 
CSF.  There was a positive association with injury severity and CSF and serum levels of 
GFAP/breakdown product.[239] The presence of GFAP/breakdown product after injury 
would facilitate the development of an autoantibody. In a TBI study, plasma taken within 
24hrs of injury from TBI patients was compared with age-matched controls.[240]  A new, 
specific IgG autoantibody response would not be expected to manifest this close to time of 
injury.  In agreement with this, it has been reported TBI subjects who had previous TBI with 
loss of consciousness had significantly higher levels of GFAPab compared to controls, but 
TBI patients who had not had previous injury did not have a significant difference from 
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controls at that early time point. [240]  This is one example of why some subjects may have 
antibodies to GFAP within a day of injury.   
 Twenty-three percent of SCI subjects had CRMP2ab at 16±7 days after SCI.  These 
results did not demonstrate significance for an association of CRMP2ab with the 
development of neuropathic pain at this peak immune response time point (T=231.0, 
p=0.08). The subjects who were CRMP2ab positive with neuropathic pain represented 
88% of CRMP2ab positive subjects and the CRMP2ab negative subjects who had 
neuropathic pain were 48% of CRMP2ab negative subjects.  Sample size analysis based 
on these data indicates a larger sample size of 64 subjects is needed to detect a significant 
difference at an 80% power with an alpha of 0.05.    
 CRMP2 is a cytoplasmic protein found in central and peripheral axons.[155] CRMPs 
participate in semaphorin-induced growth-cone collapse and influence the direction of axon 
growth, dorsal root ganglion neuron growth, dendrite specification, and axon 
regeneration.[138] It is unknown what significance the presence of the CRMP2ab has in 
chronic SCI. It is possible that the presence of CRMP2ab could impinge on CRMP2’s role 
in growth-cone collapse. Whether and how CRMP2ab is involved in inhibition of axonal 
guidance after SCI is of interest for future studies.  The CRMP family of proteins includes 
CRMP 1, 2, 3, 4 and 5.  CRMP1-4 have high sequence homology (approximately 
75%).[138] The homology may have contributed to some of the nonspecific binding that 
was observed.  No correlations were discovered with presence of CRMP2ab and level of 
injury, completeness of injury, presence of comorbid conditions, skin ulcers, spasticity, sex 
or age in post hoc analysis in the acute subjects.  Five percent of healthy volunteers had 
CRMP2ab, this is of unknown significance. Autoantibodies to CRMP-2 have been identified 
in autoimmune retinopathy and cancer-associated retinopathy (melanoma, breast cancer 
and lymphoma).[155] None of the enrolled subjects were known to have retinopathy or 
cancer.   
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The presence of GFAPab at 16 ± 7 days after SCI is a predictor of the development of 
neuropathic pain.   
 Using a threshold of 36ng/mL of GFAPab in plasma has 74% sensitivity and 73% 
specificity for predicting the development of neuropathic pain within 6 months of SCI.  
GFAPab was not found to be diagnostic of neuropathic pain in the chronic patients, but 
data indicate that higher levels of in GFAPab in the acute stage it is a fair predictor.   
 One potential method of preventing the development of GFAPab would be to inhibit 
GFAP production and release into the circulation.  There are medications that attenuate 
neuropathic pain in rodent models that inhibit glial cells activation, propentofylline, 
Ibudilast, and withaferin-A.[110, 241]  Propentofylline inhibits GFAP production and was 
shown to reduce neuropathic pain behaviors in part through its regulation of pro-
inflammatory cytokines.[110] Propentofylline and ibudilast inhibit phosphodiesterase and 
inhibit glial cell activation which has been correlated with reduced pain. [110] However, in 
human pain studies ibudilast did not have a positive effect in an opioid-overuse headache 
trial,[242] and propentofylline did not relieve pain in a post-herpetic neuralgia study.[243] 
Withaferin-A or ashwagandha is a steroidal lactone that binds and inhibits GFAP that was 
shown to have analgesic effect in rats.[192]  Additionally, reduction in GFAP protein 
expression from clomipramine, a tricyclic antidepressant, was confirmed in mouse 
astrocytes after it was identified via a screen of chemical libraries.[244]  Clomipramine, has 
been shown to reduce neuropathic pain in humans.[245]  
 
C3 and C5 remained elevated through 16 ± 7 days after SCI. 
 Plasma levels of complement C3 and C5 levels were elevated after SCI through the 
16 day time point. Serum complement elevation has been shown previously in human SCI 
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at 2 weeks to 9 years post-SCI.[24] Complement is constitutively present in the systemic 
circulation in its inactive form.  Complement is activated early following trauma as part of 
the initiation of the inflammatory cascade.  C3a and C5a are released systemically after 
complement system activation and exert pro-inflammatory effects. An increase of 
complement C3 genes is characteristic of reactive A1 astrocytes (reactive A2 astrocytes 
are neuroprotective and do not express C3); A1 astrocytes induce toxicity to synapses and 
contribute to death of neurons and mature oligodendrocytes after acute CNS injury.[162] 
After SCI, complement components are deposited in astrocytes, neurons, oligodendrocytes 
and axons of the injured cord.[45]  In mouse injury models, C3 was found at the injury site 
within one hour peaking at 24 hours post-contusion.[246]  Interestingly, C3 deficient mice 
had better locomotor scores than wild-type contused mice (p<0.001) suggesting C3 has a 
negative impact on motor function recovery. Additionally, there was more tissue 
preservation and less demyelination in spinal cords of C3 deficient mice.  Here, the 
determination of the presence of neuropathic pain was based on pain development within 6 
months and therefore acute measurements of circulating complement in the early post-
injury time period may not directly correlate.   Elevated complement may be one piece of 
the diagnostic puzzle to indicate which individuals develop neuropathic pain.[22, 213]  
However, the assumption that sequestration of complement due to GFAP or CRMP2 
breakdown would be reflected as lower plasma C3 or C5 levels was not supported by the 
data.  An alternate explanation could be that trauma to the tissue caused an activation of 
complement as part of an inflammatory reaction. 
 
B.  Weakness  
 There are several limitations to this study.  First, the samples were collected at pre-
determined time periods, therefore peak levels may not be represented for each subject, 
128 
 
and were likely not present in the chronic samples.  There were 118 SCI patients to study, 
but only 38 of them with samples available at the time observed to be the peak for the 
group autoantibody levels.  A larger sample size could strengthen these results as 
indicated in the power analysis performed using the CRMP2ab results discussed above.   
 Secondly, these studies are correlative and conclusions cannot be made on the 
nature of the presence of autoantibody causing neuropathic pain.  If the presence of 
GFAPab or CRMP2ab is found to be causal, removal of the autoantibody could be 
explored as a preventive therapy. The effect of an autoantibody to GFAP or CRMP2 may 
be from a direct antibody-antigen binding causing protein misfolding, or functional 
interference with GFAP or CRMP2, or causing a decrease in availability of the GFAP or 
CRMP2 protein. Spinal cord tissue pathology cannot be determined based on these 
studies. Or the autoantibody may be contributing to pathology through increasing 
inflammation.  Neuropathic pain may be caused by sprouting of pain fibers, 
hyperexcitability, sensitization, chronic BSCB permeability and persistent inflammation.[25, 
103, 109]  The presence of GFAPab and CRMP2ab may have contributed to the 
development of neuropathic pain by supplementing any of these processes.  Astrocytes 
play an essential role in maintaining the BSCB.  If GFAPab binds astrocytic GFAP it would 
likely disrupt astrocytes function which could contribute to a perpetually permeable cord or 
a change in the cytokines and  immune cells migrating across the BSCB; this inflammatory 
state could lead to neuropathic pain.[25, 160] If the GFAPab and CRMP2ab are formed in 
response to proteins released from cells damaged after injury, it is possible that 
autoantibody-induced damage occurs and once a threshold of nerve damage and 
hyperexcitability has been reached the presence of the autoantibody is no longer 
necessary for neuropathic pain to persist.  
 Third, while validation studies have confirmed the GFAPab and CRMP2ab 
specificity, it is possible that the autoantibody after SCI may also be polyspecific.  The 
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autoantibody may cross-react with the GFAP or CRMP2 antigen; however, it may have 
been developed in response to another agent.  Multiple examples can illustrate 
polyspecificity, for instance, rheumatic fever is caused by anti-streptococcal antibodies 
(produced after an infection) that cross-react with a cardiac tissue antigen.[247] Antibodies 
to the Epstein-Barr virus have been shown to cross react with human heterogeneous 
nuclear ribonucleoprotein L (a protein involved in the formation and function of mRNA) 
related to identity of stretches of glycine-alanine repeats.[248]   Homology exists between 
AQP4 and C. perfringens and overexpression of C. perfringens has been found in the 
intestine of NMO patients, indicating it could behave as a molecular mimic.[170] Molecular 
mimicry between Campylobacter jejuni which causes enteritis and ganglioside GM1 
causing cross-reacting antibodies  is involved in the development of Guillain-Barre 
syndrome (a demyelinating disease); anti-ganglioside GM1 has been identified in SCI.[16, 
19, 249]  These bacteria are found in the intestine, and GFAP is expressed in enteric glial 
cells.  Enteric glial cells have a response similar to that of activated astrocytes under 
inflammatory conditions.  They respond with an upregulation of GFAP, proliferate and 
hypertrophy; additionally they propagate immune signaling by secretion of IL1β, IL6 and 
TNFα, and expression of MHC class II molecules.[250]  
 In patients following trauma or severe injury intestinal bacteria can translocate 
through the disrupted gut barrier and induce systemic infection.[251-253] Mouse models 
have shown that pathological changes in the composition of the gut microbiome (“gut 
dysbiosis”) cause immune dysregulation, neuroinflammation and exacerbate neurological 
disorders.[170, 254-257] A SCI mouse study that induced gut dysbiosis via the delivery of 
broad-spectrum antibiotics demonstrated that SCI-induced gut dysbiosis is associated with 
gut-associated lymphoid tissue immune cell activation, and that dysbiosis hinders recovery 
and worsens intra-spinal inflammation.[50] However, neuropathic pain was not evaluated in 
these gut dysbiosis SCI mice.  The intestinal microbiota of 30 complete SCI patients was 
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compared to 10 healthy controls revealing that SCI patients had lower bacterial DNA 
counts of numerous butyrate producing bacteria.[258] However, symptoms of infection, 
inflammation or neuropathic pain were not evaluated. Butyrate producing bacteria play a 
key role in maintaining gut barrier function.[258]  
 Homology between common intestinal bacteria and GFAP and CRMP2 was 
explored as part of the present study. BLAST (National Center for Biotechnology 
Information, U.S. National Library of Medicine) searches were performed for GFAP or 
CRMP2 looking for homology to some specific, common intestinal bacteria such as 
Campylobacter jejuni, Helicobacter pylori (both known to have structures that are 
associated with the development of autoimmune conditions[259]), Escherichia coli, 
Enterobacter, and the Campylobacter group. While an exhaustive search was not 
performed, it is clearly evident that CRMP2 shares high homology to bacteria in the 
Enterobacter family, suggesting molecular mimicry may be involved with the response 
observed in the acute subjects.  GFAP shares homology with bacteria searched, but to a 
much lesser degree.  For instance, when searching the campylobacter group, 
dihydroorotase [Campylobacter concisus] which is bacteria commonly associated with 
irritable bowel disease, results indicated it has 43% homology with 28% identity to CRMP2.  
A refined search to evaluate only the conserved domains of CRMP2 (to increase the 
chance of homology) did not reduce the area to be searched for CRMP2.  GFAP 
conserved domains include the filament head domain (4-66) and the filament (68-376).  
Searching by the conserved domain of GFAP increased the percent homology.  For 
example, searching the head domain against Enterobacteriaceae resulted in 65% 
homology with 61% identity. This gram negative bacteria family includes Salmonella, E. 
coli and Klebsiella.  These results indicate that there is the possibility that the responses 
seen in plasma may be related to homology to pathogens to which the patient was 
previously exposed. Alternatively, concomitant inoculations with these pathogens could 
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have contributed to autoantibody formation. Regardless of the whether or not the 
autoantibody is polyspecific, it does not negate the fact that the presence of the 
autoantibodies at the 16 day time point showed a 9.5 times increased risk of neuropathic 
pain.  
 
C. Model  
 
   
 The model suggests that the injury to the spinal cord causes damage to neurons 
and axons, and that astrocytes and microglia are activated, CNS proteins are released into 
the circulation and inflammation occurs.  There is increased vascular and BSCB 
permeability and complement is activated exacerbating inflammation.  Activated B cells 
generate autoantibodies; these autoantibodies (CRMP2ab and GFAPab) may interfere with 
normal cell function, damage tissue and perpetuate inflammation resulting in neuropathic 
pain (Figure 34, 35).  
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       Figure 34.  Model of the presence of autoantibodies at the SCI injury site 
 
 
 
 
  
Figure 34.  Model of the presence of autoantibodies at the SCI injury 
site.  
The injury to the spinal cord causes damage to neurons and axons, 
astrocytes and microglia are activated, CNS proteins are released 
into the circulation and inflammation occurs, there is increased 
vascular and BSCB permeability and complement is activated 
exacerbating inflammation.  Activated B cells generate 
autoantibodies; these autoantibodies may interfere with normal cell 
function, damage tissue and perpetuate inflammation resulting in 
neuropathic pain. 
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Figure 35.  Overview Model 
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 This research makes two contributions.  It established a process for identifying 
autoantibodies and it identified two autoantibodies that are associated with the 
development of neuropathic pain within 6 months after SCI.  The work established a 
process for identifying autoantibodies in human plasma.  Using an unbiased approach, 
patterns of change in immunoreactivity produced by SCI patients’ plasma were identified 
by western blot.  The potential antigens were separated using 2-D gel electrophoresis.  
Areas with new or enhanced immunoreactivity were isolated, the corresponding gel spots 
were excised and the proteins were identified using LC-MS/MS.  The antigen candidates 
were carefully confirmed as autoantigens causing the immunoreactivity.  Critically, the 
capillary immunoassay blocking and competition studies revealed that non-specific binding 
can occur.  The identification of non-specific binding demonstrates the utility of using this 
method over other methods which might not distinguish the specificity of binding.  
    The data indicates that there is potential for a diagnostic tool to differentiate patients 
who may develop neuropathic pain within 6 months after SCI from those who do not by 
assaying levels of GFAPab and CRMP2ab in combination with complement and other 
potential factors.  Additionally, autoantibodies are likely to be present that are associated 
with other secondary pathologies.  The identification of autoantibodies produced after SCI 
may lead to new treatment targets or new prognostic indicators.   
 
D.  Future directions 
 
 GFAPab and CRMP2ab may be two of multiple autoantibodies that contribute to the 
development of neuropathic pain.   Future studies will evaluate additional autoantibody 
candidates and look at the possibility that adding to this panel of antibodies improves the 
predictive value.   
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E.  Study impact in spinal cord injury 
 
 
 Results indicating the presence of GFAPab, and GFAP and/or CRMP2ab at 16 days 
are associated with the development of neuropathic pain within 6 months after SCI builds 
on experimental studies.  Experimental mouse studies demonstrated that SCI causes 
autoantibody production and that autoantibodies impair recovery of function and worsen 
tissue damage.[5, 9]  In SCI, however they did not demonstrate an association with the 
development of autoantibodies and the subsequent development of neuropathic pain. The 
discovery of autoantibodies reactive to GFAP and CRMP2 in SCI patients may lead to the 
development of new biomarkers for prediction of the development of neuropathic pain, and 
importantly, if determined as causal, new treatments for SCI-related neuropathic pain. 
 Pain has a serious impact on the quality of life for SCI patients experiencing 
neuropathic pain.  Currently, there are no diagnostic tools available to predict who will 
develop chronic neuropathic pain, nor are there fully effective therapies available to treat 
this debilitating condition.  Ultimately, the goal is that discovery of autoantibodies predictive 
of pain will not only detect  those patients in need of intervention, but may also identify new 
areas of investigation that  can create therapies to eliminate the onset of neuropathic pain 
and its associated morbidity. 
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APPENDIX 
 
A. Protein A affinity columns  
 IgG purification was performed and affinity columns were created using recombinant 
protein A to covalently crosslink the antibody in the plasma sample.  BCA and optical 
density measurements of washes and western blots and coomassie stained gels provided 
confirmation of successful IgG purification and antibody crosslinking to Protein A.  The 
homogenized CNS tissue was applied the affinity column and the antigen/proteins were 
eluted with glycine. The antigen was then run on a Coomassie gel and Western blot.  The 
eluted antigen was to be cut out of the Coomassie gel for identification by LC-MS/MS.  
Appendix Figure 1 shows GFAP eluted from the protein A affinity column made with custom 
anti-GFAP.  Columns made with whole serum were not successful.  Therefore, the 2-D gel 
approach was taken. 
Methods 
 Antibody purification Antibody purification was performed with a Melon Gel IgG 
Spin Purification kit (Thermo Scientific, Rockford, IL).  The kit binds high abundance 
proteins like albumin and transferrin using a mild buffer at physiological pH.  It is amine-
free. Columns were prepared with gel slurry (200µl) centrifuged and washed twice with 120 
µl of purification buffer.  Samples diluted with gel purification buffer (50µl sample: 450µl 
buffer) were added to the column and mixed for 5 minutes.  Purified antibody was tested in 
a western blot, on a coomassie blue stain gel and after confirmation of protein it applied to 
the protein A affinity column. 
 Protein A affinity column Purified IgG was applied to protein A affinity 
columns(Pierce Protein A IgG Plus Orientation, Thermo Scientific, Rockford, IL) to crosslink 
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the antibody to protein A agarose. Purified IgG was diluted with antibody binding/wash 
buffer (1:1) and loaded on to equilibrated columns.  The resin was re-suspended and mixed 
at room temperature for one hour.  The resin was allowed to settle and solution pass 
through was collected for analysis of binding efficiency.  Because binding efficiency was 
insufficient as measured by BCA and spectrophotometry, the process was repeated, but 
instead the resin and sample were incubated overnight at -4°C.  Binding efficiency was 
confirmed with spectrophotometry.  The columns were washed and Crosslinking buffer was 
prepared with DSS dissolved in DMSO and immediately applied to the antibody-bound 
column.  The column was incubated for one hour for one hour on a rotator.  The resin was 
washed with crosslinking buffer and then blocked with blocking buffer to block any 
remaining non-reacted NHS-ester groups.  Resin was re-suspended and mixed.  IgG 
elution buffer was applied to elute any IgG that was not covalently bound to protein A.  The 
column was washed and completed and stored in a 0.02% sodium azide PBS solution at 
4°C for future use.  Samples coming off the column at each step were saved and efficiency 
was evaluated by spectrophotometry. 
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Results 
 
 
 
  
 Coomassie gel (left) and western blot (right) of Glial Fibrillary Acidic Protein 
(GFAP) antibody affinity column (GFAP, MW 50kD, arrow).  Affinity columns 
(AminoLink) for GFAP were created.  Starting brain extract (50ul plus 450ul PBST) was 
incubated on the column.  Flow through shows the brain proteins that were not retained 
on the column.  Glycine 1 was the first elution from the column showing the antigen 
(GFAP) that was bound to the anti-GFAP column. Western blot was probed with a 
custom anti-GFAP primary antibody (1:6000) and alkaline phosphatase secondary anti-
rabbit antibody.  As anticipated, GFAP antigen is visible on the western blot that was 
probed with custom anti-GFAP (arrow). Serum elution from healthy volunteer serum 
was not expected to and did not show GFAP.  When the columns were made using 
purified IgG from patient plasma as the antibody bound to the protein A agar, the 
proteins came off in the flow through, but did not come off on the glycine elution 
suggesting binding was not strong enough (not shown). 
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B. Immunohistochemistry (IHC) performed on monkey brain tissue. 
                            [195]                                  
 
  
Immunohistochemistry on monkey 
brain tissue.  Monkey brain tissue 
stained with human plasma taken 
16±7 days post-SCI (top).  Faint 
staining of astrocytes can be seen.  
The same tissue probed with a 
custom anti-GFAP antibody 
showing reactive astrocytes 
(bottom).  Similar to Ishida et al., 
the autoantibody was not clearly 
detectable using IHC.  As 
suggested by them, this may be 
that the epitope of the antigen is 
concealed in situ because of 
intermolecular or intramolecular 
conformation. [195] 
140 
 
Bibliography 
 
 1.  Levi R, Hultling C, Nash MS, Seiger A (1995) The Stockholm spinal cord injury 
study: 1. Medical problems in a regional SCI population. Paraplegia 33:308-315 
 2.  Siddall PJ, McClelland JM, Rutkowski SB, Cousins MJ (2003) A longitudinal study of 
the prevalence and characteristics of pain in the first 5 years following spinal cord 
injury. Pain 103:249-257 
 3.  Dijkers M, Bryce T, Zanca J (2009) Prevalence of chronic pain after traumatic spinal 
cord injury: a systematic review. J Rehabil Res Dev 46:13-29 
 4.  Diamond B, Honig G, Mader S, Brimberg L, Volpe BT (2013) Brain-reactive 
antibodies and disease. Annu Rev Immunol 31:345-385 
 5.  Ankeny DP, Lucin KM, Sanders VM, McGaughy VM, Popovich PG (2006) Spinal 
cord injury triggers systemic autoimmunity: evidence for chronic B lymphocyte 
activation and lupus-like autoantibody synthesis. J Neurochem 99:1073-1087 
 6.  Popovich PG, Stokes BT, Whitacre CC (1996) Concept of autoimmunity following 
spinal cord injury: possible roles for T lymphocytes in the traumatized central 
nervous system. J Neurosci Res 45:349-363 
 7.  Moalem G, Xu K, Yu L (2004) T lymphocytes play a role in neuropathic pain 
following peripheral nerve injury in rats. Neuroscience 129:767-777 
 8.  Moalem-Taylor G, Allbutt HN, Iordanova MD, Tracey DJ (2007) Pain hypersensitivity 
in rats with experimental autoimmune neuritis, an animal model of human 
inflammatory demyelinating neuropathy. Brain Behav Immun 21:699-710 
141 
 
 9.  Ankeny DP, Guan Z, Popovich PG (2009) B cells produce pathogenic antibodies 
and impair recovery after spinal cord injury in mice. J Clin Invest 119:2990-2999 
 10.  Palmers I, Ydens E, Put E, Depreitere B, Bongers-Janssen H, Pickkers P, Hendrix 
S, Somers V (2016) Antibody profiling identifies novel antigenic targets in spinal 
cord injury patients. J Neuroinflammation 13:243 
 11.  Hirsch IH, Sedor J, Callahan HJ, Staas WE, Jr. (1990) Systemic sperm 
autoimmunity in spinal-cord injured men. Arch Androl 25:69-73 
 12.  Siosteen A, Steen Y, Forssman L, Sullivan L (1993) Auto-immunity to spermatozoa 
and quality of semen in men with spinal cord injury. Int J Fertil 38:117-122 
 13.  Petrova NV, Ponomaryova AM, Alyoshkin VA, Eliseyev AT, Yumashev GS (1993) 
Serum rheumatoid factors in spinal cord injury patients. Paraplegia 31:265-268 
 14.  Zajarias-Fainsod D, Carrillo-Ruiz J, Mestre H, Grijalva I, Madrazo I, Ibarra A (2012) 
Autoreactivity against myelin basic protein in patients with chronic paraplegia. Eur 
Spine J 21:964-970 
 15.  Wang R, Chen J, Zhou S, Li C, Yuan G, Xu W, Wang X, Li J, Song Y, Gong N 
(1995) Enzyme-linked immunoadsorbent assays for myelin basic protein and 
antibodies to myelin basic protein in serum and CSF of patients with diseases of the 
nervous system. Hua Xi Yi Ke Da Xue Xue Bao 26:131-134 
 16.  Davies AL, Hayes KC, Dekaban GA (2007) Clinical correlates of elevated serum 
concentrations of cytokines and autoantibodies in patients with spinal cord injury. 
Arch Phys Med Rehabil 88:1384-1393 
142 
 
 17.  Taranova NP, Makarov AI, Amelina OA, Luchakova OS, Loboda EB, Leikin IB 
(1992) The production of autoantibodies to nerve tissue glycolipid antigens in 
patients with traumatic spinal cord injuries. Zh Vopr Neirokhir Im N N Burdenko21-
24 
 18.  Mizrachi Y, Ohry A, Aviel A, Rozin R, Brooks ME, Schwartz M (1983) Systemic 
humoral factors participating in the course of spinal cord injury. Paraplegia 21:287-
293 
 19.  Hayes KC, Hull TC, Delaney GA, Potter PJ, Sequeira KA, Campbell K, Popovich PG 
(2002) Elevated serum titers of proinflammatory cytokines and CNS autoantibodies 
in patients with chronic spinal cord injury. J Neurotrauma 19:753-761 
 20.  Dekaban GA, Thawer S (2009) Pathogenic antibodies are active participants in 
spinal cord injury. J Clin Invest 119:2881-2884 
 21.  Dulin JN, Karoly ED, Wang Y, Strobel HW, Grill RJ (2013) Licofelone modulates 
neuroinflammation and attenuates mechanical hypersensitivity in the chronic phase 
of spinal cord injury. J Neurosci 33:652-664 
 22.  Levin ME, Jin JG, Ji RR, Tong J, Pomonis JD, Lavery DJ, Miller SW, Chiang LW 
(2008) Complement activation in the peripheral nervous system following the spinal 
nerve ligation model of neuropathic pain. Pain 137:182-201 
 23.  Nie F, Wang J, Su D, Shi Y, Chen J, Wang H, Qin W, Shi L (2013) Abnormal 
activation of complement C3 in the spinal dorsal horn is closely associated with 
progression of neuropathic pain. Int J Mol Med 31:1333-1342 
143 
 
 24.  Rebhun J, Botvin J (1980) Complement elevation in spinal cord injury. Ann Allergy 
44:287-288 
 25.  Nesic O, Lee J, Johnson KM, Ye Z, Xu GY, Unabia GC, Wood TG, McAdoo DJ, 
Westlund KN, Hulsebosch CE, Regino Perez-Polo J (2005) Transcriptional profiling 
of spinal cord injury-induced central neuropathic pain. J Neurochem 95:998-1014 
 26.  Plunkett JA, Yu CG, Easton JM, Bethea JR, Yezierski RP (2001) Effects of 
interleukin-10 (IL-10) on pain behavior and gene expression following excitotoxic 
spinal cord injury in the rat. Exp Neurol 168:144-154 
 27.  Ankeny DP, Popovich PG (2009) Mechanisms and implications of adaptive immune 
responses after traumatic spinal cord injury. Neuroscience 158:1112-1121 
 28.   (2017) National Spinal Cord Injury Statistical Center, Facts and Figures at a 
Glance. University of Alabama at Birmingham, Birmingham, AL, 
 29.   (2013) World Health Organization Spinal Cord Injury Fact Sheet No384. WHO 
2017, 
 30.   (2008) American Spinal Injury Association: International Standards for Neurological 
Classification of Spinal Cord Injury. Atlanta, GA, 
 31.  Al-Habib AF, Attabib N, Ball J, Bajammal S, Casha S, Hurlbert RJ (2011) Clinical 
predictors of recovery after blunt spinal cord trauma: systematic review. J 
Neurotrauma 28:1431-1443 
 32.  Kirshblum S, Millis S, McKinley W, Tulsky D (2004) Late neurologic recovery after 
traumatic spinal cord injury. Arch Phys Med Rehabil 85:1811-1817 
144 
 
 33.  Mabray MC, Talbott JF, Whetstone WD, Dhall SS, Phillips DB, Pan JZ, Manley GT, 
Bresnahan JC, Beattie MS, Haefeli J, Ferguson AR (2016) Multidimensional 
Analysis of Magnetic Resonance Imaging Predicts Early Impairment in Thoracic and 
Thoracolumbar Spinal Cord Injury. J Neurotrauma 33:954-962 
 34.  Haefeli J, Mabray MC, Whetstone WD, Dhall SS, Pan JZ, Upadhyayula P, Manley 
GT, Bresnahan JC, Beattie MS, Ferguson AR, Talbott JF (2017) Multivariate 
Analysis of MRI Biomarkers for Predicting Neurologic Impairment in Cervical Spinal 
Cord Injury. AJNR Am J Neuroradiol 38:648-655 
 35.  Anderson KD, Guest JD, Dietrich WD, Bartlett BM, Curiel R, Dididze M, Green BA, 
Khan A, Pearse DD, Saraf-Lavi E, Widerstrom-Noga E, Wood P, Levi AD (2017) 
Safety of Autologous Human Schwann Cell Transplantation in Subacute Thoracic 
Spinal Cord Injury. J Neurotrauma 34:2950-2963 
 36.  Gomes-Osman J, Cortes M, Guest J, Pascual-Leone A (2016) A Systematic Review 
of Experimental Strategies Aimed at Improving Motor Function after Acute and 
Chronic Spinal Cord Injury. J Neurotrauma 33:425-438 
 37.  Anderson DK, Beattie M, Blesch A, Bresnahan J, Bunge M, Dietrich D, Dietz V, 
Dobkin B, Fawcett J, Fehlings M, Fischer I, Grossman R, Guest J, Hagg T, Hall ED, 
Houle J, Kleitman N, McDonald J, Murray M, Privat A, Reier P, Steeves J, Steward 
O, Tetzlaff W, Tuszynski MH, Waxman SG, Whittemore S, Wolpaw J, Young W, 
Zheng B (2005) Recommended guidelines for studies of human subjects with spinal 
cord injury. Spinal Cord 43:453-458 
 38.  Adriaansen JJ, Ruijs LE, van Koppenhagen CF, van Asbeck FW, Snoek GJ, van 
KD, Visser-Meily JM, Post MW (2016) Secondary health conditions and quality of 
145 
 
life in persons living with spinal cord injury for at least ten years. J Rehabil Med 
48:853-860 
 39.  Adriaansen JJ, Post MW, de GS, van Asbeck FW, Stolwijk-Swuste JM, Tepper M, 
Lindeman E (2013) Secondary health conditions in persons with spinal cord injury: a 
longitudinal study from one to five years post-discharge. J Rehabil Med 45:1016-
1022 
 40.  Krause JS, Saunders LL (2011) Health, secondary conditions, and life expectancy 
after spinal cord injury. Arch Phys Med Rehabil 92:1770-1775 
 41.  Craig A, Nicholson PK, Guest R, Tran Y, Dezarnaulds A, Hales A, Ephraums C, 
Middleton J (2015) Prospective study of the occurrence of psychological disorders 
and comorbidities after spinal cord injury. Arch Phys Med Rehabil 96:1426-1434 
 42.  Noreau L, Noonan VK, Cobb J, Leblond J, Dumont FS (2014) Spinal cord injury 
community survey: a national, comprehensive study to portray the lives of 
canadians with spinal cord injury. Top Spinal Cord Inj Rehabil 20:249-264 
 43.  Actor JK (2014) Introductory Immunology Basic Concepts for Interdisciplinary 
Applications. Elsevier, Boston 
 44.  Ramadan A, Paczesny S (2015) Various forms of tissue damage and danger 
signals following hematopoietic stem-cell transplantation. Front Immunol 6:14 
 45.  Peterson SL, Anderson AJ (2014) Complement and spinal cord injury: traditional 
and non-traditional aspects of complement cascade function in the injured spinal 
cord microenvironment. Exp Neurol 258:35-47 
146 
 
 46.  Villadangos JA, Schnorrer P (2007) Intrinsic and cooperative antigen-presenting 
functions of dendritic-cell subsets in vivo. Nat Rev Immunol 7:543-555 
 47.  Young LJ, Wilson NS, Schnorrer P, Proietto A, ten BT, Matsuki Y, Mount AM, Belz 
GT, O'Keeffe M, Ohmura-Hoshino M, Ishido S, Stoorvogel W, Heath WR, Shortman 
K, Villadangos JA (2008) Differential MHC class II synthesis and ubiquitination 
confers distinct antigen-presenting properties on conventional and plasmacytoid 
dendritic cells. Nat Immunol 9:1244-1252 
 48.  Owens GP (2017) A Neuroprimer: Principles of Central Nervous System Immunity. 
Semin Pediatr Neurol 24:145-151 
 49.  Berer K, Mues M, Koutrolos M, Rasbi ZA, Boziki M, Johner C, Wekerle H, 
Krishnamoorthy G (2011) Commensal microbiota and myelin autoantigen cooperate 
to trigger autoimmune demyelination. Nature 479:538-541 
 50.  Kigerl KA, Hall JC, Wang L, Mo X, Yu Z, Popovich PG (2016) Gut dysbiosis impairs 
recovery after spinal cord injury. J Exp Med 213:2603-2620 
 51.  Walter U, Santamaria P (2005) CD8+ T cells in autoimmunity. Curr Opin Immunol 
17:624-631 
 52.  Weindel CG, Richey LJ, Mehta AJ, Shah M, Huber BT (2017) Autophagy in 
Dendritic Cells and B Cells Is Critical for the Inflammatory State of TLR7-Mediated 
Autoimmunity. J Immunol 198:1081-1092 
 53.  Kamimura D, Yamada M, Harada M, Sabharwal L, Meng J, Bando H, Ogura H, 
Atsumi T, Arima Y, Murakami M (2013) The gateway theory: bridging neural and 
immune interactions in the CNS. Front Neurosci 7:204 
147 
 
 54.  Mancardi G, Hart BA, Capello E, Brok HP, Ben-Nun A, Roccatagliata L, Giunti D, 
Gazzola P, Dono M, Kerlero De RN, Colombo M, Uccelli A (2000) Restricted 
immune responses lead to CNS demyelination and axonal damage. J 
Neuroimmunol 107:178-183 
 55.  Genain CP, Cannella B, Hauser SL, Raine CS (1999) Identification of 
autoantibodies associated with myelin damage in multiple sclerosis. Nat Med 5:170-
175 
 56.  Wang H, Shlomchik MJ (1999) Autoantigen-specific B cell activation in Fas-deficient 
rheumatoid factor immunoglobulin transgenic mice. J Exp Med 190:639-649 
 57.  Goebel A (2016) Autoantibody pain. Autoimmun Rev 15:552-557 
 58.  Jacob N, Stohl W (2010) Autoantibody-dependent and autoantibody-independent 
roles for B cells in systemic lupus erythematosus: past, present, and future. 
Autoimmunity 43:84-97 
 59.  Liou JT, Liu FC, Mao CC, Lai YS, Day YJ (2011) Inflammation confers dual effects 
on nociceptive processing in chronic neuropathic pain model. Anesthesiology 
114:660-672 
 60.  Moalem G, Tracey DJ (2006) Immune and inflammatory mechanisms in neuropathic 
pain. Brain Res Rev 51:240-264 
 61.  Thacker MA, Clark AK, Marchand F, McMahon SB (2007) Pathophysiology of 
peripheral neuropathic pain: immune cells and molecules. Anesth Analg 105:838-
847 
148 
 
 62.  Moalem G, Gdalyahu A, Shani Y, Otten U, Lazarovici P, Cohen IR, Schwartz M 
(2000) Production of neurotrophins by activated T cells: implications for 
neuroprotective autoimmunity. J Autoimmun 15:331-345 
 63.  Schori H, Yoles E, Schwartz M (2001) T-cell-based immunity counteracts the 
potential toxicity of glutamate in the central nervous system. J Neuroimmunol 
119:199-204 
 64.  Friedmann I, Hauben E, Yoles E, Kardash L, Schwartz M (2001) T cell-mediated 
neuroprotection involves antithrombin activity. J Neuroimmunol 121:12-21 
 65.  Friedmann I, Yoles E, Schwartz M (2001) Thrombin attenuation is neuroprotective in 
the injured rat optic nerve. J Neurochem 76:641-649 
 66.  Zorner B, Schwab ME (2010) Anti-Nogo on the go: from animal models to a clinical 
trial. Ann N Y Acad Sci 1198 Suppl 1:E22-E34 
 67.  Hauben E, Ibarra A, Mizrahi T, Barouch R, Agranov E, Schwartz M (2001) 
Vaccination with a Nogo-A-derived peptide after incomplete spinal-cord injury 
promotes recovery via a T-cell-mediated neuroprotective response: comparison with 
other myelin antigens. Proc Natl Acad Sci U S A 98:15173-15178 
 68.  Ulndreaj A, Badner A, Fehlings MG (2017) Promising neuroprotective strategies for 
traumatic spinal cord injury with a focus on the differential effects among anatomical 
levels of injury. F1000Res 6:1907 
 69.  Kil K, Zang YC, Yang D, Markowski J, Fuoco GS, Vendetti GC, Rivera VM, Zhang 
JZ (1999) T cell responses to myelin basic protein in patients with spinal cord injury 
and multiple sclerosis. J Neuroimmunol 98:201-207 
149 
 
 70.  Bryce TN, Biering-Sorensen F, Finnerup NB, Cardenas DD, Defrin R, Lundeberg T, 
Norrbrink C, Richards JS, Siddall P, Stripling T, Treede RD, Waxman SG, 
Widerstrom-Noga E, Yezierski RP, Dijkers M (2012) International spinal cord injury 
pain classification: part I. Background and description. March 6-7, 2009. Spinal Cord 
50:413-417 
 71.  Finnerup NB, Haroutounian S, Kamerman P, Baron R, Bennett DL, Bouhassira D, 
Cruccu G, Freeman R, Hansson P, Nurmikko T, Raja SN, Rice AS, Serra J, Smith 
BH, Treede RD, Jensen TS (2016) Neuropathic pain: an updated grading system for 
research and clinical practice. Pain 
 72.  Colloca L, Ludman T, Bouhassira D, Baron R, Dickenson AH, Yarnitsky D, Freeman 
R, Truini A, Attal N, Finnerup NB, Eccleston C, Kalso E, Bennett DL, Dworkin RH, 
Raja SN (2017) Neuropathic pain. Nat Rev Dis Primers 3:17002 
 73.  Mehta S, Guy SD, Bryce TN, Craven BC, Finnerup NB, Hitzig SL, Orenczuk S, 
Siddall PJ, Widerstrom-Noga E, Casalino A, Cote I, Harvey D, Kras-Dupuis A, Lau 
B, Middleton JW, Moulin DE, O'Connell C, Parrent AG, Potter P, Short C, Teasell R, 
Townson A, Truchon C, Wolfe D, Bradbury CL, Loh E (2016) The CanPain SCI 
Clinical Practice Guidelines for Rehabilitation Management of Neuropathic Pain 
after Spinal Cord: screening and diagnosis recommendations. Spinal Cord 54 Suppl 
1:S7-S13 
 74.  IASP (2015) IASP Taxonomy. In: H.Merskey, N.Bogduk (eds) 2015 International 
Association for the Study of Pain, pp 209-214 
 75.  Finnerup NB (2017) Neuropathic pain and spasticity: intricate consequences of 
spinal cord injury. Spinal Cord 
150 
 
 76.  Wrigley PJ, Gustin SM, McIndoe LN, Chakiath RJ, Henderson LA, Siddall PJ (2013) 
Longstanding neuropathic pain after spinal cord injury is refractory to transcranial 
direct current stimulation: a randomized controlled trial. Pain 154:2178-2184 
 77.  Dworkin RH, O'Connor AB, Kent J, Mackey SC, Raja SN, Stacey BR, Levy RM, 
Backonja M, Baron R, Harke H, Loeser JD, Treede RD, Turk DC, Wells CD (2013) 
Interventional management of neuropathic pain: NeuPSIG recommendations. Pain 
154:2249-2261 
 78.  Burke D, Fullen BM, Lennon O (2017) Pain profiles in a community dwelling 
population following spinal cord injury: a national survey. J Spinal Cord Med1-20 
 79.  Guy S, Mehta S, Leff L, Teasell R, Loh E (2014) Anticonvulsant medication use for 
the management of pain following spinal cord injury: systematic review and 
effectiveness analysis. Spinal Cord 52:89-96 
 80.  Burchiel KJ, Hsu FP (2001) Pain and spasticity after spinal cord injury: mechanisms 
and treatment. Spine (Phila Pa 1976 ) 26:S146-S160 
 81.  Tamburin S, Borg K, Caro XJ, Jann S, Clark AJ, Magrinelli F, Sobue G, Werhagen 
L, Zanette G, Koike H, Spath PJ, Vincent A, Goebel A (2014) Immunoglobulin g for 
the treatment of chronic pain: report of an expert workshop. Pain Med 15:1072-1082 
 82.  Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, 
Hansson P, Hughes R, Nurmikko T, Serra J (2008) Neuropathic pain: redefinition 
and a grading system for clinical and research purposes. Neurology 70:1630-1635 
151 
 
 83.  Widerstrom-Noga E, Biering-Sorensen F, Bryce TN, Cardenas DD, Finnerup NB, 
Jensen MP, Richards JS, Richardson EJ, Siddall PJ (2016) The International Spinal 
Cord Injury Pain Extended Data Set (Version 1.0). Spinal Cord 54:1036-1046 
 84.  Widerstrom-Noga E, Loeser JD, Jensen TS, Finnerup NB (2017) AAPT Diagnostic 
Criteria for Central Neuropathic Pain. J Pain 
 85.  Sengul G (2015) Chapter 5 - Primary Afferent Projections to the Spinal Cord A2 - 
Paxinos, George. The Rat Nervous System (Fourth Edition). Academic Press, San 
Diego, pp 77-85 
 86.  Melzack R, Wall PD (1965) Pain mechanisms: a new theory. Science 150:971-979 
 87.  Mendell LM (2014) Constructing and deconstructing the gate theory of pain. Pain 
155:210-216 
 88.  Martins I, Tavares I (2017) Reticular Formation and Pain: The Past and the Future. 
Front Neuroanat 11:51 
 89.  Gwak YS, Hulsebosch CE (2011) GABA and central neuropathic pain following 
spinal cord injury. Neuropharmacology 60:799-808 
 90.  Watson JL, Hala TJ, Putatunda R, Sannie D, Lepore AC (2014) Persistent at-level 
thermal hyperalgesia and tactile allodynia accompany chronic neuronal and 
astrocyte activation in superficial dorsal horn following mouse cervical contusion 
spinal cord injury. PLoS One 9:e109099 
 91.  Wrigley PJ, Press SR, Gustin SM, Macefield VG, Gandevia SC, Cousins MJ, 
Middleton JW, Henderson LA, Siddall PJ (2009) Neuropathic pain and primary 
somatosensory cortex reorganization following spinal cord injury. Pain 141:52-59 
152 
 
 92.  Henderson LA, Gustin SM, Macey PM, Wrigley PJ, Siddall PJ (2011) Functional 
reorganization of the brain in humans following spinal cord injury: evidence for 
underlying changes in cortical anatomy. J Neurosci 31:2630-2637 
 93.  Wasner G, Lee BB, Engel S, McLachlan E (2008) Residual spinothalamic tract 
pathways predict development of central pain after spinal cord injury. Brain 
131:2387-2400 
 94.  Bedi SS, Yang Q, Crook RJ, Du J, Wu Z, Fishman HM, Grill RJ, Carlton SM, 
Walters ET (2010) Chronic spontaneous activity generated in the somata of primary 
nociceptors is associated with pain-related behavior after spinal cord injury. J 
Neurosci 30:14870-14882 
 95.  Bedi SS, Lago MT, Masha LI, Crook RJ, Grill RJ, Walters ET (2012) Spinal cord 
injury triggers an intrinsic growth-promoting state in nociceptors. J Neurotrauma 
29:925-935 
 96.  Yang Q, Wu Z, Hadden JK, Odem MA, Zuo Y, Crook RJ, Frost JA, Walters ET 
(2014) Persistent pain after spinal cord injury is maintained by primary afferent 
activity. J Neurosci 34:10765-10769 
 97.  Chung K, Lee BH, Yoon YW, Chung JM (1996) Sympathetic sprouting in the dorsal 
root ganglia of the injured peripheral nerve in a rat neuropathic pain model. J Comp 
Neurol 376:241-252 
 98.  Lekan HA, Chung K, Yoon YW, Chung JM, Coggeshall RE (1997) Loss of dorsal 
root ganglion cells concomitant with dorsal root axon sprouting following segmental 
nerve lesions. Neuroscience 81:527-534 
153 
 
 99.  McLachlan EM, Janig W, Devor M, Michaelis M (1993) Peripheral nerve injury 
triggers noradrenergic sprouting within dorsal root ganglia. Nature 363:543-546 
 100.  Leem JW, Kim HK, Hulsebosch CE, Gwak YS (2010) Ionotropic glutamate receptors 
contribute to maintained neuronal hyperexcitability following spinal cord injury in 
rats. Exp Neurol 224:321-324 
 101.  Drew GM, Siddall PJ, Duggan AW (2004) Mechanical allodynia following contusion 
injury of the rat spinal cord is associated with loss of GABAergic inhibition in the 
dorsal horn. Pain 109:379-388 
 102.  Detloff MR, Fisher LC, McGaughy V, Longbrake EE, Popovich PG, Basso DM 
(2008) Remote activation of microglia and pro-inflammatory cytokines predict the 
onset and severity of below-level neuropathic pain after spinal cord injury in rats. 
Exp Neurol 212:337-347 
 103.  Gwak YS, Hulsebosch CE (2009) Remote astrocytic and microglial activation 
modulates neuronal hyperexcitability and below-level neuropathic pain after spinal 
injury in rat. Neuroscience 161:895-903 
 104.  Gwak YS, Hulsebosch CE (2011) Neuronal hyperexcitability: a substrate for central 
neuropathic pain after spinal cord injury. Curr Pain Headache Rep 15:215-222 
 105.  Du J, Zhou S, Carlton SM (2006) Kainate-induced excitation and sensitization of 
nociceptors in normal and inflamed rat glabrous skin. Neuroscience 137:999-1013 
 106.  Carlton SM, Coggeshall RE (2002) Inflammation-induced up-regulation of 
neurokinin 1 receptors in rat glabrous skin. Neurosci Lett 326:29-32 
154 
 
 107.  Carlton SM, Zhou S, Coggeshall RE (1996) Localization and activation of substance 
P receptors in unmyelinated axons of rat glabrous skin. Brain Res 734:103-108 
 108.  Carlton SM, Zhou S, Coggeshall RE (1998) Evidence for the interaction of 
glutamate and NK1 receptors in the periphery. Brain Res 790:160-169 
 109.  Carlton SM, Du J, Tan HY, Nesic O, Hargett GL, Bopp AC, Yamani A, Lin Q, Willis 
WD, Hulsebosch CE (2009) Peripheral and central sensitization in remote spinal 
cord regions contribute to central neuropathic pain after spinal cord injury. Pain 
147:265-276 
 110.  Gwak YS, Hulsebosch CE, Leem JW (2017) Neuronal-Glial Interactions Maintain 
Chronic Neuropathic Pain after Spinal Cord Injury. Neural Plast 2017:2480689 
 111.  Vogel C, Rukwied R, Stockinger L, Schley M, Schmelz M, Schleinzer W, Konrad C 
(2017) Functional Characterization of At-Level Hypersensitivity in Patients With 
Spinal Cord Injury. J Pain 18:66-78 
 112.  Alexander JK, Popovich PG (2009) Neuroinflammation in spinal cord injury: 
therapeutic targets for neuroprotection and regeneration. Prog Brain Res 175:125-
137 
 113.  Walters ET (2014) Neuroinflammatory contributions to pain after SCI: roles for 
central glial mechanisms and nociceptor-mediated host defense. Exp Neurol 
258:48-61 
 114.  Gwak YS, Unabia GC, Hulsebosch CE (2009) Activation of p-38alpha MAPK 
contributes to neuronal hyperexcitability in caudal regions remote from spinal cord 
injury. Exp Neurol 220:154-161 
155 
 
 115.  Yang L, Blumbergs PC, Jones NR, Manavis J, Sarvestani GT, Ghabriel MN (2004) 
Early expression and cellular localization of proinflammatory cytokines interleukin-
1beta, interleukin-6, and tumor necrosis factor-alpha in human traumatic spinal cord 
injury. Spine (Phila Pa 1976 ) 29:966-971 
 116.  Meisner JG, Marsh AD, Marsh DR (2010) Loss of GABAergic interneurons in 
laminae I-III of the spinal cord dorsal horn contributes to reduced GABAergic tone 
and neuropathic pain after spinal cord injury. J Neurotrauma 27:729-737 
 117.  Alexander JJ, Anderson AJ, Barnum SR, Stevens B, Tenner AJ (2008) The 
complement cascade: Yin-Yang in neuroinflammation--neuro-protection and -
degeneration. J Neurochem 107:1169-1187 
 118.  Siddall PJ, Yezierski RP, Loeser JD (2000) Pain following spinal cord injury: clinical 
features, prevalence, and taxonomy. IASP Newsletter 2000; 3-7. 
 119.  Siddall PJ, Taylor DA, Cousins MJ (1997) Classification of pain following spinal cord 
injury. Spinal Cord 35:69-75 
 120.  Bennett M (2001) The LANSS Pain Scale: the Leeds assessment of neuropathic 
symptoms and signs. Pain 92:147-157 
 121.  Bennett MI, Smith BH, Torrance N, Potter J (2005) The S-LANSS score for 
identifying pain of predominantly neuropathic origin: validation for use in clinical and 
postal research. J Pain 6:149-158 
 122.  Melzack R (1987) The short-form McGill Pain Questionnaire. Pain 30:191-197 
156 
 
 123.  Skoda D, Kranda K, Bojar M, Glosova L, Baurle J, Kenney J, Romportl D, 
Pelichovska M, Cvachovec K (2006) Antibody formation against beta-tubulin class 
III in response to brain trauma. Brain Res Bull 68:213-216 
 124.  Blair JA, Wang C, Hernandez D, Siedlak SL, Rodgers MS, Achar RK, Fahmy LM, 
Torres SL, Petersen RB, Zhu X, Casadesus G, Lee HG (2016) Individual Case 
Analysis of Postmortem Interval Time on Brain Tissue Preservation. PLoS One 
11:e0157209 
 125.  Porchet R, Probst A, Bouras C, Draberova E, Draber P, Riederer BM (2003) 
Analysis of glial acidic fibrillary protein in the human entorhinal cortex during aging 
and in Alzheimer's disease. Proteomics 3:1476-1485 
 126.  Korolainen MA, Auriola S, Nyman TA, Alafuzoff I, Pirttila T (2005) Proteomic 
analysis of glial fibrillary acidic protein in Alzheimer's disease and aging brain. 
Neurobiol Dis 20:858-870 
 127.  Cole AR, Noble W, van AL, Plattner F, Meimaridou R, Hogan D, Taylor M, 
LaFrancois J, Gunn-Moore F, Verkhratsky A, Oddo S, LaFerla F, Giese KP, Dineley 
KT, Duff K, Richardson JC, Yan SD, Hanger DP, Allan SM, Sutherland C (2007) 
Collapsin response mediator protein-2 hyperphosphorylation is an early event in 
Alzheimer's disease progression. J Neurochem 103:1132-1144 
 128.  Skold K, Alm H, Scholz B (2013) The impact of biosampling procedures on 
molecular data interpretation. Mol Cell Proteomics 12:1489-1501 
 129.  Burgess-Cassler A, Johansen JJ, Santek DA, Ide JR, Kendrick NC (1989) 
Computerized quantitative analysis of coomassie-blue-stained serum proteins 
separated by two-dimensional electrophoresis. Clin Chem 35:2297-2304 
157 
 
 130.  O'Farrell PH (1975) High resolution two-dimensional electrophoresis of proteins. J 
Biol Chem 250:4007-4021 
 131.  Darie CC, Deinhardt K, Zhang G, Cardasis HS, Chao MV, Neubert TA (2011) 
Identifying transient protein-protein interactions in EphB2 signaling by blue native 
PAGE and mass spectrometry. Proteomics 11:4514-4528 
 132.  Shevchenko A, Wilm M, Vorm O, Mann M (1996) Mass spectrometric sequencing of 
proteins silver-stained polyacrylamide gels. Anal Chem 68:850-858 
 133.  Sokolowska I, Woods AG, Gawinowicz MA, Roy U, Darie CC (2012) Identification of 
potential tumor differentiation factor (TDF) receptor from steroid-responsive and 
steroid-resistant breast cancer cells. J Biol Chem 287:1719-1733 
 134.  Sokolowska I, Gawinowicz MA, Ngounou Wetie AG, Darie CC (2012) Disulfide 
proteomics for identification of extracellular or secreted proteins. Electrophoresis 
33:2527-2536 
 135.  Sokolowska I, Dorobantu C, Woods AG, Macovei A, Branza-Nichita N, Darie CC 
(2012) Proteomic analysis of plasma membranes isolated from undifferentiated and 
differentiated HepaRG cells. Proteome Sci 10:47 
 136.  Hergenroeder GW, Moore AN, Schmitt KM, Redell JB, Dash PK (2016) Identification 
of autoantibodies to glial fibrillary acidic protein in spinal cord injury patients. 
Neuroreport 27:90-93 
 137.  Ciesielski-Treska J, Goetschy JF, Aunis D (1984) Proteolytic degradation of 
vimentin and glial fibrillary acidic protein in rat astrocytes in primary culture. Eur J 
Biochem 138:465-471 
158 
 
 138.  Charrier E, Reibel S, Rogemond V, Aguera M, Thomasset N, Honnorat J (2003) 
Collapsin response mediator proteins (CRMPs): involvement in nervous system 
development and adult neurodegenerative disorders. Mol Neurobiol 28:51-64 
 139.  Hensley K, Venkova K, Christov A, Gunning W, Park J (2011) Collapsin response 
mediator protein-2: an emerging pathologic feature and therapeutic target for 
neurodisease indications. Mol Neurobiol 43:180-191 
 140.  Vincent P, Collette Y, Marignier R, Vuaillat C, Rogemond V, Davoust N, Malcus C, 
Cavagna S, Gessain A, huca-Gayet I, Belin MF, Quach T, Giraudon P (2005) A role 
for the neuronal protein collapsin response mediator protein 2 in T lymphocyte 
polarization and migration. J Immunol 175:7650-7660 
 141.  Gogel S, Lange S, Leung KY, Greene ND, Ferretti P (2010) Post-translational 
regulation of Crmp in developing and regenerating chick spinal cord. Dev Neurobiol 
70:456-471 
 142.  Williamson T, Gordon-Weeks PR, Schachner M, Taylor J (1996) Microtubule 
reorganization is obligatory for growth cone turning. Proc Natl Acad Sci U S A 
93:15221-15226 
 143.  Kaneko S, Iwanami A, Nakamura M, Kishino A, Kikuchi K, Shibata S, Okano HJ, 
Ikegami T, Moriya A, Konishi O, Nakayama C, Kumagai K, Kimura T, Sato Y, 
Goshima Y, Taniguchi M, Ito M, He Z, Toyama Y, Okano H (2006) A selective 
Sema3A inhibitor enhances regenerative responses and functional recovery of the 
injured spinal cord. Nat Med 12:1380-1389 
159 
 
 144.  Kotaka K, Nagai J, Hensley K, Ohshima T (2017) Lanthionine ketimine ester 
promotes locomotor recovery after spinal cord injury by reducing neuroinflammation 
and promoting axon growth. Biochem Biophys Res Commun 483:759-764 
 145.  Quach TT, Duchemin AM, Rogemond V, Aguera M, Honnorat J, Belin MF, 
Kolattukudy PE (2004) Involvement of collapsin response mediator proteins in the 
neurite extension induced by neurotrophins in dorsal root ganglion neurons. Mol Cell 
Neurosci 25:433-443 
 146.  Nagai J, Owada K, Kitamura Y, Goshima Y, Ohshima T (2016) Inhibition of CRMP2 
phosphorylation repairs CNS by regulating neurotrophic and inhibitory responses. 
Exp Neurol 277:283-295 
 147.  Jones LL, Margolis RU, Tuszynski MH (2003) The chondroitin sulfate proteoglycans 
neurocan, brevican, phosphacan, and versican are differentially regulated following 
spinal cord injury. Exp Neurol 182:399-411 
 148.  Detloff MR, Quiros-Molina D, Javia AS, Daggubati L, Nehlsen AD, Naqvi A, Ninan V, 
Vannix KN, McMullen MK, Amin S, Ganzer PD, Houle JD (2016) Delayed Exercise 
Is Ineffective at Reversing Aberrant Nociceptive Afferent Plasticity or Neuropathic 
Pain After Spinal Cord Injury in Rats. Neurorehabil Neural Repair 30:685-700 
 149.  Tang XQ, Tanelian DL, Smith GM (2004) Semaphorin3A inhibits nerve growth 
factor-induced sprouting of nociceptive afferents in adult rat spinal cord. J Neurosci 
24:819-827 
 150.  Ondarza AB, Ye Z, Hulsebosch CE (2003) Direct evidence of primary afferent 
sprouting in distant segments following spinal cord injury in the rat: colocalization of 
GAP-43 and CGRP. Exp Neurol 184:373-380 
160 
 
 151.  Christensen MD, Hulsebosch CE (1997) Spinal cord injury and anti-NGF treatment 
results in changes in CGRP density and distribution in the dorsal horn in the rat. Exp 
Neurol 147:463-475 
 152.  Nakamura M, Bregman BS (2001) Differences in neurotrophic factor gene 
expression profiles between neonate and adult rat spinal cord after injury. Exp 
Neurol 169:407-415 
 153.  Brittain JM, Duarte DB, Wilson SM, Zhu W, Ballard C, Johnson PL, Liu N, Xiong W, 
Ripsch MS, Wang Y, Fehrenbacher JC, Fitz SD, Khanna M, Park CK, Schmutzler 
BS, Cheon BM, Due MR, Brustovetsky T, Ashpole NM, Hudmon A, Meroueh SO, 
Hingtgen CM, Brustovetsky N, Ji RR, Hurley JH, Jin X, Shekhar A, Xu XM, Oxford 
GS, Vasko MR, White FA, Khanna R (2011) Suppression of inflammatory and 
neuropathic pain by uncoupling CRMP-2 from the presynaptic Ca(2)(+) channel 
complex. Nat Med 17:822-829 
 154.  Moutal A, Dustrude ET, Largent-Milnes TM, Vanderah TW, Khanna M, Khanna R 
(2017) Blocking CRMP2 SUMOylation reverses neuropathic pain. Mol Psychiatry 
 155.  Adamus G, Bonnah R, Brown L, David L (2013) Detection of autoantibodies against 
heat shock proteins and collapsin response mediator proteins in autoimmune 
retinopathy. BMC Ophthalmol 13:48 
 156.  Zhang Z, Ottens AK, Sadasivan S, Kobeissy FH, Fang T, Hayes RL, Wang KK 
(2007) Calpain-mediated collapsin response mediator protein-1, -2, and -4 
proteolysis after neurotoxic and traumatic brain injury. J Neurotrauma 24:460-472 
161 
 
 157.  Jin X, Sasamoto K, Nagai J, Yamazaki Y, Saito K, Goshima Y, Inoue T, Ohshima T 
(2016) Phosphorylation of CRMP2 by Cdk5 Regulates Dendritic Spine Development 
of Cortical Neuron in the Mouse Hippocampus. Neural Plast 2016:6790743 
 158.  Ackery AD, Norenberg MD, Krassioukov A (2007) Calcitonin gene-related peptide 
immunoreactivity in chronic human spinal cord injury. Spinal Cord 45:678-686 
 159.  Freeman MR (2010) Specification and morphogenesis of astrocytes. Science 
330:774-778 
 160.  Sofroniew MV (2015) Astrocyte barriers to neurotoxic inflammation. Nat Rev 
Neurosci 16:249-263 
 161.  Argaw AT, Asp L, Zhang J, Navrazhina K, Pham T, Mariani JN, Mahase S, Dutta 
DJ, Seto J, Kramer EG, Ferrara N, Sofroniew MV, John GR (2012) Astrocyte-
derived VEGF-A drives blood-brain barrier disruption in CNS inflammatory disease. 
J Clin Invest 122:2454-2468 
 162.  Liddelow SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L, 
Bennett ML, Munch AE, Chung WS, Peterson TC, Wilton DK, Frouin A, Napier BA, 
Panicker N, Kumar M, Buckwalter MS, Rowitch DH, Dawson VL, Dawson TM, 
Stevens B, Barres BA (2017) Neurotoxic reactive astrocytes are induced by 
activated microglia. Nature 541:481-487 
 163.  Fitch MT, Silver J (2008) CNS injury, glial scars, and inflammation: Inhibitory 
extracellular matrices and regeneration failure. Exp Neurol 209:294-301 
162 
 
 164.  Davies SJ, Goucher DR, Doller C, Silver J (1999) Robust regeneration of adult 
sensory axons in degenerating white matter of the adult rat spinal cord. J Neurosci 
19:5810-5822 
 165.  Wanner IB, Anderson MA, Song B, Levine J, Fernandez A, Gray-Thompson Z, Ao 
Y, Sofroniew MV (2013) Glial scar borders are formed by newly proliferated, 
elongated astrocytes that interact to corral inflammatory and fibrotic cells via 
STAT3-dependent mechanisms after spinal cord injury. J Neurosci 33:12870-12886 
 166.  Cregg JM, DePaul MA, Filous AR, Lang BT, Tran A, Silver J (2014) Functional 
regeneration beyond the glial scar. Exp Neurol 253:197-207 
 167.  Faulkner JR, Herrmann JE, Woo MJ, Tansey KE, Doan NB, Sofroniew MV (2004) 
Reactive astrocytes protect tissue and preserve function after spinal cord injury. J 
Neurosci 24:2143-2155 
 168.  Bush TG, Puvanachandra N, Horner CH, Polito A, Ostenfeld T, Svendsen CN, 
Mucke L, Johnson MH, Sofroniew MV (1999) Leukocyte infiltration, neuronal 
degeneration, and neurite outgrowth after ablation of scar-forming, reactive 
astrocytes in adult transgenic mice. Neuron 23:297-308 
 169.  Middeldorp J, Hol EM (2011) GFAP in health and disease. Prog Neurobiol 93:421-
443 
 170.  Colpitts SL, Kasper LH (2017) Influence of the Gut Microbiome on Autoimmunity in 
the Central Nervous System. J Immunol 198:596-604 
 171.  Hulsebosch CE (2008) Gliopathy ensures persistent inflammation and chronic pain 
after spinal cord injury. Exp Neurol 214:6-9 
163 
 
 172.  Ribotta MG, Menet V, Privat A (2004) Glial scar and axonal regeneration in the 
CNS: lessons from GFAP and vimentin transgenic mice. Acta Neurochir Suppl 
89:87-92 
 173.  Ahadi R, Khodagholi F, Daneshi A, Vafaei A, Mafi AA, Jorjani M (2015) Diagnostic 
Value of Serum Levels of GFAP, pNF-H, and NSE Compared With Clinical Findings 
in Severity Assessment of Human Traumatic Spinal Cord Injury. Spine (Phila Pa 
1976 ) 40:E823-E830 
 174.  Papa L, Brophy GM, Welch RD, Lewis LM, Braga CF, Tan CN, Ameli NJ, Lopez 
MA, Haeussler CA, Mendez Giordano DI, Silvestri S, Giordano P, Weber KD, Hill-
Pryor C, Hack DC (2016) Time Course and Diagnostic Accuracy of Glial and 
Neuronal Blood Biomarkers GFAP and UCH-L1 in a Large Cohort of Trauma 
Patients With and Without Mild Traumatic Brain Injury. JAMA Neurol 73:551-560 
 175.  Van Geel WJ, De Reus HP, Nijzing H, Verbeek MM, Vos PE, Lamers KJ (2002) 
Measurement of glial fibrillary acidic protein in blood: an analytical method. Clin 
Chim Acta 326:151-154 
 176.  Vos PE, Lamers KJ, Hendriks JC, van HM, Beems T, Zimmerman C, van GW, de 
RH, Biert J, Verbeek MM (2004) Glial and neuronal proteins in serum predict 
outcome after severe traumatic brain injury. Neurology 62:1303-1310 
 177.  Kataoka H, Kono H, Patel Z, Kimura Y, Rock KL (2014) Evaluation of the 
contribution of multiple DAMPs and DAMP receptors in cell death-induced sterile 
inflammatory responses. PLoS One 9:e104741 
 178.  Takeuchi O, Akira S (2010) Pattern recognition receptors and inflammation. Cell 
140:805-820 
164 
 
 179.  Radbruch A, Muehlinghaus G, Luger EO, Inamine A, Smith KG, Dorner T, Hiepe F 
(2006) Competence and competition: the challenge of becoming a long-lived plasma 
cell. Nat Rev Immunol 6:741-750 
 180.  Rahman ZS (2011) Impaired clearance of apoptotic cells in germinal centers: 
implications for loss of B cell tolerance and induction of autoimmunity. Immunol Res 
51:125-133 
 181.  Chen GY, Nunez G (2010) Sterile inflammation: sensing and reacting to damage. 
Nat Rev Immunol 10:826-837 
 182.  Kono H, Rock KL (2008) How dying cells alert the immune system to danger. Nat 
Rev Immunol 8:279-289 
 183.  Scaffidi P, Misteli T, Bianchi ME (2002) Release of chromatin protein HMGB1 by 
necrotic cells triggers inflammation. Nature 418:191-195 
 184.  Van der Borght K, Scott CL, Nindl V, Bouche A, Martens L, Sichien D, Van MJ, 
Vanheerswynghels M, De PS, Saeys Y, Ludewig B, Gillebert T, Guilliams M, 
Carmeliet P, Lambrecht BN (2017) Myocardial Infarction Primes Autoreactive T 
Cells through Activation of Dendritic Cells. Cell Rep 18:3005-3017 
 185.  Zhang W, Lavine KJ, Epelman S, Evans SA, Weinheimer CJ, Barger PM, Mann DL 
(2015) Necrotic myocardial cells release damage-associated molecular patterns that 
provoke fibroblast activation in vitro and trigger myocardial inflammation and fibrosis 
in vivo. J Am Heart Assoc 4:e001993 
 186.  Hill JH, Ward PA (1971) The phlogistic role of C3 leukotactic fragments in 
myocardial infarcts of rats. J Exp Med 133:885-900 
165 
 
 187.  Merle NS, Noe R, Halbwachs-Mecarelli L, Fremeaux-Bacchi V, Roumenina LT 
(2015) Complement System Part II: Role in Immunity. Front Immunol 6:257 
 188.  Sayah S, Jauneau AC, Patte C, Tonon MC, Vaudry H, Fontaine M (2003) Two 
different transduction pathways are activated by C3a and C5a anaphylatoxins on 
astrocytes. Brain Res Mol Brain Res 112:53-60 
 189.  Green NM, Marshak-Rothstein A (2011) Toll-like receptor driven B cell activation in 
the induction of systemic autoimmunity. Semin Immunol 23:106-112 
 190.  Green NM, Moody KS, Debatis M, Marshak-Rothstein A (2012) Activation of 
autoreactive B cells by endogenous TLR7 and TLR3 RNA ligands. J Biol Chem 
287:39789-39799 
 191.  Mandrekar JN (2010) Receiver operating characteristic curve in diagnostic test 
assessment. J Thorac Oncol 5:1315-1316 
 192.  Yang Z, Wang KK (2015) Glial fibrillary acidic protein: from intermediate filament 
assembly and gliosis to neurobiomarker. Trends Neurosci 38:364-374 
 193.  Hol EM, Pekny M (2015) Glial fibrillary acidic protein (GFAP) and the astrocyte 
intermediate filament system in diseases of the central nervous system. Curr Opin 
Cell Biol 32:121-130 
 194.  Iorio R, Damato V, Evoli A, Gessi M, Gaudino S, Di L, V, Spagni G, Sluijs JA, Hol 
EM (2017) Clinical and immunological characteristics of the spectrum of GFAP 
autoimmunity: a case series of 22 patients. J Neurol Neurosurg Psychiatry 
 195.  Ishida K, Kaneko K, Kubota T, Itoh Y, Miyatake T, Matsushita M, Yamada M (1997) 
Identification and characterization of an anti-glial fibrillary acidic protein antibody 
166 
 
with a unique specificity in a demented patient with an autoimmune disorder. J 
Neurol Sci 151:41-48 
 196.  Zhang Z, Zoltewicz JS, Mondello S, Newsom KJ, Yang Z, Yang B, Kobeissy F, 
Guingab J, Glushakova O, Robicsek S, Heaton S, Buki A, Hannay J, Gold MS, 
Rubenstein R, Lu XC, Dave JR, Schmid K, Tortella F, Robertson CS, Wang KK 
(2014) Human traumatic brain injury induces autoantibody response against glial 
fibrillary acidic protein and its breakdown products. PLoS One 9:e92698 
 197.  Pang Z, Kushiyama A, Sun J, Kikuchi T, Yamazaki H, Iwamoto Y, Koriyama H, 
Yoshida S, Shimamura M, Higuchi M, Kawano T, Takami Y, Rakugi H, Morishita R, 
Nakagami H (2017) Glial fibrillary acidic protein (GFAP) is a novel biomarker for the 
prediction of autoimmune diabetes. FASEB J 
 198.  Gomez-Tourino I, Camina-Darriba F, Otero-Romero I, Rodriguez MA, Hernandez-
Fernandez A, Gonzalez-Fernandez A, Pena-Gonzalez E, Rodriguez J, Rodriguez-
Segade S, Varela-Calvino R (2010) Autoantibodies to glial fibrillary acid protein and 
S100beta in diabetic patients. Diabet Med 27:246-248 
 199.  Raad M, Nohra E, Chams N, Itani M, Talih F, Mondello S, Kobeissy F (2014) 
Autoantibodies in traumatic brain injury and central nervous system trauma. 
Neuroscience 281:16-23 
 200.  Beck KD, Nguyen HX, Galvan MD, Salazar DL, Woodruff TM, Anderson AJ (2010) 
Quantitative analysis of cellular inflammation after traumatic spinal cord injury: 
evidence for a multiphasic inflammatory response in the acute to chronic 
environment. Brain 133:433-447 
167 
 
 201.  Yokobori S, Zhang Z, Moghieb A, Mondello S, Gajavelli S, Dietrich WD, Bramlett H, 
Hayes RL, Wang M, Wang KK, Bullock MR (2015) Acute diagnostic biomarkers for 
spinal cord injury: review of the literature and preliminary research report. World 
Neurosurg 83:867-878 
 202.  Kwon BK, Stammers AM, Belanger LM, Bernardo A, Chan D, Bishop CM, 
Slobogean GP, Zhang H, Umedaly H, Giffin M, Street J, Boyd MC, Paquette SJ, 
Fisher CG, Dvorak MF (2010) Cerebrospinal fluid inflammatory cytokines and 
biomarkers of injury severity in acute human spinal cord injury. J Neurotrauma 
27:669-682 
 203.  Baines AC, Brodsky RA (2017) Complementopathies. Blood Rev 31:213-223 
 204.  Oikonomopoulou K, Ricklin D, Ward PA, Lambris JD (2012) Interactions between 
coagulation and complement--their role in inflammation. Semin Immunopathol 
34:151-165 
 205.  Brennan FH, Anderson AJ, Taylor SM, Woodruff TM, Ruitenberg MJ (2012) 
Complement activation in the injured central nervous system: another dual-edged 
sword? J Neuroinflammation 9:137 
 206.  Kumar V, Abbas A, Fausto N, Mitchell R (2007) Acute and Chronic Inflammation. In: 
Kumar V, Abbas A, Fausto N, Mitchell R (eds) Robbins Basic Pathology. Saunders 
Elsevier, Philadelphia, pp 31-58 
 207.  Morgan BP, Marchbank KJ, Longhi MP, Harris CL, Gallimore AM (2005) 
Complement: central to innate immunity and bridging to adaptive responses. 
Immunol Lett 97:171-179 
168 
 
 208.  Dempsey PW, Allison ME, Akkaraju S, Goodnow CC, Fearon DT (1996) C3d of 
complement as a molecular adjuvant: bridging innate and acquired immunity. 
Science 271:348-350 
 209.  Coulthard LG, Woodruff TM (2015) Is the complement activation product C3a a 
proinflammatory molecule? Re-evaluating the evidence and the myth. J Immunol 
194:3542-3548 
 210.  Brennan FH, Gordon R, Lao HW, Biggins PJ, Taylor SM, Franklin RJ, Woodruff TM, 
Ruitenberg MJ (2015) The Complement Receptor C5aR Controls Acute 
Inflammation and Astrogliosis following Spinal Cord Injury. J Neurosci 35:6517-6531 
 211.  Carroll MC (2004) The complement system in regulation of adaptive immunity. Nat 
Immunol 5:981-986 
 212.  Twining CM, Sloane EM, Schoeniger DK, Milligan ED, Martin D, Marsh H, Maier SF, 
Watkins LR (2005) Activation of the spinal cord complement cascade might 
contribute to mechanical allodynia induced by three animal models of spinal 
sensitization. J Pain 6:174-183 
 213.  Griffin RS, Costigan M, Brenner GJ, Ma CH, Scholz J, Moss A, Allchorne AJ, Stahl 
GL, Woolf CJ (2007) Complement induction in spinal cord microglia results in 
anaphylatoxin C5a-mediated pain hypersensitivity. J Neurosci 27:8699-8708 
 214.  Truedsson L, Bengtsson AA, Sturfelt G (2007) Complement deficiencies and 
systemic lupus erythematosus. Autoimmunity 40:560-566 
 215.  Roumenina LT, Sene D, Radanova M, Blouin J, Halbwachs-Mecarelli L, Dragon-
Durey MA, Fridman WH, Fremeaux-Bacchi V (2011) Functional complement C1q 
169 
 
abnormality leads to impaired immune complexes and apoptotic cell clearance. J 
Immunol 187:4369-4373 
 216.  Anderson AJ, Robert S, Huang W, Young W, Cotman CW (2004) Activation of 
complement pathways after contusion-induced spinal cord injury. J Neurotrauma 
21:1831-1846 
 217.  Gomo R, Sibanda EN (2002) Determination of normal ranges for serum C3 and C4 
levels in an adult Zimbabwean population. Cent Afr J Med 48:137-141 
 218.  Ritchie RF, Palomaki GE, Neveux LM, Navolotskaia O, Ledue TB, Craig WY (2004) 
Reference distributions for complement proteins C3 and C4: a practical, simple and 
clinically relevant approach in a large cohort. J Clin Lab Anal 18:1-8 
 219.  Sissons JG, Liebowitch J, Amos N, Peters DK (1977) Metabolism of the fifth 
component of complement, and its relation to metabolism of the third component, in 
patients with complement activation. J Clin Invest 59:704-715 
 220.  Glovsky MM, Ward PA, Johnson KJ (2004) Complement determinations in human 
disease. Ann Allergy Asthma Immunol 93:513-522 
 221.  Nguyen HX, Galvan MD, Anderson AJ (2008) Characterization of early and terminal 
complement proteins associated with polymorphonuclear leukocytes in vitro and in 
vivo after spinal cord injury. J Neuroinflammation 5:26 
 222.  Hecke F, Schmidt U, Kola A, Bautsch W, Klos A, Kohl J (1997) Circulating 
complement proteins in multiple trauma patients--correlation with injury severity, 
development of sepsis, and outcome. Crit Care Med 25:2015-2024 
170 
 
 223.  Hulsebosch CE, Hains BC, Crown ED, Carlton SM (2009) Mechanisms of chronic 
central neuropathic pain after spinal cord injury. Brain Res Rev 60:202-213 
 224.  Corcione A, Casazza S, Ferretti E, Giunti D, Zappia E, Pistorio A, Gambini C, 
Mancardi GL, Uccelli A, Pistoia V (2004) Recapitulation of B cell differentiation in the 
central nervous system of patients with multiple sclerosis. Proc Natl Acad Sci U S A 
101:11064-11069 
 225.  Dalakas MC (2008) B cells as therapeutic targets in autoimmune neurological 
disorders. Nat Clin Pract Neurol 4:557-567 
 226.  Dervieux T, Conklin J, Ligayon JA, Wolover L, O'Malley T, Alexander RV, Weinstein 
A, Ibarra CA (2017) Validation of a multi-analyte panel with cell-bound complement 
activation products for systemic lupus erythematosus. J Immunol Methods 446:54-
59 
 227.  Bernasconi NL, Traggiai E, Lanzavecchia A (2002) Maintenance of serological 
memory by polyclonal activation of human memory B cells. Science 298:2199-2202 
 228.  Arpin C, Dechanet J, Van KC, Merville P, Grouard G, Briere F, Banchereau J, Liu 
YJ (1995) Generation of memory B cells and plasma cells in vitro. Science 268:720-
722 
 229.  Arpin C, Banchereau J, Liu YJ (1997) Memory B cells are biased towards terminal 
differentiation: a strategy that may prevent repertoire freezing. J Exp Med 186:931-
940 
171 
 
 230.  Ettinger R, Sims GP, Fairhurst AM, Robbins R, da Silva YS, Spolski R, Leonard WJ, 
Lipsky PE (2005) IL-21 induces differentiation of human naive and memory B cells 
into antibody-secreting plasma cells. J Immunol 175:7867-7879 
 231.  Ettinger R, Sims GP, Robbins R, Withers D, Fischer RT, Grammer AC, Kuchen S, 
Lipsky PE (2007) IL-21 and BAFF/BLyS synergize in stimulating plasma cell 
differentiation from a unique population of human splenic memory B cells. J 
Immunol 178:2872-2882 
 232.  Chao PZ, Hsieh MS, Lee FP, Chen SY, Cheng CW, Chang HW, Lin YT, Ting LL, Lin 
YF, Chen CH (2015) Serum level of interleukin-21 is elevated in chronic 
rhinosinusitis. Am J Rhinol Allergy 29:e1-e6 
 233.  Segal JL, Gonzales E, Yousefi S, Jamshidipour L, Brunnemann SR (1997) 
Circulating levels of IL-2R, ICAM-1, and IL-6 in spinal cord injuries. Arch Phys Med 
Rehabil 78:44-47 
 234.  Younes A, Snell V, Consoli U, Clodi K, Zhao S, Palmer JL, Thomas EK, Armitage 
RJ, Andreeff M (1998) Elevated levels of biologically active soluble CD40 ligand in 
the serum of patients with chronic lymphocytic leukaemia. Br J Haematol 100:135-
141 
 235.  Zaaqoq AM, Namas R, Almahmoud K, Azhar N, Mi Q, Zamora R, Brienza DM, 
Billiar TR, Vodovotz Y (2014) Inducible protein-10, a potential driver of neurally 
controlled interleukin-10 and morbidity in human blunt trauma. Crit Care Med 
42:1487-1497 
 236.  Meffre E, Wardemann H (2008) B-cell tolerance checkpoints in health and 
autoimmunity. Curr Opin Immunol 20:632-638 
172 
 
 237.  Ahmed R, Gray D (1996) Immunological memory and protective immunity: 
understanding their relation. Science 272:54-60 
 238.  Tzeng SF, Hsiao HY, Mak OT (2005) Prostaglandins and cyclooxygenases in glial 
cells during brain inflammation. Curr Drug Targets Inflamm Allergy 4:335-340 
 239.  Yang Z, Bramlett HM, Moghieb A, Yu D, Wang P, Lin F, Bauer C, Selig TM, Jaalouk 
E, Weissman AS, Rathore DS, Romo P, Zhang Z, Hayes RL, Wang MY, Dalton DW, 
Wang KK (2017) Temporal Profile and Severity Correlation of a Panel of Rat Spinal 
Cord Injury Protein Biomarkers. Mol Neurobiol 
 240.  Wang KK, Yang Z, Yue JK, Zhang Z, Winkler EA, Puccio AM, az-Arrastia R, 
Lingsma HF, Yuh EL, Mukherjee P, Valadka AB, Gordon WA, Okonkwo DO, Manley 
GT, Cooper SR, ms-O'Connor K, Hricik AJ, Inoue T, Maas AI, Menon DK, Schnyer 
DM, Sinha TK, Vassar MJ (2016) Plasma Anti-Glial Fibrillary Acidic Protein 
Autoantibody Levels during the Acute and Chronic Phases of Traumatic Brain Injury: 
A Transforming Research and Clinical Knowledge in Traumatic Brain Injury Pilot 
Study. J Neurotrauma 
 241.  Lim DW, Kim JG, Lim EY, Kim YT (2017) Antihyperalgesic effects of ashwagandha 
(Withania somnifera root extract) in rat models of postoperative and neuropathic 
pain. Inflammopharmacology 
 242.  Johnson JL, Kwok YH, Sumracki NM, Swift JE, Hutchinson MR, Johnson K, 
Williams DB, Tuke J, Rolan PE (2015) Glial Attenuation With Ibudilast in the 
Treatment of Medication Overuse Headache: A Double-Blind, Randomized, 
Placebo-Controlled Pilot Trial of Efficacy and Safety. Headache 55:1192-1208 
173 
 
 243.  Landry RP, Jacobs VL, Romero-Sandoval EA, DeLeo JA (2012) Propentofylline, a 
CNS glial modulator does not decrease pain in post-herpetic neuralgia patients: in 
vitro evidence for differential responses in human and rodent microglia and 
macrophages. Exp Neurol 234:340-350 
 244.  Cho W, Brenner M, Peters N, Messing A (2010) Drug screening to identify 
suppressors of GFAP expression. Hum Mol Genet 19:3169-3178 
 245.  Langohr HD, Stohr M, Petruch F (1982) An open and double-blind cross-over study 
on the efficacy of clomipramine (Anafranil) in patients with painful mono- and 
polyneuropathies. Eur Neurol 21:309-317 
 246.  Qiao F, Atkinson C, Song H, Pannu R, Singh I, Tomlinson S (2006) Complement 
plays an important role in spinal cord injury and represents a therapeutic target for 
improving recovery following trauma. Am J Pathol 169:1039-1047 
 247.  Gulizia JM, Cunningham MW, McManus BM (1991) Immunoreactivity of anti-
streptococcal monoclonal antibodies to human heart valves. Evidence for multiple 
cross-reactive epitopes. Am J Pathol 138:285-301 
 248.  Lindsey JW, deGannes SL, Pate KA, Zhao X (2016) Antibodies specific for Epstein-
Barr virus nuclear antigen-1 cross-react with human heterogeneous nuclear 
ribonucleoprotein L. Mol Immunol 69:7-12 
 249.  Prendergast MM, Kosunen TU, Moran AP (2001) Development of an immunoassay 
for rapid detection of ganglioside GM(1) mimicry in Campylobacter jejuni strains. J 
Clin Microbiol 39:1494-1500 
174 
 
 250.  Rosenbaum C, Schick MA, Wollborn J, Heider A, Scholz CJ, Cecil A, Niesler B, 
Hirrlinger J, Walles H, Metzger M (2016) Activation of Myenteric Glia during Acute 
Inflammation In Vitro and In Vivo. PLoS One 11:e0151335 
 251.  Faries PL, Simon RJ, Martella AT, Lee MJ, Machiedo GW (1998) Intestinal 
permeability correlates with severity of injury in trauma patients. J Trauma 44:1031-
1035 
 252.  De-Souza DA, Greene LJ (2005) Intestinal permeability and systemic infections in 
critically ill patients: effect of glutamine. Crit Care Med 33:1125-1135 
 253.  Deitch EA, Kemper AC, Specian RD, Berg RD (1992) A study of the relationship 
among survival, gut-origin sepsis, and bacterial translocation in a model of systemic 
inflammation. J Trauma 32:141-147 
 254.  Sampson TR, Debelius JW, Thron T, Janssen S, Shastri GG, Ilhan ZE, Challis C, 
Schretter CE, Rocha S, Gradinaru V, Chesselet MF, Keshavarzian A, Shannon KM, 
Krajmalnik-Brown R, Wittung-Stafshede P, Knight R, Mazmanian SK (2016) Gut 
Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of 
Parkinson's Disease. Cell 167:1469-1480 
 255.  Schirmer M, Smeekens SP, Vlamakis H, Jaeger M, Oosting M, Franzosa EA, Ter 
HR, Jansen T, Jacobs L, Bonder MJ, Kurilshikov A, Fu J, Joosten LAB, Zhernakova 
A, Huttenhower C, Wijmenga C, Netea MG, Xavier RJ (2016) Linking the Human 
Gut Microbiome to Inflammatory Cytokine Production Capacity. Cell 167:1125-1136 
 256.  Yarandi SS, Peterson DA, Treisman GJ, Moran TH, Pasricha PJ (2016) Modulatory 
Effects of Gut Microbiota on the Central Nervous System: How Gut Could Play a 
175 
 
Role in Neuropsychiatric Health and Diseases. J Neurogastroenterol Motil 22:201-
212 
 257.  Forsythe P, Kunze WA (2013) Voices from within: gut microbes and the CNS. Cell 
Mol Life Sci 70:55-69 
 258.  Gungor B, Adiguzel E, Gursel I, Yilmaz B, Gursel M (2016) Intestinal Microbiota in 
Patients with Spinal Cord Injury. PLoS One 11:e0145878 
 259.  Moran AP, Prendergast MM (2001) Molecular mimicry in Campylobacter jejuni and 
Helicobacter pylori lipopolysaccharides: contribution of gastrointestinal infections to 
autoimmunity. J Autoimmun 16:241-256 
 
  
  
176 
 
Vita 
 
 Georgene W. Hergenroeder graduated from Duke University, Durham, N.C. magna 
cum laude with a Bachelor of Science in Nursing and a Master of Health Administration.  
While at Duke, she received the Duke University President’s Award for Leadership, and the 
Duke University Service Award.  She worked as a neonatal intensive care nurse at Mount 
Sinai Hospital, NY, NY and at Duke University Hospital, Durham, NC and in maternal-child 
nursing at Duke University Hospital, Durham, NC and in Houston, TX.  After receiving her 
MHA she worked as a health care consultant for the Medical Information Consulting 
Division of Arthur Anderson & Co. and in research at Kelsey-Seybold Foundation and 
Baylor College of Medicine.  She is an Assistant Professor-Research in the Vivian L. Smith 
Department of Neurosurgery, McGovern Medical School at UTHealth, Houston, TX.  She 
has received independent research grants from Mission Connect/TIRR Foundation, The 
Department of Health and Human Services, and Texas Department of State Health 
Services, and she has collaborated on projects funded by the Vivian L. Smith Foundation 
for Neurologic Injury, The Staman Ogilvie Fund for Spinal Cord Injury Recovery, 
Rehabilitation & Research, The National Institutes of Health and The Department of 
Defense.   In August 2013 she entered The University of Texas MD Anderson Cancer 
Center UTHealth Graduate School of Biomedical Sciences and joined the laboratory of Dr. 
Pramod Dash in March 2014. 
 
